Articles

Men’s hair loss is a booming multi-billion-dollar industry, yet the vast majority of over-the-counter products fall short when measured against rigorous clinical evidence. This landscape is cluttered with quick-fix promises, leaving consumers sifting through marketing claims with little scientific support. Among all topical hair regrowth options, minoxidil is one of the most extensively studied. It is also one of two FDA-approved treatments for male pattern hair loss (in its topical form). 

In this comprehensive guide, we rank our top minoxidil picks of 2026 across Best Overall, Best Value, and other categories to help you navigate the crowded hair loss market with more clarity and confidence.

Quick Look: Best Minoxidil for Men in 2026

Product	Strength	Format	Customization	Price	Best:
Ulo	7%	Solution	High	$41.65	Overall
Ulo	1.25 mg / 2.25 mg	Oral chewable	High	$39	Convenience for Oral
Kirkland Minoxidil	5%	Solution	None	$17.99	Value
Rogaine	5%	Solution/Foam	None	$49.97	Sensitive Scalp
Keeps	5%	Solution/Foam/Spray	Low	$16.67	Subscription Convenience
Happy Head	5-8%	Solution/Gel	High	$59	Strength

What is Minoxidil and How Does it Work?

Minoxidil was originally developed to treat high blood pressure and is now widely used in both topical and oral forms as a first-line therapy for androgenic alopecia (AGA).

What is Minoxidil?

Minoxidil was first introduced in the 1970s as a powerful oral vasodilator for resistant hypertension. Clinicians soon noticed a frequent side effect, generalized increased hair growth (hypertrichosis).{{Gupta, A.K., Talukder, M., Venkataraman, M., Bamimore, M.A. (2021). Minoxidil: a comprehensive review. Journal of Dermatological Treatment. 33(4). 1896-1906. Available at: https://doi.org/10.1080/09546634.2021.1945527}} This led to the development of topical formulations specifically for AGA. Today, 2-5% topical minoxidil is FDA-approved for both male and female pattern hair loss and is used off-label for other alopecias.

How Does Minoxidil Work?

Minoxidil is a potassium-channel opener that causes vasodilation and improves microcirculation around hair follicles.{{Hussein, R.S., Dayel, S.B., Abahussein, O., El-Sherbiny, A.A. (2024). Applications and efficacy of minoxidil in dermatology. Skin Health and Disease. 4(6). E472. Available at: https://doi.org/10.1002/ski2.472}} It also acts as a prodrug; sulfotransferase converts it to minoxidil sulfate, which prolongs the anagen (growth) phase and shortens the telogen (resting) phase, shifting more hair follicles into active growth.{{Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Advances in Dermatology and Allergology. 39(3). 472-478. Available at: https://doi.org/10.5114/ada.2020.99947}} Additional data suggests that induction of key growth factors like vascular endothelial growth factor (VEGF) and activation of Wnt/ꞵ-catenin signaling further support hair regrowth.{{Gupta, A.K., Talukder, M., Shemer, A., Piraccini, B.M., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: https://doi.org/10.1159/0000531890}} 

Although minoxidil doesn’t target dihydrotestosterone, it can improve the effectiveness of other treatments by targeting multiple other targets. When combined with anti-DHT drugs like finasteride, which reduce the hormonal trigger of AGA, minoxidil provides a complementary, non-hormonal pathway. The two treatments have been shown to provide synergistic improvement in hair density in men.{{Asad, N., Naseer, M., Ghafoor, R. (2024). Efficacy of Topical Finasteride 0.25% with Minoxidil 5% versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of Drugs in Dermatology. 23(11). 1003-1008. Available at: https://doi.org/10.36849/JDD.7826}} 

OTC vs Prescription-Strength

Over-the-counter (OTC) minoxidil solutions (2% and 5%) can be effective for many men, but absorption and vehicle limits mean “stronger” drug percentages above 5% often add irritation rather than results unless the entire formulation is engineered and supervised medically. 

Early minoxidil development work showed a clear dose-response between low strengths (1-2%) and mid-strength (5%) solutions, with 5% yielding larger gains in hair counts and shaft diameter in AGA.{{Olsen, E.A., Dunlap, F.E., Funicella, T., Koperski, J.A., Swinehart, J.M., Tschen, E.H., Trancik, R.J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 47(3). 377-385. Available at: https://doi.org/10.1067/mjd.2002.124088}}

Other companies offer concentrations of 10% or over; however, recent head-to-head studies have shown that 5% topical minoxidil is moderately superior to the higher concentration.{{Ghonemy, S., Alarawi, A., Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. Journal of Dermatological Treatment. 32(2). 236-241. Available at: https://doi.org/10.1080/09546634.2019.1654070}} Additionally, the 10% minoxidil was associated with more marked irritation.

So, with that in mind, let’s take a look at some of our top minoxidil picks of 2026.

Best Minoxidil Picks for Men

#1 Best Overall: Ulo Minoxidil Rx

Pros:	Cons:
✓ Clinically-backed combinations	✗Prescription products are only available in the USA
✓ Ongoing medical monitoring and a user-friendly platform
✓ Quality-tested ingredients free of irritants

Ulo’s Minoxidil Rx takes the top spot for men who want a data-driven, medically supervised approach rather than a one-size-fits-all bottle. Custom strengths and evidence-based optional add-ons allow precise targeting for hair regrowth. 

Their high-strength concentration can be combined with tretinoin 0.01% to enhance absorption and efficacy, as well as cetirizine 1%, melatonin 0.01% for antioxidant protection, and caffeine 0.2% to boost circulation, which further improves the product’s effectiveness.

This treatment begins at $49 per month, increasing to $54 if you choose to have all of the add-ons.  

Bottom Line: Ulo’s customizable, science-driven minoxidil prescription offers one of the most advanced, value-conscious options for men who are serious about long-term hair regrowth.

#2. Best for Convenience: Ulo Dissolving Chews

Pros:	Cons:
✓ Rapid-dissolve, orange-flavored chewable tablet	✗ Premium pricing
✓ No water required, just chew
✓ Available with 1.25 mg or 2.25 mg oral minoxidil
✓ Option to combine minoxidil with 1 mg finasteride in one daily dose
✓ Prescription and ongoing support from licensed providers

Ulo’s Dissolving Chews are designed for men who want the convenience of oral minoxidil without swallowing traditional tablets or appyling topical solutions every day. These orange-flavored chewables dissolve rapidly in the mouth and require no water.

The formula is available with 1.25 mg or 2.25 mg minoxidil, with the option to add 1 mg finasteride for men who want to address both hair growth and DHT-related miniaturization in a single daily treatment. This makes it particularly convenient for those already using both medications separately or who find topical applications difficult to maintain.

Bottom Line: For men who prefer oral minoxidil but dislike swallowing pills, Ulo’s Dissolving Chews offer a convenient, delicious alternative, with the added option of combining minoxidil and finasteride in one daily dose.

Minoxidil Dissolving Chews

A rapidly-dissolving chewable tablet with minoxidil.

For maximum convenience, in a delicious orange flavor. Available in 1.25 mg and 2.5 mg doses.

Shop Minoxidil Dissolving Chews

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

#3 Best Value – Kirkland Signature Minoxidil 5%

Pros:	Cons:
✓ Lowest cost we could find for 6 months’ worth.	✗Contains propylene glycol, which can cause irritation or dryness in some users.
✓ Same core 5% minoxidil strength.	✗ No customization possible for strength or add-on ingredients.
✓ Widely available at multiple stores, including Amazon, Costco, etc.	✗ No medical consultation or tailoring of treatment included.
✓ Simple formula.

Kirkland Signature Minoxidil 5% is the classic value choice for me who want an over-the-counter treatment without paying for branding or bundled medical services. You get a standard 5% solution similar in strength to more expensive competitors, making it ideal for cost-conscious users who are happy to follow a simple twice-daily routine and do not need personalized compounding. 

Bottom line: If you want the most affordable entry point into 5% minoxidil, Kirkland’s no-frills formula is hard to beat for sheer value per effective dose.

#4 Best for Sensitive Scalps: Rogaine 5% Foam

Pros:	Cons:
✓ Clinically proven 5% minoxidil strength	✗On the higher end in terms of price.
✓ Foam vehicle is propylene glycol-free, so it is usually better tolerated on sensitive or irritated scalps.	✗ Fixed strength for men with no customization or add-on actives.
✓ Quick drying, less greasy texture	✗ No medical consultation or tailoring of treatment included.
✓ Widely available OTC

Rogaine 5% is a strong pick for men who need minoxidil but find traditional liquid formulas too irritating or cosmetically heavy. The foam format avoids common irritants found in many solutions and tends to be more comfortable for daily use, which can improve adherence and long-term outcomes.

Bottom Line: For sensitive scalps that still need full-strength 5% minoxidil, Rogaine Foam provides a gentler, easy-to-use option that balances proven efficacy with better tolerability.

#5 Best Subscription Convenience: Keeps Minoxidil

Pros:	Cons:
✓ Automatic subscription refills so you rarely run out or miss doses.	✗More expensive than buying generic minoxidil in bulk.
✓ Offers both 5% foam and 5% solution to suit different scalp and styling preferences.	✗ Limited to preset strengths and formulas with no true custom compounding.
✓ Option to bundle with finasteride and other treatments for a complete regimen.
✓ Online prescribing and follow-up.

Keeps Minoxidil is designed for men who value a set-and-forget routine, trading a price increase ($16.67 for 3 months compared to Kirkland’s $17.99 for 6 months) for automatic deliveries and integrated telehealth support. The ability to pair minoxidil with finasteride and keep everything managed through a single platform could make adherence simpler for busy users.

Bottom Line: If you want 5% minoxidil with minimal hassle, Keeps’ subscription model is a strong fit for convenience-focused men who prefer not to manage refills and prescriptions on their own. 

#6 Best High-Strength Formula: Happy Head

Pros:	Cons:
✓ Offers high-strength minoxidil concentrations beyond standard 5%.	✗Higher strengths may carry a greater risk of irritation or systemic absorption.
✓ Can be combined with topical finasteride and other actives in a single solution.	✗ More expensive than generic 5% minoxidil and some standard telehealth offerings.
✓ Telehealth model with online consultation and prescription management.	✗Corticosteroids used to offset irritation from propylene glycol.
✓ Multiple formula options aimed at men who have plateaued on basic OTC products.

Happy Head is built for men who want to move past entry-level minoxidil and explore higher-strength, prescription-only blends under medical oversight. By pairing elevated minoxidil concentrations (8%) with agents like tretinoin and topical finasteride, Happy Head targets users seeking a more comprehensive protocol. With that said, some ingredients included, like the carrier agent propylene glycol, which is used in their base formula, can cause irritation. To offset this, Happy Head uses corticosteroids; however, this may cause skin thinning long-term.

You can read more about corticosteroid usage in hair loss treatments here.

Bottom Line: Happy Head delivers a good jump in strength for minoxidil users who need to increase efficacy. 

Timeline: What Results to Expect from Minoxidil

It’s important that realistic expectations are set for regrowth when starting out on your minoxidil usage journey.

Timeframe	What to Expect	Clinical Evidence
Months 0-3	This is the initial shedding phase, which usually resolves in the first 4-8 weeks.	{{Nohria, A., Desai, D., Sikora, M., Mandal, S., Shapiro, J., Lo Sicco, K. (2024). Combating “dread shed”: The impact of overlapping topical and oral minoxidil on temporary hair shedding during oral minoxidil initiation. JAAD International. 15. 220-224. Available at: https://doi.org/10.1016/j.jdin.2024.03.005}}
Months 3-6	Early visible improvements, like the appearance of new hairs, can be expected.	{{Amit, K., Mansukh, G., Satyaprakash, M., Dhiraj, D., Hanmant, B. (2023). Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus. 15(7). E41681. Available at: https://doi.org/10.7759/cureus.41681}}
Months 6-12	Cosmetic changes peak, with stronger hair, increased density, and most coverage is seen.	{{Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available at: https://doi.org/10.1016/s0190-9622(87)70092-9}}
Months 12+	Further gains plateau, continued use needed to maintain improvements.	{{Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available at: https://doi.org/10.1016/s0190-9622(87)70092-9}}

Consistency is Everything

Minoxidil works by prolonging the anagen phase and shortening the telogen phase. Regular dosing maintains these effects at the follicle level; repeatedly missing applications reduces the cumulative time that hair follicles spend in a pro-growth, anagen-biased state.{{Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2(1). 186-194. Available at: https://doi.org/https://doi.org/10.1111/j.1365-2133.2004.05785.x}}

Because human scalp follicles cycle slowly (anagen can last years), many follicles need months of uninterrupted exposure before visible density gains can be seen.{{Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499948/ (Accessed: November 2025)}} This is why most guidance recommends at least 6 months of continuous use before judging the response.

Why Stopping Reverses Progress

Minoxidil is not disease-modifying for AGA, meaning that it does not correct androgen-driven miniaturization but counteracts it while present by improving hair cycle dynamics and follicle size. When treatment is stopped, these pharmacologic effects wane, and follicles gradually revert toward their genetically determined, androgen-sensitive pattern.

Clinical and patient information sources consistently note that any gain from minoxidil is maintained only while therapy continues. After discontinuation, increased shedding and loss of density over months are typical, ultimately leading to a reversal of gains to the original starting point.

What Minoxidil Formulations are Available?

You can buy minoxidil in several different vehicles that differ mainly in tolerability, practicality, and how well they fit a given scalp and routine. Choosing the “best” format is less about raw efficacy and more about matching the base to skin sensitivity and your preference of application.

• Foam – Best for Sensitive Skin: Propylene glycol-free foams were developed to reduce contact dermatitis and dryness seen with classic liquid solutions. Reviews note lower rates of irritation and quicker drying, which makes them better for patients with reactive or dry scalps.{{Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714}}

• Liquid – Best for Cost-Effectiveness: Traditional solutions with alcohol and propylene glycol are widely available, inexpensive, and easy to use, but they may cause increased itching, flaking, and stinging. This formulation may suit users with non-sensitive skin who are price-conscious.

• Spray – Easiest for Coverage: Spray tops or aerosolized formats can make it faster to hit broad thinning areas, especially in longer hair. However, the product may end up more on the hair shafts or adjacent skin.

• Gel – Targeted and Controlled: Gel or cream-gel vehicles (often from compounders) sit where you place them, minimize dripping, and are useful for localized areas such as temples or post-transplant zones. 

• Liposomal Delivery: Newer liposomal or phospholipid bases aim to enhance follicular penetration while limiting systemic absorption and irritation. This is usually marketed as an “advanced delivery” method.

Side Effects and Safety

Minoxidil is generally well tolerated, but like any active drug, it can cause local irritation, a transient shedding phase, and very rare systemic effects, especially in people with underlying skin or cardiovascular issues.

Common local side effects include:

• Itching
• Flaking
• Redness
• Burning
• Temporary shedding 

Systemic and heart-related side effects are very rare with correctly used topical minoxidil, but case reports and product information advise seeking medical help if symptoms like chest pain, palpitations, dizziness, or unexplained swelling occur, as these could reflect systemic absorption or accidental ingestion. Risk is higher with oral minoxidil or overdose, where hypotension, tachycardia, and even heart failure have been documented.{{Tripathee, S., Benyovszky, A., Devbhandari, R., Quiza, K., Boris, J. (2024). A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure. Cureus. 16(8). E66039. Available at: https://doi.org/10.7759/cureus.66039}} 

To minimize problems, many clinicians suggest starting once daily and titrating up, choosing foam or gentler vehicles to reduce dermatitis, and using custom compounded formulas (for example, lower alcohol, lower strength, or liposomal bases) in those with sensitive or disease-prone scalps. 

People with chronic inflammatory scalp conditions such as active psoriasis, eczema, or severe seborrheic dermatitis are typically advised to get the primary condition under control before adding topical minoxidil or other actives, as applying them to an inflamed barrier increases irritation, may worsen the disease, and can unpredictably alter absorption.{{Junge, A., Jic-Hoesli, S.R., Bossart, S., Simon, D., de Viragh, P., Hunger, R.E., Heidemeye, K., Seyed Jafari, S.M. (2025). Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation.  Acta Dermato-Venereologica. 105. 42401. Available at: https://doi.org/10.2340/actadv.v105.42401}} 

Final Verdict – Best Minoxidil for Men in 2026

In 2026, several minoxidil-based options stand out for different priorities, from cost to customization. All of them rely on the same core ingredient, but vehicle, strength, and add-ons make a real-world difference in adherence and results. 

Whichever route you choose, there is strong evidence that consistent minoxidil use can stabilize loss and improve density for many men, and modern platforms make it easier than ever to find a formulation that fits your scalp, schedule, and risk tolerance.

Oral minoxidil has become a widely used off-label option for androgenic alopecia (AGA) in men and women, despite initially being approved only as an antihypertensive medication decades ago.

Oral minoxidil is increasingly offered to address specific unmet needs in AGA treatment: 

• Topical non-responders: Some people don’t see satisfactory results with topical minoxidil, possibly due to inadequate absorption, variations in scalp skin properties, or genetic factors affecting drug metabolism.
• Scalp sensitivity/irritation: Topical minoxidil can cause local side effects such as itching, flaking, or dermatitis due to the vehicle (especially propylene glycol) or the active ingredient itself. Switching to oral minoxidil bypasses these local reactions.
• Simpler routines/adherence: Oral dosing eliminates the need for daily topical application, which can be messy, time-consuming, or interfere with hair styling. For some, this leads to better long-term adherence and quality of life.

Regrowth with oral minoxidil can be variable, however. This variability mainly stems from biological differences between patients. Because minoxidil is a prodrug that requires conversion by the enzyme sulfotransferase (SULT1A1) into its active form, individual variation in enzyme activity strongly influences response.{{Ramos, P.M., Goren, A., Sinclair, R., Miot, H.A. (2020). Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss. Journal of the European Academy of Dermatology and Venereology. 34(1). E40-e41. Available at: https://doi.org/10.1111/jdv.15891}}  

Interested in Oral Minoxidil?

Low-dose oral minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Unfortunately, what most people see online are extremely successful oral minoxidil before and after photos (which you’ll see below), which can lead people to believe that they will experience more regrowth than they actually might.

In this article, we will explore what the likely (not just possible) results are and what the clinical trials show.

But first, let’s have a quick refresher on what oral minoxidil is.

What is Oral Minoxidil?

Oral minoxidil is a tablet medication originally developed as a vasodilator for severe hypertension, but now increasingly used off-label at low doses to treat AGA and other hair loss conditions. It enhances scalp flow and prolongs the growth phase (anagen) of hair follicles, primarily by increasing prostaglandin E2 and vascular endothelial growth factor (VEGF). 

Oral minoxidil acts by opening ATP-sensitive potassium channels in vascular smooth muscle, which increases perifollicular blood flow. It also prolongs the anagen phase of the hair cycle. Unlike topical minoxidil, which requires local sulfotransferase enzyme activity in the scalp for conversion to its active form, oral minoxidil is metabolized systemically via hepatic sulfotransferase, potentially bypassing poor scalp enzyme activity in some individuals.{{Kaiser, M., Abdin, R., Gaumond, S.I., Issa, N.T., Jiminez, J.J. (2023). Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Clinical, Cosmetic and Investigational Dermatology. 16. 1387-1406. Available at: https://doi.org/10.2147/CCID.S385861}} 

For hair loss, oral minoxidil is prescribed at significantly reduced dosages compared to antihypertensive therapy – typically:

• 0.25 mg – 1.25 mg for women
• 2.5 mg – 5 mg for men
• Adverse effects are much less frequent at these low doses but may include hypertrichosis (excess unwanted body hair), fluid retention, and, rarely, cardiovascular effects.{{Bloch, L.D., Carlos, R.M.D. (2024). Side Effects’ Frequency Assessment of Low Dose Oral Minoxidil in Male Androgenetic Alopecia Patients. Skin Appendage Disorders. 11(1). 14-18. Available at: https://doi.org/10.1159/00539969}} 

While oral minoxidil is not FDA-approved for hair loss, a number of studies show its efficacy. 

Minoxidil Dissolving Chews

A rapidly-dissolving chewable tablet with minoxidil.

For maximum convenience, in a delicious orange flavor. Available in 1.25 mg and 2.5 mg doses.

Shop Minoxidil Dissolving Chews

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

The Evidence

You can see a complete table of oral minoxidil studies here, but we have picked a few to show.

Study One – AGA (Female)

Vahabi-Amlashi et al (2021) conducted a triple-blind, randomized clinical trial in 72 women with female pattern hair loss, comparing oral minoxidil 0.25 mg daily to 2% topical minoxidil twice daily over 36 weeks.{{Vahabi-Amlashi, S., Layegh, P., Kiafar, B., Hoseininezhad, M., Abbaspour, M., Khaniki, S.H., Forouzanfar, M., Sabeti, V. (2021). A randomized clinical trial on the therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss. Dermatological Therapy. 34(6). E15131. Available at: https://doi.org/10.1111/dth.15131}} 

• Measured outcomes included hair shedding, Sinclair scores by three independent evaluators, trichoscopy assessments of hair density and diameter, and safety labs (liver, kidney, electrolytes).
• Both groups showed significant improvement in hair diameter and density:
  • Group 1 (oral): 13% improvement in hair density.
  • Group 2 (topical): 6% improvement in hair density.
• Sinclair and shedding scores decreased significantly in both groups by the end of the study.
• There was no significant difference between groups in any measured endpoint. 
• Oral minoxidil showed slightly better improvement in hair density; topical minoxidil showed slightly better improvement in hair diameter.
• Adverse events:
  • Group 1 (oral): hirsutism (7.7%), gastrointestinal intolerance (7.7%), weight gain (3.8%), hypotension (3.8%), leading to withdrawal.
  • Group 2 (topical): hirsutism (8%).

Study Two – AGA (Male)

Panchaprateep and Lueangarun (2020) conducted an open-label, prospective single-arm study in 30 men with AGA, treated with 5 mg oral minoxidil once daily for 24 weeks.{{Panchaprateep, R., Lueangarun, S. (2020). Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatology and Therapy. 10. 1345-1357. Available at: https://doi.org/10.1007/s13555-020-00448-x}}

• Statistically significant increase in total hair count at 24 weeks (+35.1±18.9 hairs/cm2; p=0.003).
• Hair diameter improved by 15.2% from baseline (p<0.001).
• Global photographic assessment: 43% of patients achieved an “excellent improvement” score by study end.
• High rate of hypertrichosis (93.3% at 24 weeks); pedal edema was reported in 3 patients, resolving after 2-3 months in all cases.
• No serious cardiovascular side effects were observed.

Study Three – AGA and TE (Male and Female)

Feaster et al. (2023) performed a multicenter retrospective study in 210 patients (50 men, 160 women) with AGA and/or telogen effluvium (TE), comparing low-dose oral minoxidil (0.625 – 2.5 mg daily) to a control (no minoxidil or other non-minoxidil treatments) over 52 weeks.{{Feaster, B., Onamusi, T., Cooley, J.E., McMichael, A.J. (2023). Oral minoxidil use in androgenetic alopecia and telogen effluvium. Archives of Dermatological Research. 315(2). 201-205. Available at: https://doi.org/10.1007/s00403-022-02331-5}} 

• Group 1 (oral minoxidil): 52.4% of patients showed clinical improvement in hair growth; 41.9% had hair loss stabilization; 5.7% experienced worsening.
• These results were significantly better than the control group (p=0.001). 
• The mean duration of oral minoxidil use was 25.1 months (range 12-54); the most common dose was 1.25 mg daily.
• Adverse effects were uncommon (9.5% of patients), generally mild, and included:
  • Hypertrichosis (4.8%)
  • Edema (1.9%)
  • Hair shedding (1%)
  • Lower extremity cramping (1%)
  • Palpitations (1%)
  • Scalp dysesthesia (1%)
• There were no serious side effects or study withdrawals due to adverse events in the analyzed population.

Overall, these studies demonstrate that oral minoxidil is an effective and generally well-tolerated treatment option for both AGA and TE in men and women. Across the studies, clinical improvements were observed, with similar efficacy to topical minoxidil.

However, the results that people show online are usually more dramatic than what is seen in clinical studies. 

What’s Possible ≠ What’s Probable

When reviewing outcomes, such as oral minoxidil before and after photos, it’s essential to distinguish what can happen from what is likely to happen. Take a look at the example we have created below. The scattered data points represent the full spectrum of possible individual results, while the central trendline shows the average, reflecting the most common or expected response.

These anecdotes (arrows on the graphs) often highlight “hyper-responders”. These are individuals who experience notably dramatic hair regrowth. They may have higher SULT1A1 activity, leading to higher levels of minoxidil activation.

These accounts, although genuine, illustrate results that surpass what most people can achieve. Problems can then arise when people fixate on these exceptional outcomes and assume that their experience will be similar. If their own hair growth is slower or less impressive, they might discontinue treatment early, or wrongly conclude that it isn’t working.

Impressive results are more frequently shared than modest improvements as a result of survivorship bias. This bias happens when only the most impressive successes receive attention, while the many cases with typical or less remarkable outcomes are overlooked or not reported.

Survivorship bias can distort our understanding of how hair loss treatments perform. Online narratives often draw attention to the most extreme cases, either astonishing successes or clear failures, while the more typical moderate outcomes that most people experience are rarely seen or discussed.

Now that we have covered the clinical evidence, strategies, and reasonable expectations for oral minoxidil, let’s now look into 10 firsthand accounts of oral minoxidil before and after photos shared by real users on Reddit.

Oral Minoxidil Success Stories

Keep in mind that the experiences below are purely anecdotal in nature and are not subject to any independent verification. They strictly reflect the individual journeys of each poster and should not be construed as reliable clinical evidence or medical advice.

Case 1: Male (29), Oral minoxidil monotherapy (11 months, 5 mg nightly)

This Redditor began oral minoxidil monotherapy at a dose of 2.5 mg before increasing to 5 mg once nightly. He had switched from topical minoxidil after a year of subpar results. He experienced shedding in the early months of therapy, with visible regrowth by month 3, and a major improvement in hair density by 11 months. Overall, the patient was satisfied with thicker scalp coverage, a fuller beard and brows, and did not report any significant side effects.

Case 2: Male (26), finasteride and oral minoxidil (2 years total; 1 mg finasteride and 2.5 mg oral minoxidil daily)

This 26-year-old used a combination of 1 mg finasteride and 2.5 mg oral minoxidil once daily, having switched from topical to oral minoxidil one year into treatment. He reported notable improvement one year into therapy, with visible regrowth by the 4-month mark. He did not report any shedding or other side effects after switching from topical to oral formulations. After two years of treatment, the patient reported marked hair thickening and cosmetic improvement.

Case 3: Female, oral minoxidil monotherapy (2 years; 2.5 mg daily, titrated up from 1.25 mg)

This user reported one her progress with oral minoxidil monotherapy over 2 years. She started at a daily dose of 1.25 mg, before increasing to 2.5 mg. She had tried vitamins, spironolactone, oils, and Nioxin/Nizoral without benefit for one year prior. Shedding started shortly after beginning the protocol and normalized by the fourth month. She reported visible improvement within one year, and by the end of the second year, she had notable improvement in ponytail thickness and part density. She also reported that her hair looked and felt close to pre-loss baseline. The user did not report any significant side effects.

Case 4: Female (24), Oral and topical minoxidil (9 months topical 5% foam; 6 months oral 0.625 – 1.25 mg nightly)

This 24-year-old began minoxidil monotherapy with 5% foam nightly, before adding oral minoxidil 0.625 mg three months later, and titrating to 1.25 mg nightly the following month. She continued both nightly for six months. She did not note any noticeable shedding on the foam, nor after incorporating 0.625 mg orally. She reported steady baby hairs and a reduction in hair loss at ~6-9 months alongside thickening compared to the baseline, and mentioned that her hair felt and looked much closer to its pre-loss condition overall. She also reported faster growth of facial/body hair (hypertrichosis), water retention, and bloating after salt meals, and occasional stronger heartbeat at night, after incorporating oral minoxidil, though this last symptom did resolve.

Case 5: Male, oral minoxidil (6 weeks shown; 5 mg daily) and weekly microneedling

This male Redditor used oral minoxidil 5 mg once daily in addition to microneedling once weekly with a pen device. The poster also noted no side effects from finasteride, implying that they might have used it alongside the other treatments. He reported an initial shedding phase at around week 3 and rapid visible coverage by week 6 into treatment. In commenting on the progress to date, he noted fuller coverage compared to baseline and said his beard was slightly thicker without any apparent increase in body hair. He did not report any side effects.

Case 6: Female, oral minoxidil + spironolactone (1 year; 1.25 mg oral minoxidil daily, 50 mg spironolactone daily)

The poster took oral minoxidil 1.25 mg once daily, in addition to spironolactone 50 mg once daily (started at 100 mg but reduced the dose due to drowsiness). She noted visible improvement after about 5 months of consistent use, with shedding slowing markedly around weeks 7-8. At the one-year mark, she reported noticeably fuller hair at the part and temples, with ongoing gradual thickening, and “good hair days”. She reported increased body and facial hair from oral minoxidil, which she managed by waxing, and did not report any noticeable weight gain or low-blood-pressure symptoms. 

Case 7: Female, oral minoxidil monotherapy (6 months; 1.25 mg daily, titrated from 0.625 mg)

This female Redditor took oral minoxidil 1.25 mg once daily for six months, having started from the initial dose of 0.625 mg. She supplemented with vitamin B12 injections every two weeks for pernicious anemia, daily shampooing, higher protein intake, and therapy/stress management. She reported steady improvement in hair through month 6, despite a brief “dread shed” in the initial month. Unfortunately, the images don’t show the same hair pulled back, so we can’t see exactly how much improvement was gained. She did report increased facial hair, which she has been managing by shaving/dermaplaning.

Case 8: Female, oral minoxidil monotherapy (1 year; 1.25 mg daily)

This user took oral minoxidil 1.25 mg once daily for one year. She also used Nizoral shampoo on the same timeline. Her hair loss was first diagnosed as telogen effluvium that did not resolve, and she now suspects AGA. She reported modest shedding in the first 2 months, then gradual thickening over the year. The photos showed some improvement, but the patient stated that she is not fully back to baseline. Regarding side effects, she noted increased body hair growth and mild dizziness in the first month that resolved.

Case 9: Male, self-made oral minoxidil (3 months; ingested diluted topical solution)

This male Redditor switched from applying topical minoxidil to drinking a diluted solution mixed with water. He reported taking “a few drops” per dose, having discontinued application of the topical preparation to the scalp. At the three-month mark, the Redditor reported clearly greater overall density and said results were still improving. He did not report any side effects, except for some extra body hair. 

We should mention that we do not recommend ingesting topical minoxidil – if oral therapy is pursued, it is advised to use a prescribed oral dose under medical supervision to control dosing and avoid health risks.

Case 10: Female, oral minoxidil monotherapy (12 months; dose not reported)

This user reported taking oral minoxidil at an unspecified dose for about one year. The photos show modest improvements around the parting. The poster did not report any side effects. Notwithstanding the sparse information provided by this Redditor, multiple commenters observed hair thickening and density gains in the before-and-after photos.

Strategies to Optimize Oral Minoxidil Response

To maximize the benefits of oral minoxidil, consistent use and patience are essential as optimal regrowth often takes 6-8 months to fully manifest. Combining oral minoxidil with other treatments like finasteride or dutasteride, platelet-rich plasma (PRP), or low-level laser therapy (LLLT) can improve results for those who do not respond sufficiently to minoxidil alone. Recent studies support the efficacy of combination regimens, particularly oral minoxidil plus finasteride, with one retrospective study finding significant and clinically meaningful improvements.{{Johnson, H., Huang, D., Clift, A.K., Bersch-Ferreira, A., Guimaraes, G.A. (2025). Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service Evaluation. Cureus. 17(1). E77549. Available at: https://doi.org/10.7759/cureus.77549}} 

People using oral minoxidil, especially at 2.5 mg or more and in combination with other treatments, should keep an eye on potential side effects. This can help catch rare but potentially serious side effects like edema or changes in blood pressure. Regular follow-ups can ensure that any adverse effects are detected early and that the regimen can be safely adjusted to maintain a balance between safety and efficacy. This patient-tailored management increases the likelihood of achieving the best possible outcomes while minimizing health risks.

Probable Regrowth Timeline

Based on the available evidence, the expected regrowth timeline for oral minoxidil is around 8 months.

Months 0-3: Possible increased shedding; no visible gains

• Temporary shedding can occur as follicles transition into a new growth cycle.
• This process often resolves within the first 4-8 weeks and is seen as an early sign that the treatment is starting to take effect.

Months 3-6: First positive density changes for many

• Early visible improvements, such as reduced shedding and appearance of fine new hairs, can be expected.
• Thicker, darker regrowth starts to become apparent for most users during this period.

Months 6-8: Maximal visible benefits

• Cosmetic changes peak, with stronger hair, increased density, and the greatest coverage observed. 
• This is the period of maximum regrowth for most individuals. 

Months 8-12+

• Further gains plateau.
• Continued daily use is needed to maintain improvements.
• Some might consider combination treatment at this point to increase growth outcomes.

Safety and Side Effects

While oral minoxidil can avoid local irritation occurring with the topical formulation, some safety concerns do remain.

Oral minoxidil use does carry a risk of cardiovascular issues like pericardial effusion, especially at the high doses used for blood pressure control. At hair loss doses (0.25 – 5 mg), such events are rare and tend to be individual rather than predictable. 

The majority of side effects, such as excess body hair, mild ankle swelling, lightheadedness, or palpitations, are mild and usually resolve with dose adjustments or stopping the medication. 

Large safety studies have shown that serious side effects are exceedingly rare in otherwise healthy individuals taking low-dose oral minoxidil, with only a small percentage discontinuing treatment due to adverse effects. 

A gradual dose escalation is recommended to minimize side effects with oral minoxidil. Recent studies have shown that a 2.5 mg daily dose is as effective as 5 mg for treating male pattern hair loss, but with a better safety profile, and this supports 2.5 mg as a preferred starting dose for men.{{Fonseca, L.P.C., Miot, H.A., Chaves, C.R.P., Ramos, P.M. (2025). Oral Minoxidil 2.5 mg vs 5 mg for Male Androgenetic Alopecia: A Double-Blind Randomized Clinical Trial. Journal of the American Academy Dermatology. 15. Available at: https://doi.org/10.1016/j.jaad.2025.09.031}} 

If you want to use a higher dose, sublingual minoxidil may be beneficial for reducing the risk of cardiovascular side effects.{{Gupta, A.K., Bamimore, M.A., Williams, G., Talukder, M. (2025). Comparative Efficacy of Minoxidil and 5-Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta-Analysis Study of Current Empirical Evidence. Journal of Cosmetic Dermatology. 62(2). 257-259. Available at: https://doi.org/10.1111/ijd.163737}} 

Practical Takeaways

• Oral minoxidil is an effective and generally well-tolerated alternative for people who cannot use topical minoxidil or do not respond to it.
• Clinical trial results typically show stabilization or modest regrowth. Hyper-responder cases seen online are possible but not common. 
• Careful dose selection (0.25 – 2.5 mg daily) minimizes side effects while maintaining efficacy.
• Consistent, long-term use is key; optimal results generally take 6-8 months to appear and require ongoing treatment to maintain gains.
• Combining oral minoxidil with other therapies such as finasteride, dutasteride, PRP, or LLLT may improve outcomes for partial responders.

Final Thoughts

Oral minoxidil use is growing, but should be recognized as an off-label option (albeit backed by a solid body of emerging evidence.. Most users can expect stabilization or noticeable yet modest regrowth rather than dramatic transformation. The best outcomes come with realistic expectations, consistent use over several months, and regular medical supervision to ensure safety. By focusing on average, evidence-based results rather than rare hyper-responder anecdotes, patients can make balanced decisions and maintain long-term adherence to their treatment plan.

Topical minoxidil has been a cornerstone of androgenic alopecia (AGA) treatment since its FDA approval in the 1980s. With millions of users worldwide, it stands as one of the most widely adopted therapies for hair loss, supported by decades of clinical evidence, and an enormous body of real-world anecdotes, reviews, and before-and-after photos. 

However, results with minoxidil can be highly variable, and this variability can be traced in part to biological differences, particularly in the activity of the sulfotransferase enzyme (SULT1A1), which is responsible for converting minoxidil into its active form. Not everyone sulfates minoxidil effectively, meaning that while some achieve meaningful regrowth, others see little to no improvement. 

Interested in Topical Minoxidil?

High-strength topical minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Adding to this challenge is the influence of online topical minoxidil before and after photos (like you can see below), which can create inflated expectations compared to the more modest, probable outcomes seen in practice. 

This article will break through that noise to answer a critical question: when it comes to minoxidil, what is actually the most probable result, not just possible? 

First, let’s take a look at what topical minoxidil is.

Refresher: What is Topical Minoxidil?

Topical minoxidil was the first therapy ever approved by the FDA for the treatment of AGA, making it a landmark in the medical management of pattern hair loss.{{Suchonwanit, P., Thammarucha, S., Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786}} Introduced in the 1980s, it has since become one of the most widely available and researched treatments across the globe. Its primary action is as a potassium channel opener, which helps to stimulate blood flow, prolong the hair’s growth phase (anagen), and increase follicle size, mechanisms that together can support thicker, denser hair regrowth over time.{{Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 150(2). 186-194. Available at: https://doi.org/10.1111/j.1365-2133.2004.05785.x}}

Minoxidil is known as a “pro-drug”, meaning that it needs to be activated within the body to exert its effect. The enzyme responsible for this is called sulfotransferase or, more specifically, SULT1A1. The level of sulfotransferase activity differs depending on the individual, which means that the effectiveness of treatment also differs depending on who you are.{{Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Advances in Dermatology and Allergology. 39(3). 472-478. Available at: https://doi.org/10.5114/ada.2020.99947}} 

Formulations typically come in 2% and 5% strengths. The 2% solution was originally FDA-approved for women, while the 5% concentration was approved for men; however, both are now commonly used off-label across genders. Beyond these standard strengths, compounding pharmacies have made higher concentrations available for patients seeking more individualized treatment approaches, with some online telehealth providers (such as Ulo) offering customized formulations. Standard dose topical minoxidil is available over-the-counter in most countries, ensuring accessibility without the need for a prescription.

Minoxidil Dissolving Chews

A rapidly-dissolving chewable tablet with minoxidil.

For maximum convenience, in a delicious orange flavor. Available in 1.25 mg and 2.5 mg doses.

Shop Minoxidil Dissolving Chews

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

The Evidence

Topical minoxidil’s robust efficacy for hair regrowth is supported by dozens of high-quality randomized controlled trials (RCTs) and meta-analyses across men and women, consistently demonstrating average increases in hair count of around 10-20% over 6-12 months. 

We have collated many of these studies into a table, which you can look at here. However, we have summarised some of the most recent topical minoxidil studies.

Liang et al. (2022)

• Prospective, evaluator-blinded RCT with 120 women with female pattern hair loss (FPHL) assigned to three groups: 5% topical minoxidil alone; 5% minoxidil + oral spironolactone (80-100 mg); and 5% minoxidil and microneedling every 2 weeks.{{Liang, X., Chang, Y., Wu, H., Liu, Y., Zhao, J., Wang, L., Zhuo, F. (2022). Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Frontiers in Medicine. 11(9). 905140. Available at: https://doi.org/10.3389/fmed.2022.905140}}
• Duration: 24 weeks; outcomes measured included dermascope, ultrasound biomicroscopy, physician, and patient assessments.
• Effective rate at week 2:
  • 55.27% (topical minoxidil)
  • 86.49% (topical minoxidil and oral spironolactone)
  • 95% (topical minoxidil and microneedling)
• Combo therapies (Groups 2&3) outperformed topical minoxidil alone for hair density, shaft diameter, scalp/thickness, shedding, and quality of life; Group 3 showed the greatest benefit.
• Adverse effects were reported across all groups; more menstrual disorders were reported in the spironolactone group. Main limitations: small sample, exclusion of severe cases, possible bias from unblinded treatments.

Hassan et al. (2022)

• Comparative study in 60 women with FPHL: 5% minoxidil topical foam and oral vitamin D3, minoxidil foam only, or vitamin D3 for 12 weeks (plus 15 controls for vitamin D comparison).{{Hassan, G.F.R., Sadoma, M.E.T., Elbatsh, M.M., Ibrahim, Z.A. (2022). Treatment with oral vitamin D alone, topical minoxidil, or combination of both in patients with female pattern hair loss: A comparative clinical and dermoscopic study. Journal of Cosmetic Dermatology. 21(9). 3917-3924. Available at: https://doi.org/10.1111/jocd.14743}} 
• Primary outcomes: reduction in thin hair count and Ludwig stage improvement via clinical and dermoscopic evaluation. 
• Best results from combination therapy (minoxidil foam and vitamin D3), followed by minoxidil foam alone; vitamin D3 monotherapy had minimal effect.
• Vitamin D3 appeared to enhance minoxidil efficacy, though the sample size was small, and adverse events were not reported. 

Bao et al. (2022)

• RCT with 71 men, split into: 5% topical minoxidil twice daily, electrodynamic microneedling every 3 weeks, or topical minoxidil and microneedling combined.{{Bao, L., Zong, H., Fang, S., Zheng, L., Li, Y. (2019). Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/ꞵ-catening signaling pathway. Journal of Dermatological Treatment. 33(1). 483-493. Available at: https://doi.org/10.1080/09546634.2020.1770162}}
• Follow-up: 24 weeks, with an additional 6-month observation period.
• All treatments increased non-vellus hair density; the combined group had the greatest improvements in hair density and diameter. 
• The combination group received additional scalp massages (potential confounder); 12 participants experienced adverse reactions (dermatitis, dandruff, lymph node enlargement), none severe.

Singh et al. (2020)

• Double-blind, placebo-controlled RCT in 80 men: Groups received either 5% topical minoxidil, 5% topical minoxidil and PRP injections, placebo, or PRP alone.{{Singh, S.K., Kumar, V., Rai, T. (2020). Comparison of efficacy of platelet-rich plasma therapy with or without topical 5% minoxidil in male-type baldness: A randomized, double-blind placebo control trial. Indian Journal of Dermatology, Venereology, and Leprology. 86(2). 150-157. Available at: https://doi.org/10.4103/ijdvl.IJDVL_589_18}}
• 12 weeks’ treatment with 2-month follow-up; outcome: changes in total, terminal, vellus, and non-vellus hair density, pigmentation, and global assessments.
• Highest hair density and satisfaction with topical minoxidil and PRP; both monotherapies are better than placebo, but the combo was most effective.
• Limitations: short-term follow-up, some subjective outcomes; low adverse event rate (mostly mild, e.g., scalp pruritus, facial hair growth).

Overall, when you look across all of the data, consistent benefits are seen with topical minoxidil usage. However, these results are variable. The key reason for this is differences in sulfotransferase activity. As we mentioned before, minoxidil is a pro-drug, and it needs to be enzymatically activated to exert its effect. We will go into more detail about this below.

What’s Possible ≠ What’s Probable

When evaluating treatment outcomes, especially online minoxidil before and after photos, it’s important to separate possibility from probability. The scattered data points below show the full range of what might occur for individuals, while the central trendline reflects the average outcome (i.e., what typically happens).

Online anecdotes often showcase what we would call “hyper-responders” – people who experience dramatic results. These people may also have higher levels of sulfotransferase activity.

These stories, while real, represent outcomes that are well above average. The issue arises when patients focus only on these peak results and expect the same for themselves. If their own progress seems slower or less dramatic, they may stop prematurely or mistakenly believe the treatment is ineffective.

Dramatic results are often showcased more than modest outcomes because of survivorship bias. This bias occurs when only the most striking successes are noticed or shared, while the many average or less impressive results go unreported.

Why Results Are Variable: The SULT1A1 Enzyme

Minoxidil must be converted into minoxidil sulfate by the sulfotransferase enzyme SULT1A1, which is present in the outer root sheath of hair follicles, to become pharmacologically active and stimulate hair growth. 

Several peer-reviewed studies confirm that the level of SULT1A1 activity in scalp follicles is a key determinant of how well a patient responds to minoxidil therapy.{{Goren, A., Castano, J.A., McCoy, J., Bermudez, F., Lotti, T. (2014). Novem enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatologic Therapy. 27(3). 171-173. Available at: https://doi.org/10.1111/dth.12111}} Enhancing SULT1A1 activity, such as by using enzyme-boosting adjuvants, has been shown in recent trials to convert a majority of prior non-responders into responders, further confirming the mechanistic role of this enzyme.{{Chandrashekar, B.S., Chandu, M., Shenoy, C., Chander, A., Roopa, M.S. (2024). SULT1A1 enzyme booster to amplify topical minoxidil response in androgenic alopecia: a single-center prospective study. International Journal of Research in Medical Sciences. 12(11). Available at: https://doi.org/10.18203/2320-6012.ijrms20243362}} 

This enzyme-based variability explains why two people can apply minoxidil in the same way but see very different outcomes, and why more than half of users may see only limited or no benefit despite consistent application.

Fixing the Enzymatic Problem

A number of evidence-based strategies exist to improve minoxidil response. These include microneeding, retinoic acid co-application, formulation changes, consistency, and combination therapy.

Microneedling

Multiple systematic reviews and clinical trials confirm microneedling significantly improves minoxidil efficacy. A 2023 meta-analysis showed that combining the two led to a significantly greater increase in hair count compared to minoxidil alone, regardless of needle depth or device used. Hair count improvements are notable after 12 to 24 weeks of combined treatment.{{Ahmed, K.M.A., Kozaa, Y.A., Abuawwad, M.T., Al-Najdawi, A.I., Mahmoud, Y.W., Ahmed, A.M., Taha, M.J.J., Fadhli, T., Giannopoulou, A. (2025). Evaluating the efficacy and safety of combined microneedling therapy versus topical Minoxidil in androgenetic alopecia: a systematic review and meta-analysis. Archives of Dermatological Research. 317(1). 528. Available at: https://doi.org/10.1007/s00403-025-04032-1}} 

You can read more about how microneedling improves minoxidil efficacy here.

Retinoic Acid (Tretinoin)

Topical tretinoin has been shown in peer-reviewed studies to upregulate follicular SULT1A1, thereby enhancing the conversion of minoxidil to its active form. In a 2019 study, tretinoin not only improved clinical response in difficult cases but also increased scalp SULT1A1 activity, supporting its role as a mechanistic booster.{{Sharma, A., Goren, A., Dhurat, R., Agrawal, S., Sinclair, R., Trueb, R.M., Vano-Galvan, S., Chen, G., Tan, Y., Kovacevic, M. (2019). Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatologic Therapy. 32(3). E12915. Available at: https://doi.org/10.1111/dth.12915}}

You can see the benefits of adding retinoic acid in our Compare Treatments graph below.

Learn more about retinoic acid and its effects on sulfotransferase here.

Formulation Adjustments (Foam vs. Solution 2% vs. 5%)

Clinical research shows that 5% minoxidil is more effective than 2% for both men and women. Foam is as effective as a solution but better tolerated, with reduced risk of contact dermatitis due to the absence of propylene glycol. Some evidence suggests liquid formulations might yield slightly higher absorption, but both forms are clinically comparable.{{Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714}} 

Consistency and Adherence

Missed doses can reduce topical minoxidil efficacy. Some clinical guidance suggests that missing minoxidil applications even once per week can diminish results, and consistent, daily use is necessary to achieve and maintain hair regrowth.{{Shadi, Z. (2023). Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia. Dermatology and Therapy. 13(5). 1157-1169. Available at: https://doi.org/10.1007/s13555-023-00919-x}} 

Combination Therapy

Combining minoxidil with finasteride/dutasteride, PRP, low-level laser therapy (LLLT), or, in resistant cases, oral minoxidil, provides superior results versus monotherapy. Meta-analyses and randomized trials consistently find greater improvement in hair density, count, and patient satisfaction when using combination regimens.{{Xia, Y., Chen, H., Chen, Y., Chen, Z. (2025). Relative efficacy of minoxidil in combination with other treatments for androgenic alopecia: a network meta-analysis based on randomized controlled trials. Frontiers in Medicine. 12. Available at: https://doi.org/10.3389/fmed.2025.1638496}} 

So, what do online topical minoxidil before and after photos look like?

Online Topical Minoxidil Successes

Now that we have discussed how topical minoxidil works, potential regimens, and likely timelines, here are 10 reports published by Reddit users with before and after photos.

Disclaimer: The stories below are unverified anecdotes. Consequently, they illustrate individual outcomes and should not be construed as clinical proof or medical advice.

Case 1: Male (age unknown), 6 months on topical minoxidil monotherapy (5% once daily)

This individual applied 5% topical minoxidil once daily for six months. They chose topical minoxidil out of a general preference for avoiding oral medications. From the before-and-after photos, diffuse thinning can be observed from the center of the crown, and the protocol yielded a noticeable increase in crown density by month six. No side effects or early shedding have been reported.

Case 2: Female (age unknown), about 5 months on topical minoxidil monotherapy (5% once nightly)

This user applied 5% topical minoxidil once nightly for about 5 months, using a liquid solution that she purchased over the counter after a telemedicine consult. She stated that she had AGA and did not note any other treatment. Based on both her comments and photos, she experienced marked improvement in hair density and coverage, stating that minoxidil “saved her hair” and that she wishes she had started earlier. She did not describe any notable early shedding, but noted dry scalp and some dandruff as potential side effects.

Case 3: Male (age unknown), 60 days on topical minoxidil monotherapy (5% foam nightly)

This Redditor applied 5% minoxidil foam once nightly before bed for two months without any concurrent treatment. He reports the typical amount applied daily as “one cap-full”, rinsed out the next morning. The user has Crohn’s disease with prior nutrient absorption issues, and chose to avoid ifnasteride due to side-effect concerns. He had about one year of noticeable thinning before starting. Upon starting minoxidil, shedding increased for the first two weeks, then eased. The first measurable improvement was visible by day 30, with clear density gains at day 60. The crown region improved the fastest, while hairline changes were slower.

Case 4: Female (age unknown), 1 year 5 months on topical minoxidil foam (5% once daily)

This user had AGA with prior telogen effluvium, reporting diffuse thinning along the part and temples and a reportedly high daily shedding. She began therapy with Rogaine Men’s Foam 5% once nightly, supported by Ketoconazole 2% shampoo once weekly. At 2 months of treatment, “peach fuzz”/baby hairs were visible at the hairline and temples. At 6 months, there was a noticeable density across the top with new hairs evident but still short. After 1 year and 5 months of therapy, she notes ongoing thickening and widespread new hair growth. She also reported that her shower shed decreased from ~70 hairs to ~10-15, with visual density improving at the part and temples. She reported a mild scalp itch at the start and subtle peach-fuzz on the upper lip and chin as side effects. 

Case 5: Male (age unknown), 2.5 months on topical minoxidil (5% liquid 1 mL twice daily)

This male user, likely with AGA, reported recession at the hairline and thinning at the crown after 2.5 months of using a Rogaine-style 5% liquid at 2 mL/day, without any concurrent DHT blocker. He experienced an early shedding phase ~1 month into treatment, which stabilized with continued use. He exhibited visible thickening at the hairline and crown by 2.5 months of therapy. He did not report any systemic or local side effects and plans to continue minoxidil while considering adding weekly microneedling and/or topical finasteride if progression resumes. 

Other Redditors have used combination treatments to further improve their hair regrowth. As you can see below, some of the results look dramatic.

Case 6: Male (age unknown), 3 months on topical combo (minoxidil 5% and finasteride 0.1% once nightly)

This user had thinning at the hairline and vertex areas of the scalp and began treatment to improve hair density and maintenance. He applied a single compounded solution (Novegrow) containing minoxidil 5% and finasteride 0.1%, once nightly, for three months before reporting on progress. Additionally, he dermarolled his scalp with a 0.5 mm needle twice weekly and supplemented with daily biotin and a multivitamin. He reported mild shedding in the first two weeks of therapy, and by month 3, he noted visible thickening and improved coverage. He did not report any side effects and added that the once-daily schedule was practical and helped with adherence.

Case 7: Male (25), 11 months on combination therapy (finasteride 1 mg daily and topical minoxidil foam 5% once daily)

This Redditor exhibited typical AGA with frontal recession and diffuse vertex thinning. His core regimen is oral finasteride 1 mg daily and minoxidil 5% foam (Kirkland) once daily. He noted he took regular ice/cold baths, ensured an increased water intake, engaged in exercise, avoided junk food, and did not smoke. He saw noticeable thickening from around 6 months after several shedding cycles. By month 11, he experienced substantial cosmetic improvement, with some commenters even comparing the results to transplant-level density. He did not report any adverse effects from finasteride or minoxidil, and subjectively felt less “brain fog” after starting finasteride.

Case 8: Male (37), 4 months on topical minoxidil 5% and topical finasteride 0.1% (1 mL nightly)

This male had crown-predominant thinning with a stable hairline at baseline. His core regimen is a single combined solution containing minoxidil 5% and finasteride 0.1%, applied to the crown only. He did not report any microneedling or supplementation. He reported that shedding began around week 3 and was “heavy” for approximately 4 weeks. The shedding tapered and largely stopped at the 2.5-month mark. By month 4, he achieved visible crown regrowth and thickening compared to the baseline, despite the application being limited to the crown. He perceived an increase in overall density and did not report any side effects.

Case 9: Male (34), about 12 months on topical finasteride 0.3% and minoxidil 6% (twice daily)

This male reported on his progress after using a combination of topical finasteride 0.3% and minoxidil 6% treatment twice daily for nearly one year. He first experienced hair thinning and hairline recession beginning in his late 20s. Alongside the topical treatments, he also applied a dermastamp at approximately 1.5 mm every 10 days. He reported significant shedding during the first two months of treatment along with mild chest tenderness in the first month, which resolved after temporarily halving the topical dose. He reported month-on-month thickening, with clear improvement by months 7-8 and robust density by the one-year mark.

Case 10: Male (22), 90 days on finasteride 1 mg and minoxidil 5% twice daily plus dermarolling

This user with early temple recession began a combination therapy of finasteride 1 mg oral daily, minoxidil 5% foam twice daily, and dermaoll 1.5 mm weekly. He experienced noticeable shedding at weeks 3-6 of therapy, and at the 90-day progress mark, he reported visible filling in of the temple and general thickening of the hair. He did not report any side effects and noted that pushing through the initial shedding phase was crucial to his progress thus far.

Probable Regrowth Timeline

Based on the available evidence, we have mapped out a likely regrowth timeline (although some may experience results faster or later).

Months 0-3: Initial shedding

• Temporary shedding may occur as follicles shift into a new growth phase.
• This usually resolves within the first 4-8 weeks.

Months 3-6: Early cosmetic improvements

• Early visible improvements, such as reduced shedding and appearance of fine new hairs, can be expected.
• Thicker, darker regrowth starts to become apparent for most users during this period.

Months 6-12: Peak cosmetic changes

• Cosmetic changes peak, with stronger hair, increased density, and the greatest coverage observed.
• This is the period of maximum regrowth for most individuals.

Months 12+: Plateau, maintenance, & slight regression

• Further gains plateau, with 5-year studies showing hair counts remaining above baseline –– but with some loss in “peak” results from year one. Continued daily use is needed to maintain improvements, as stopping treatment leads to a gradual reversal within a few months.

Safety and Side Effects

Local side effects are relatively common with topical minoxidil, especially with the liquid formulations. The principal culprits are propylene glycol and ethanol, which frequently cause redness, itching, dryness, and a dandruff-like scaling of the scalp.{{Makhlouf, A., Elnawawy, T. (2023). Hair regrowth boosting via minoxidil cubosomes: Formulation development, in vivo hair regrowth evaluation, histopathological examination and confocal laser microscopy imaging. International Journal of Pharmacology. 634. 122665. Available at: https://doi.org/10.1016/j.ijpharm.2023.122665}} Patients with sensitive skin are particularly prone to these adverse reactions and may experience contact dermatitis, which can make long-term use uncomfortable.

The foam formulation is generally better tolerated because it lacks propylene glycol. Most clinical trials and user surveys report fewer cases of scalp irritation, itching, or flaking with foam compared to the liquid version.{{Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714}} 

While systemic absorption of topical minoxidil is rare, some users may experience unwanted side effects such as dizziness and the growth of facial or body hair away from the application site. These effects are more likely if the medication is used excessively or applied to broken or abraded skin, which can increase absorption. We do not recommend using topical products if you have an inflammatory scalp condition – deal with that problem first, and then take a look at topical hair regrowth products.

Overall, when used as directed, topical minoxidil has a strong safety profile, with most side effects limited to mild local irritation.

Practical Takeaways

• Topical minoxidil is effective and well-established, but clinical results vary between individuals.
• Most patients achieve stabilization of hair loss with modest regrowth, though complete restoration is uncommon.
• Response depends partly on scalp sulfotransferase enzyme activity, which explains why some non-responders see little or no improvement.
• Best results come with consistent, long-term use and may be enhanced by adjuncts such as microneedling or topical retinoids to improve absorption and efficacy.

Final Thoughts

When evaluating minoxidil, it is important to recognize it as the most widely accessible and evidence-backed treatment for androgenetic alopecia. While outcomes can vary, most users see stabilization and modest regrowth rather than dramatic reversal. Success depends on realistic expectations, consistent use, and optimized regimens that may include adjunctive therapies. Applying a framework that emphasizes the likely trendline over anecdotal extremes can help you stay committed, avoid discouragement, and make informed decisions grounded in evidence and personal treatment goals.

Ketoconazole shampoo has long been used for dandruff and seborrheic dermatitis, two common scalp conditions associated with flaking, itching, redness, and changes in the scalp microbiome. More recently, ketoconazole has gained attention among people with androgenetic alopecia (AGA). Human studies have reported reductions in shedding and improvements in hair-shaft diameter and anagen hair percentage, although the evidence for hair growth is still far smaller than that for established treatments like minoxidil and finasteride.{{Fields JR, Vonu PM, Monir RL, Schoch JJ. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Dermatol Ther. 2020;33(1):e13202. https://doi.org/10.1111/dth.13202}}

Ketoconazole shampoos typically come in 1% and 2% concentrations, with 2% only available as a prescription. Shampoo formulations can also vary significantly in surfactant content, fragrance, and overall tolerability. For people with thinning, dry, chemically treated, or easily damaged hair, those differences are as important as strength. In this guide, we compare the 10 best ketoconazole shampoos of 2026 across OTC, prescription, telehealth, and online pharmacy options to help you choose formulas that balance efficacy, tolerability, and convenience.

Ketoconazole Shampoo

The top natural ingredients for hair growth.

Take the next step in your hair growth journey with a world-class ketoconazole shampoo. Ingredients, doses, & concentrations built by science.

Shop Shampoo

Quick Look: Top 10 Ketoconazole Shampoos for 2026

Ulo Thickening+ Ketoconazole Shampoo	0.9%	Online / Provider-guided	Overall
Nizoral 2-in-1 Shampoo + Conditioner	1%	OTC	Conditioning
Nizoral Anti-Dandruff Shampoo	1%	OTC	OTC
Keeps Ketoconazole Shampoo	2%	Prescription / Telehealth	Men’s hair loss telehealth
Generic Ketoconazole Shampoo	2%	Prescription / Pharmacy	Value prescription
Strut Health Ketoconazole Shampoo	2%	Prescription / Telehealth	Men’s & women’s hair loss telehealth
EasyDerm Ketoconazole Shampoo	2%	Prescription / Teledermatology	Budget option
TelyRx Ketoconazole Shampoo	2%	Prescription / Telehealth	Fast online access
AlgoRx Ketoconazole Shampoo	2%	Prescription / Telehealth	Alternative telehealth
RedBox Rx Ketoconazole Shampoo	2%	Prescription / Telehealth	Low-cost telehealth

Before we get into our list, let’s take a look at what ketoconazole is, how it works, and why it has become increasingly popular among people with hair loss.

What Is Ketoconazole Shampoo?

Ketoconazole is an antifungal medication used to treat fungal and yeast-associated skin conditions. On the scalp, it’s used primarily for dandruff and seborrheic dermatitis, both of which are strongly associated with Malassezia yeasts. Malassezia normally lives on the scalp, but changes in yeast populations, sebum composition, barrier function, and inflammatory signaling can contribute to symptoms. Ketoconazole works by interfering with ergosterol synthesis, an important component of fungal cell membranes, which helps reduce Malassezia populations.

The anti-dandruff effects of ketoconazole are well established. In one multicenter study of patients with seborrheic dermatitis or moderate to severe dandruff, 2% ketoconazole shampoo used twice weekly for two to four weeks produced an excellent response in a large majority of participants. {{Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995;132(3):441-445. https://doi.org/10.1111/j.1365-2133.1995.tb08680.x}} Another randomized study compared 2% ketoconazole with 1% zinc pyrithione in 331 people with severe dandruff or seborrheic dermatitis. Both worked, although ketoconazole produced a greater reduction in total dandruff severity after four weeks.{{Piérard-Franchimont C, Goffin V, Decroix J, Piérard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Physiol. 2002;15(6):434-441. https://doi.org/10.1159/000066452}} Thus, for dandruff and seborrheic dermatitis, ketoconazole has a strong body of evidence to support its use.

What Evidence Is There for Ketoconazole in Hair Loss?

There is less evidence for ketoconazole as a hair-loss treatment than for its efficacy in dandruff treatment. Nevertheless, a few human studies have reported improvements in hair shedding, hair-shaft diameter, and the proportion of hairs in anagen, particularly in men with androgenetic alopecia and dandruff.

Study One

One of the longest studies followed 39 men with AGA for 21 months. Twenty-seven used 2% ketoconazole shampoo two to four times weekly, while 12 used an unmedicated shampoo. Researchers also followed 22 age-matched men without AGA, split between ketoconazole and unmedicated shampoo, to see whether any change was specific to people with pattern hair loss.

Based on the study, the researchers created an AGA pilary index, which combined the number of hairs in anagen with average hair-shaft diameter. Because both measures tend to deteriorate as AGA progresses, a rising index would suggest an improvement in the overall condition.

Results

Among men without AGA, shampoo choice made little difference to the pilary index. Among men with AGA, however, the treatment appeared to have a beneficial effect. The unmedicated-shampoo group showed a gradual decline, while the ketoconazole group began to improve after roughly six months, plateauing around month 15.{{Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474-477. https://doi.org/10.1159/000017954}}

Study Two

A second study looked at 150 men with telogen effluvium related to AGA and associated dandruff. Participants were randomized to use one of three anti-dandruff shampoos — 1% ketoconazole, 1% piroctone olamine, or 1% zinc pyrithione — two to three times weekly for six months.

Researchers tracked hair shedding, hair density, anagen percentage, hair-shaft diameter, and sebum output as their parameters for treatment efficacy (or lack thereof).

Results

All three shampoos rapidly improved itching and dandruff, but none produced a meaningful change in hair density. The more notable changes were in shedding, anagen percentage, and hair-shaft diameter.

Hair shedding fell by 17.3% with ketoconazole, 16.5% with piroctone olamine, and 10.1% with zinc pyrithione. Anagen percentage increased by 4.9%, 7.9%, and 6.8%, respectively. Mean hair-shaft diameter increased by 5.4% with ketoconazole and 7.7% with piroctone olamine, while it decreased by 2.2% with zinc pyrithione. Sebum output fell by 4.8% with ketoconazole and 2.9% with piroctone olamine, but increased by 5.5% with zinc pyrithione.

In this study, 1% ketoconazole had no measurable effect on total hair density, but it did reduce shedding, increase the proportion of hairs in anagen, and increase average shaft diameter. For someone with dandruff plus shedding, those are potentially useful effects even without a significant increase in hair count.{{Piérard-Franchimont C, Goffin V, Henry F, Uhoda I, Braham C, Piérard GE. Nudging hair shedding by antidandruff shampoos: a comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. Int J Cosmet Sci. 2002;24(5):249-256. https://doi.org/10.1046/j.1467-2494.2002.00145.x}}

Other Studies

Ketoconazole has also been tested as a component of combination regimens. In one open randomized study of 100 men with AGA, the best results were seen with finasteride plus minoxidil, followed by finasteride plus ketoconazole, finasteride alone, and minoxidil alone. {{Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29(8):489-498. https://doi.org/10.1111/j.1346-8138.2002.tb00314.x}}

A separate 15-man pilot study used a much more aggressive multidrug regimen that could include ketoconazole shampoo alongside finasteride, dutasteride, and minoxidil. All participants showed hair growth, but because several treatments were used at the same time, it is impossible to determine how much ketoconazole contributed individually.{{Rafi AW, Katz RM. Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. ISRN Dermatology. 2011:241953. https://doi.org/10.5402/2011/241953}}

Altogether, the evidence from human studies suggests that ketoconazole may improve certain hair-loss-related outcomes, particularly shedding, anagen percentage, and hair-shaft diameter. The evidence is still much weaker than for minoxidil, finasteride, or dutasteride, making it a reasonable adjunct but not a standalone therapy.

1% versus 2% Ketoconazole Shampoo

In the United States, ketoconazole shampoos are available over the counter but are limited to 1% or less ketoconazole. Shampoos containing 2% ketoconazole are available by prescription. Based on the available evidence, both 1% and 2% help to control dandruff, seborrheic dermatitis, and other inflammatory scalp conditions. The Rx-strength 2%, however, outperforms the 1% concentration for supporting scalp health and may also have an advantage for hair density.

The overall formulation of the shampoo also matters. Ketoconazole must be tolerable enough for consistent use, particularly for people already using topical hair-loss treatments that can cause dryness or irritation. While 1% ketoconazole formulations generally have more ingredient flexibility due to their over-the-counter status, prescription formulas generally contain the same generic ingredients across the board.

With that in mind, let’s take a look at our top 10 ketoconazole shampoos of 2026.

Best Ketoconazole Shampoos

#1 Best Overall: Ulo Thickening+ Ketoconazole Shampoo

✓ Contains 0.9% ketoconazole	✗ Lower ketoconazole concentration than prescription 2% shampoos
✓ Sulfate-free	✗ Less widely available than traditional OTC shampoos
✓ Formulated to be non-drying
✓ Designed specifically for thinning hair
✓ The only ketoconazole shampoo with caffeine
✓ Integrated with a hair loss treatment platform

Ulo’s Thickening+ Ketoconazole Shampoo is our go-to option for people who want to add ketoconazole to a broader hair-loss routine. It contains 0.9% ketoconazole in a sulfate-free base designed to be non-drying, which sets it apart from many traditional medicated shampoos that can leave the hair feeling dry, brittle, or difficult to manage.

Dryness itself does not accelerate androgenetic alopecia, but brittle or coarse hair can increase breakage that may affect the appearance of hair. For someone using ketoconazole several times per week, cosmetic tolerability is an important factor in treatment adherence.

Ulo also formulates the shampoo specifically for thinning hair, including additional supportive ingredients like caffeine, saw palmetto, and rosemary. The addition of these beneficial ingredients make it the most robust formulation on the list. At 0.9%, the ketoconazole concentration is slightly below the conventional 1% concentration, but it likely approximates the effect of 1% ketoconazole.

Ulo’s broad hair-loss telemedicine platform also provides additional treatments for hair loss, making it easy to access ketoconazole and other medications in one place.

Bottom Line: Ulo is our top overall option for people using ketoconazole as part of a longer-term hair-loss routine. Its gentle, sulfate-free formula approximates the 1% concentration seen in clinical studies for a shampoo that maximizes tolerability for long-term adherence. Ulo’s broader telemedicine platform makes it simple to access hair-loss medications alongside ketoconazole shampoo.

#2 Nizoral 2-in-1 Shampoo + Conditioner

✓ Contains 1% ketoconazole	✗ May still be drying compared with a dedicated conditioner
✓ Available without a prescription	✗ Contains sulfates
✓ More conditioning than standard Nizoral
✓ Designed to leave hair softer and more manageable

Nizoral 2-in-1 combines 1% ketoconazole with a more conditioning shampoo base, making it our preferred OTC option for people who like ketoconazole but dislike the way traditional medicated shampoos leave their hair feeling. It is intended for twice-weekly use and is marketed for color-treated, chemically processed, and gray hair.

However, the formula still contains sulfates and may still be relatively drying. Online reviews are mixed when it comes to post-wash dryness.{{Walmart customer reviews. https://www.walmart.com/reviews/product/5761431665}}

Importantly, a 2-in-1 formula will not replace a dedicated conditioner for everyone, particularly if the mid-lengths and ends are already very dry or damaged.

Bottom Line: If standard ketoconazole works for your scalp but leaves your hair feeling too dry, Nizoral 2-in-1 offers the same 1% ketoconazole concentration in a more conditioning format. However, the formula does contain sulfates, and overall customer experiences with post-shower hair feel are mixed.

#3 Nizoral Anti-Dandruff Shampoo

✓ 1% ketoconazole available without a prescription	✗ May be drying for some hair types
✓ Strong clinical evidence for dandruff	✗ Contains drying sulfates
✓ Widely available in the U.S.

Nizoral Anti-Dandruff Shampoo is one of the most established ketoconazole shampoos available in the United States. It contains 1% ketoconazole and can be purchased without a prescription, making it a straightforward option for people who want to treat dandruff without going through a provider.

The main drawback of Nizoral is tolerability. Nizoral contains sulfates as its main surfactants, which can be drying to the hair and scalp. This may be an obstacle to long-term use.

Bottom Line: Nizoral Anti-Dandruff Shampoo remains one of the easiest ways to try clinically established 1% ketoconazole without a prescription, although dry or easily damaged hair may do better with a more conditioning formula.

#4 Keeps Ketoconazole Shampoo

✓ Prescription-strength 2% ketoconazole	✗ Requires a prescription
✓ Integrated telehealth platform	✗ Only available for men
✓ Accessible pricing
✓ Delivered directly to the patient

Keeps offers prescription 2% ketoconazole shampoo through its telehealth hair-loss platform. It is intended for people who want a higher-strength option, particularly when over-the-counter treatment has not been sufficient or a protocol targeted toward hair density is desired. At $11 per month, it’s one of the more accessibly priced ketoconazole shampoos.

Keeps also makes sense for people who already use the platform for another hair-loss treatment. The convenience is the main selling point: Eligible users can complete the medical consultation online and have the prescription handled through the same platform.

However, Keeps does not provide its telehealth services to women. Women looking to use Rx-strength ketoconazole shampoo will need to look elsewhere.

Bottom Line: Keeps is a strong option for people who want 2% ketoconazole inside an existing telehealth hair-loss regimen, especially when OTC treatment has not been enough or a higher concentration is preferred for individual goals. However, Keeps is only available for men.

#5 Generic Ketoconazole Shampoo

✓ Prescription-strength 2% ketoconazole	✗ Requires a prescription in the U.S.
✓ Insurance may cover treatment and pharmacies may offer specific discount pricing	✗ Traditional formulations may be drying
✓ Easy to access for those already seeing a physician	✗ Less convenient if you don’t have access to a physician

Generic 2% ketoconazole is the simplest prescription option for people who already have access to a healthcare provider or health insurance. Pharmacies may have specific discount pricing or insurance may cover the cost of treatment, making it one of the most accessible options for specific individuals.

Like others, the generic shampoo formulations likely contain sulfates that could be drying with consistent use. Appointment wait times and physician access may also be an impediment to medication access, compared to telehealth, which typically rolls prescription and pharmacy fulfillment into one convenient service.

Bottom Line: If you already have prescription access and simply want 2% ketoconazole without added treatment features, generic ketoconazole is the best option on this list.

#6 Strut Health Ketoconazole Shampoo

✓ Prescription-strength 2% ketoconazole	✗ Requires online medical review
✓ Available for both men and women	✗ No major formulation advantage over standard 2% ketoconazole shampoo
✓ Starts at $25 for 120 mL
✓ Can be paired with other hair loss treatments through their telehealth platform

Strut offers 2% ketoconazole through its telehealth platform for both men and women, which makes it one of the more flexible telehealth options on this list. A 120 mL bottle currently starts at $25, and the online process includes physician review, direct shipping, and access to other prescription hair-loss treatments through the same platform. Like other shampoos in the list, it likely contains sulfates that may contribute to hair dryness.

Bottom Line: Strut is a strong 2% option for men and women who want prescription ketoconazole integrated into a broader telehealth hair-loss routine.

#7 EasyDerm Ketoconazole Shampoo

✓ Prescription-strength 2% ketoconazole	✗ Narrower hair-loss treatment platform
✓ $15/month listed price	✗ Generic formula may be drying
✓ Dermatologist-reviewed treatment
✓ 120 mL listed as a three-month supply

EasyDerm is one of the most accessible ketoconazole shampoos. Its 2% ketoconazole shampoo is currently listed at $15 per month, and is available for both men and women. Treatment is reviewed by a licensed dermatologist and shipped directly to the patient.

For someone whose main goal is getting prescription-strength ketoconazole at a low advertised monthly price, EasyDerm has a clear advantage. However, compared to other telehealth platforms, the breadth of its hair-loss treatments is narrower and there is no formulation advantage over other shampoos.

Bottom Line: EasyDerm is our best budget teledermatology option for 2% ketoconazole, particularly for people who want a dermatologist review without paying the higher monthly cost of some hair-loss platforms.

#8 TelyRx Ketoconazole Shampoo

✓ 2% ketoconazole	✗ $22 provider review fee for new prescriptions
✓ No prior prescription needed to start	✗ Standard generic formulation rather than a hair-focused shampoo
✓ Licensed-provider review available online
✓ HSA/FSA eligible

TelyRx is built around fast prescription access rather than a hair-loss program. It currently offers generic 2% ketoconazole shampoo at $38.99 for a 120 mL bottle. Patients who do not already have a prescription can complete an online health assessment and pay a one-time $22 provider review fee, while patients with an existing prescription can transfer it directly. But, unlike other telehealth platforms, a broad range of treatment options for hair loss is not available.

Bottom Line: TelyRx is a convenient option for fast online access to generic 2% ketoconazole, especially for people who want to avoid scheduling a traditional office visit.

#9 AlgoRx Ketoconazole Shampoo

✓ Prescription-strength 2% ketoconazole	✗ Higher total cost once review and shipping are included
✓ Fully online clinical review	✗ Generic formula likely contains sulfates
✓ Integrated with a broader hair-loss and general-health telemedicine platform
✓ HSA/FSA eligible

AlgoRx offers 2% ketoconazole through a fully online prescription process and positions the shampoo within its broader telehealth platform. The product is available as a 120 mL bottle, with a one-time purchase currently listed at $45 and subscription medication pricing listed at $39.60 before provider review ($15) and shipping charges ($15), making it one of the more expensive options on this list. The main benefit is convenience for people who already use AlgoRx or want ketoconazole alongside other hair-loss treatments or treatments for other aspects of health.

Bottom Line: AlgoRx is a reasonable 2% telehealth option for people who value an integrated hair-loss and general-health telemedicine platform, but the shampoo itself remains a generic formulation with no distinct advantages over other options.

#10 RedBox Rx Ketoconazole Shampoo

✓ Prescription-strength 2% ketoconazole	✗ $25 consultation fee
✓ $20/month medication-equivalent pricing	✗ Focused on dandruff rather than broader hair-loss treatment
✓ Online doctor consultation
✓ Free shipping and HSA/FSA eligibility

RedBox Rx offers 2% ketoconazole through an online consultation, with transparent pricing and direct-to-home delivery. Its price at the time of writing is $60 for two 120 mL bottles. However, there is also a one-time $25 fee for an online doctor consultation, bringing the total to $85. Compared to other options, it’s a higher-cost option with no distinct formulation differentiation. Moreover, the breadth of hair-loss treatments offered on the telehealth platform is more limited than other telehealth platforms.

Bottom Line: RedBox Rx is a pricier route to prescription 2% ketoconazole with online medical review, and it offers fewer hair-loss-specific features than the platforms ranked above it, with minimal differentiation for formulation.

How Often Should You Use Ketoconazole Shampoo?

Ketoconazole shampoos do not need to be used every day. In fact, with sulfate-containing formulations, daily use could cause excessive dryness of the hair or scalp. Most clinical studies have employed frequencies of two to three times per week. In the 176-person study of 1% ketoconazole, participants applied the shampoo twice weekly for four weeks.{{Go IH, Wientjens DP, Koster M. A double-blind trial of 1% ketoconazole shampoo versus placebo in the treatment of dandruff. Mycoses. 1992;35(3-4):103-105. https://doi.org/10.1111/j.1439-0507.1992.tb00828.x}} The larger 2% study involving 575 participants also used ketoconazole twice weekly for two to four weeks. Responders could then move to less-frequent maintenance, with once-weekly treatment reducing relapse compared with placebo.{{Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995;132(3):441-445. https://doi.org/10.1111/j.1365-2133.1995.tb08680.x}}

Directions also vary by product and company. TelyRx advises users to leave its ketoconazole shampoo on for about five minutes before rinsing, and Keeps similarly recommends approximately five minutes of contact time.{{TelyRx. Ketoconazole Shampoo, 2%. https://telyrx.com/ketoconazole-shampoo. Accessed September 2026.)}}{{Keeps. Ketoconazole Shampoo 2%. https://www.keeps.com. Accessed September 2026.)}}

Many shampoo formulations preclude more consistent use due to the drying effects of sulfates. However, gentler formulas like Ulo’s Thickening+ Ketoconazole Shampoo can be used as often as daily without the drying effects of sulfates. That said, whether daily use provides a significant advantage over two to three times weekly has yet to be proven.

Why Formulation Matters

Ketoconazole concentration is one important factor in treatment, but overall formulation also plays a role. Surfactant content (and the type of surfactants used) determines how aggressively a shampoo removes oil and debris, conditioning agents affect how the hair feels afterward, and fragrances, preservatives, and other ingredients can all influence tolerability.

This is relevant because dryness is one of the most common complaints with traditional medicated shampoos. A 2026 randomized comparison of selenium disulfide with 2% ketoconazole specifically noted that anti-dandruff shampoos can leave hair dry and difficult to manage, which may affect adherence.{{Farris PK, Barbosa V, Houshmand EB, Kovylkina N. Beyond efficacy: 0.6% selenium disulfide shampoo matches 2% ketoconazole for seborrheic dermatitis with superior cosmesis. J Drugs Dermatol. 2026;25(4):338. https://jddonline.com/articles/beyond-efficacy-06-selenium-disulfide-shampoo-matches-2-ketoconazole-seborrheic-dermatitis-with-superior-cosmesis-S1545961626P9746X/}}

For people with androgenetic alopecia, this is more than a minor cosmetic detail. Dry, brittle, or frizzy hair can make existing thinning look worse even when existing density has not changed. Brittle hair can also contribute to breakage from styling, which may affect hair appearance and fullness, especially in individuals with longer hair.

How Safe Is Ketoconazole Shampoo?

Topical ketoconazole is generally well tolerated. A systematic review of 40 studies involving 4,566 participants found topical ketoconazole to be clinically effective for Malassezia-associated skin conditions and generally safe, although allergic contact dermatitis can occur.{{Choi FD, Juhasz MLW, Atanaskova Mesinkovska N. Topical ketoconazole: a systematic review of current dermatological applications and future developments. J Dermatol Treat. 2019;30(8):760-771. https://doi.org/10.1080/09546634.2019.1573309}}

Potential local side effects include the following:

• Dryness
• Scalp irritation
• Itching
• Burning or stinging
• Changes in hair texture
• Contact dermatitis

Prescription ketoconazole labeling also lists dry skin, skin irritation, and changes in hair texture among possible adverse effects.{{Keeps. Ketoconazole Shampoo 2%. https://www.keeps.com. Accessed September 2026.}} It should be noted that irritation is not necessarily caused by ketoconazole itself. Surfactants, fragrance, preservatives, and other ingredients can independently contribute to dryness or irritation. If ketoconazole shampoos cause irritation, it may be worth shopping around to find a formula that works for your hair before giving up on ketoconazole altogether.

Final Verdict

Ketoconazole is one of the better-supported medicated shampoo ingredients for dandruff, seborrheic dermatitis, and scalp inflammation. There is also some evidence suggesting that it may support hair growth in people with androgenetic alopecia, including reductions in shedding and improvements in hair-shaft diameter and percentage of anagen hairs. However, the evidence is still much smaller than what exists for more established treatments like minoxidil, finasteride, and dutasteride.

The best ketoconazole shampoo therefore depends on your goals and preferences. For more severe dandruff or seborrheic dermatitis, a 2% prescription formula may make the most sense. For milder dandruff, or for someone using ketoconazole alongside a long-term hair-loss routine, formulation and tolerability are of more importance, particularly if dryness makes consistent use difficult.

Ulo Thickening+ Ketoconazole Shampoo is our top pick because it combines 0.9% ketoconazole with a sulfate-free formula designed specifically for thinning hair. The sulfate-free formulation seeks to maximize tolerability and minimize obstacles to treatment adherence. Nizoral 2-in-1 and Nizoral Anti-Dandruff Shampoo are also notable OTC options, while Keeps, generic ketoconazole, Strut, EasyDerm, TelyRx, AlgoRx, and RedBox Rx all provide different routes to prescription-strength 2% ketoconazole.

Ultimately, ketoconazole is best utilized as a complementary treatment rather than a standalone solution for androgenetic alopecia. The evidence for its use is strongest for dandruff and seborrheic dermatitis, with the 2% concentration demonstrating a positive effect on hair density. However, its benefits, like all approaches to addressing hair loss, are dependent on consistency. A ketoconazole shampoo should therefore be selected based on your needs and preferences, including factors like tolerability or severity of existing scalp conditions. The good news is that there are now enough over-the-counter, prescription, and telehealth options that you should be able to find a solution that fits your scalp, hair type, treatment goals, and tolerance for long-term use.

The hair loss industry is rife with quick-fix solutions, fleeting fads, and ineffective natural supplements. There are, however, tried-and-tested prescription medications that can reliably combat hair loss and promote regrowth. Does this mean we can rely on Rx vendors to always provide safe, dependable, and evidence-based treatments? Unfortunately, the world of prescription hair loss medication can be prone to the same issues that plague over-the-counter solutions. What’s worse, Rx drugs pose a real danger of severe side effects.

Happy Head is a telehealth company specializing in hair-loss medications. For many years, we happily recommended their products: they provided proven treatments and were one of the only places to find effective options like topical dutasteride. Unfortunately, issues have become apparent that are typical of wider problems with the hair loss industry.

If you’ve been using Happy Head and are pleased with the results, there should be nothing to worry about. Their offerings of minoxidil, finasteride, and dutasteride, among others, are powerful tools against hair loss and can drive real, meaningful improvements.

However, their model has critical oversights, some involving consumer safety, and after years of voicing our concerns with no changes, we were inspired to launch Ulo to fix these exact problems. This article will detail the six major reasons why we lost faith in recommending them to our readers.

Interested in Topical Dutasteride?

Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Concern #1: Genetic Testing for Hair Loss Treatments

In an industry with a limited number of established pharmaceutical options, it can be hard to stand out. Happy Head’s unique selling point is its DNA Kit and Customized Hair Growth Treatment, which, they claim, reveals which treatments will work for your unique DNA. 

The pitch is this: there are certain gene variants that underlie how hair loss develops, and others that can predict how well hair loss drugs will work. For $298, Happy Head provides a home DNA test; you take a swab and send it back for analysis. This enables them to generate reports on your personal genetic makeup and recommend treatments accordingly.

They provide two reports:

• Hair and Scalp Report – This identifies “Genetic predispositions for 33 hair, scalp, and related micronutrient traits.”
• Treatment Insight Report – Identifying “14-16 genetic traits for medication sensitivity and baldness patterns.”

It sounds impressively technical, but what is the science behind this “breakthrough innovation”?

The Genetics of Hair Loss

It’s important to note that genetic factors are heavily involved in our predisposition to hair loss. Androgenic alopecia (AGA) is highly heritable, with family studies suggesting genetics account for around 80% of predisposition in men. It is, however, a polygenic trait, meaning that many genes each contribute small effects rather than a single “baldness gene.”{{Heath, A. C., Nyholt, D. R., Gillespie, N. A., & Martin, N. G. (2003). Genetic basis of male pattern baldness. *Journal of Investigative Dermatology.* 121(6). 1561–1564. Available at: https://doi.org/10.1111/j.1523-1747.2003.12615.x}}

AGA is driven by hormonal activity: as levels of an androgen called dihydrotestosterone (DHT) rise, it can cause miniaturization of hair follicles that progressively shortens the hair growth phase, leading to hairs that are thin, short, and sparse.{{Trüeb, R. M. (2002). Molecular mechanisms of androgenetic alopecia. *Experimental Gerontology.* 37(8–9). 981–990. Available at: https://doi.org/10.1016/S0531-5565(02)00093-1}} Because of this association with androgen activity, the androgen receptor locus (region of DNA) is most heavily associated with hair loss.{{Sadasivam, I. P., Sambandam, R., Kaliyaperumal, D., & Dileep, J. E. (2024). Androgenetic alopecia in men: An update on genetics. *Indian Journal of Dermatology.* 69(3). 282. Available at: https://doi.org/10.4103/ijd.ijd_729_23}}

Other genes involved in androgen activity, such as SRD5A2, which plays a role in androgen metabolism, are also associated with susceptibility to hair loss. Genes involved in other pathways important to hair follicle development, such as the WNT pathway, may also play a role.{{Gupta, A. K., Dennis, D. J., Economopoulos, V., & Piguet, V. (2026). The genetic landscape of androgenetic alopecia: Current knowledge and future perspectives. *Biology.* 15(2). 192. Available at: https://doi.org/10.3390/biology15020192}} 

This research may tell us how likely someone is to develop AGA as they grow older. Of course, for most people already seeking treatment for AGA, this information isn’t particularly useful. Clinical diagnosis is typically based on the appearance of the hair, scalp examination, and family history, rather than on genetic tests. However, there are some cases where genetic insights might be useful. 

Treatments that target hormonal aspects of AGA, like finasteride and dutasteride, won’t work for other causes of hair loss. Some hair loss is the result of nutrient deficiencies, many of which are caused by genetic variation. For example, biotin deficiency can lead to alopecia because biotin is essential for keratin production, a key component of hair. Mutations in the BTD gene, encoding an enzyme called biotinidase, which is essential for the body to use biotin, can therefore cause hair loss. However, most biotin deficiencies are diagnosed in children, and hair loss is apparent from a young age.{{Yang, Y., Yang, J. Y., & Chen, X. J. (2020). Biotinidase deficiency characterized by skin and hair findings. *Clinics in Dermatology.* 38(4). 477–483. Available at: https://doi.org/10.1016/j.clindermatol.2020.03.004}} 

The autoimmune condition alopecia areata may also have a genetic basis, and predispositions have been identified in genes involved in the immune system.{{Biran, R., Zlotogorski, A., & Ramot, Y. (2015). The genetics of alopecia areata: new approaches, new findings, new treatments. *Journal of Dermatological Science.* 78(1). 11–20. Available at: https://doi.org/10.1016/j.jdermsci.2015.01.004}}

The Hair and Scalp Report provided by Happy Head after DNA testing lists genetic predispositions for 33 traits, ranging from autoimmune hair loss (e.g., alopecia areata) to scalp hydration and vitamin deficiencies. If you thought you had AGA, but instead had a different cause of hair loss, some insight into the underlying genetics could prove useful in rare cases. 

However, clinicians typically distinguish among different forms of alopecia by physical examination and, in rare cases, by blood tests. If you want to understand your hair loss, visiting a physician is a far more reliable route. What’s more, the Rx products that Happy Head offers require a diagnosis prior to being prescribed, so you will have to see a healthcare practitioner regardless of your underlying genetics.

Can Genetics Predict Responses to Hair Loss Drugs?

The main promise of Happy Head’s genetic testing is that it can identify “which treatments will work for your unique DNA”. Given the range of options available to people suffering from hair loss and the sometimes unpredictable nature of treatment responses, it’s an enticing prospect. But does the science back up Happy Head’s bold claims?

We’ve investigated the potential of genetic testing for personalized hair loss treatment before, and you can read our in-depth report here.

Happy Head provides a Treatment Insight Report, which highlights “14-16 genetic traits for medication sensitivity and baldness patterns”. Helpfully, the company has detailed these genetic traits, the associated genes, and the studies supporting their use, so we can assess how powerful their predictions might be. You can find the full list here.

What Does the Genetic Test Actually Look At?

The test assesses the presence of a kind of genetic variation called single-nucleotide polymorphisms (SNPs, normally pronounced “snips”). DNA is made up of genes, which in turn are comprised of individual units called nucleotides. When a gene is “read”, the sequence of nucleotides will determine what protein is made, and therefore what effect the gene will have. SNPs are variations in these nucleotides; change the nucleotide, and you might change the impact of the gene.{{Nelson, M. R., Marnellos, G., Kammerer, S., Hoyal, C. R., Shi, M. M., Cantor, C. R., & Braun, A. (2004). Large-scale validation of single nucleotide polymorphisms in gene regions. *Genome Research.* 14(8). 1664–1668. Available at: https://doi.org/10.1101/gr.2421604}},{{National Human Genome Research Institute. (n.d.). Single nucleotide polymorphisms (SNPs). *Genome.gov.* Available at: https://www.genome.gov/genetics-glossary/Single-Nucleotide-Polymorphisms-SNPs}}

For example, if we know that a SNP changes the activity of a gene involved in drug metabolism, we might be able to predict how well certain drugs are going to work. 

We’ll take a look at the “genetic traits” identified in the Happy Head test and see if SNPs in the genes they assess might have predictive power. Most of these traits are related to drug efficacy: “Minoxidil Effectiveness”, “ Dutasteride Metabolism”, etc. 

Which SNPs Can Predict Response to Therapy?

First, we’ll take a look at the limited cases where SNPs might actually provide some insight.

Minoxidil is FDA-approved for androgenic alopecia and is a reliable treatment with many years of clinical evidence. However, the efficacy of minoxidil can be unpredictable, and one source of the variation in response has been identified: an enzyme called SULT1A1. For minoxidil to work, it needs to first be converted into minoxidil sulfate in the body. This conversion is performed by sulfotransferases, most notably SULT1A1.

Consequently, the amount of SULT1A1 in the scalp may predict the amount of active minoxidil.{{Pietrauszka, K., & Bergler-Czop, B. (2022). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Advances in Dermatology and Allergology / Postępy Dermatologii i Alergologii. 39(3). 472–478. Available at: https://doi.org/10.5114/ada.2020.99947}} Therefore, the gene that produces SULT1A1, also called SULT1A1 (gene names get italicised), could impact minoxidil efficacy.

One study found that a SNP in the SULT1A1 gene can alter the activity of the enzyme.{{Yu, X., Dhakal, I. B., Beggs, M., Edavana, V. K., Williams, S., Zhang, X., Mercer, K., et al. (2010). Functional genetic variants in the 3′-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. *Toxicological Sciences.* 118(2). 391–403. Available at: https://doi.org/10.1093/toxsci/kfq296}} However, they also concluded that this genetic variation can’t account for the differences in SULT1A1 activity observed in the total population. 

The key factor in the efficacy of minoxidil is the activity of SULT1A1 in the scalp. Having the gene that makes a certain enzyme doesn’t mean that it’s expressed (turned on) in all the cells and tissues in the body. As such, there are likely to be multiple underlying mechanisms for differences in SULT1A1 activity in the scalp. Still, the evidence suggests that variations in the SULT1A1 gene could predict minoxidil activity. 

There is also limited evidence that certain genes may be linked to responsiveness to dutasteride. A 2019 study looked at SNPs across the whole genomes of men who had taken dutasteride and assessed if specific genes correlated with response.{{Rhie, A., Son, H.-Y., Kwak, S. J., Lee, S., Kim, D. Y., Lew, B.-L., Sim, W.-Y., et al. (2019). Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia. *PLoS One.* 14(9). e0222533. Available at: https://doi.org/10.1371/journal.pone.0222533}}

From a sample of 42 men, the researchers looked for genes in which SNPs most commonly occurred among the best and worst responders. They identified a handful of genes that may be associated with response to dutasteride.

The sample size is quite small, and the correlation between the presence of SNPs and response to dutasteride isn’t that strong. Importantly, the predictive power of the identified genes is cumulative: the model the researchers used considers multiple genes simultaneously, rather than the predictive power of SNPs in individual genes. 

The Happy Head Treatment Insights include four of the six genes most associated with dutasteride effectiveness in the study. However, these are spread over three different “traits”. The predictive power of their model is therefore likely to be weak. However, the evidence does provide some scientific basis for the insights from the genetic test.

How Strong is the Evidence Overall?

We’ve looked at two examples where elements of Happy Head’s “genetic traits” might have some predictive power. SULT1A1 expression is likely associated with minoxidil efficacy, whereas genetic determinants of dutasteride efficacy would require stronger, more robust models that incorporate multiple genes to have any predictive value. 

So what about the evidence supporting the other traits? Unfortunately, the DNA testing approach for personalized hair loss plans is largely based on over-extrapolation from data with little or no link to hair loss.

For example, Trait #5, Finasteride Effectiveness, lists SRD5A1 and SRD5A2 as genes related to this trait. The literature cited includes research that shows these genes are associated with prostate cancer and benign prostate hyperplasia, and one study that suggests variations in SRD5A2 can be associated with decreased risk of hair loss.{{Hayes, V. M., Severi, G., Padilla, E. J. D., Morris, H. A., Tilley, W. D., Southey, M. C., English, D. R., et al. (2007). 5α‐reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. *International Journal of Cancer.* 120(4). 776–780. Available at: https://doi.org/10.1002/ijc.22408}},{{Li, X., Huang, Y., Fu, X., Chen, C., Zhang, D., Yan, L., Xie, Y., Mao, Y., & Li, Y. (2010). Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer. *Mutagenesis.* 26(3). 371–383. Available at: https://doi.org/10.1093/mutage/geq103}}  

The implication is that, because SRD5A2 is associated with higher DHT levels, this would increase finasteride efficacy, as finasteride inhibits DHT. However, there is no clinical evidence at all to suggest this is the case. 

Happy Head also cites a review paper that outlines some ways genetic markers could provide personalized AGA medicine. Interestingly, the authors of the paper work for a company called Fagron Genomics, which manufactures genetic tests for personalized AGA medicine.{{Vila-Vecilla, L., Russo, V., & Torres de Souza, G. (2024). Genomic markers and personalized medicine in androgenetic alopecia: a comprehensive review. *Cosmetics.* 11(5). 148. Available at: https://doi.org/10.3390/cosmetics11050148}}

Trait #9 is Topical Retinoic Acid Effectiveness, which lists associated genes as CRABP2, CYP26B1, and RXRG. Retinoic acid is a common additive in hair loss, especially in the form of tretinoin. However, the research cited by Happy Head to support the use of these genes for prediction has no relation to hair loss or AGA. One paper discusses CRABP2 in skin aging, while another highlights the role of CYP26 in cancer.{{Bielli, A., Scioli, M. G., D’Amico, F., Tarquini, C., Agostinelli, S., Costanza, G., Doldo, E., et al. (2019). Cellular retinoic acid binding protein-II expression and its potential role in skin aging. *Aging (Albany NY).* 11(6). 1619. Available at: https://doi.org/10.18632/aging.101813}},{{Stevison, F., Jing, J., Tripathy, S., & Isoherranen, N. (2015). Role of retinoic acid-metabolizing cytochrome P450s, CYP26, in inflammation and cancer. *Advances in Pharmacology.* 74. 373–412. Available at: https://doi.org/10.1016/bs.apha.2015.04.006}} 

One study shows that changes in CRABP2 expression can increase serum retinoic acid levels in the umbilical cord of newborns. The relevance of the finding to hair loss is unclear.{{Manolescu, D. C., El-Kares, R., Lakhal-Chaieb, L., Montpetit, A., Bhat, P. V., & Goodyer, P. (2010). Newborn serum retinoic acid level is associated with variants of genes in the retinol metabolism pathway. *Pediatric Research.* 67(6). 598–602. Available at: https://doi.org/10.1203/PDR.0b013e3181dcf18a}}

The story is similar for the rest of the genetic traits: over-extrapolation of limited data from tangentially related studies. While genetic variation may be able to provide meaningful insights into hair loss drug efficacy in the future, there is currently insufficient data to back up Happy Head’s bold claims.

Concern #2: Topical Latanoprost

Latanoprost has become a popular component of topical hair loss treatments since a 2011 study suggested that it could increase hair density in men with AGA.{{Blume-Peytavi, U., Lönnfors, S., Hillmann, K., & Garcia Bartels, N. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. *Journal of the American Academy of Dermatology.* 66(5). 794–800. Available at: https://doi.org/10.1016/j.jaad.2011.05.026}} However, serious concerns have been raised about the drug’s long-term safety and efficacy. 

Originally developed as a medication for glaucoma, latanoprost was tested as a treatment for AGA when users of the drug noted increased hair growth in their eyelashes. The 2011 study demonstrated significant increases in hair counts and hair density for 0.1% topical latanoprost compared to placebo. However, 50% of men in the study didn’t show any improvement at all, or got worse.

Given these results from a small study (16 participants in total), a 2018 follow-up study compared latanoprost with minoxidil and explored combination therapies. Unfortunately, the study design was flawed, with high participant dropout rates and poorly defined study groups and procedures.{{Bloch, L. D., Escudeiro, C. C., Sarruf, F. D., & Sakai Valente, N. Y. (2018). Latanoprost and minoxidil: comparative double-blind, placebo-controlled study for the treatment of hair loss. *Surgical & Cosmetic Dermatology.* 10(1). 39–43. Available at: https://doi.org/10.5935/scd1984-8773.20181011015}}

Other studies investigating latanoprost for alopecia areata have proven inconclusive, with low response rates.{{Mehta, J. S., Raman, J., Gupta, N., & Thoung, D. (2003). Cutaneous latanoprost in the treatment of alopecia areata. *Eye.* 17(3). 444–446. Available at: https://doi.org/10.1038/sj.eye.6700354}},{{Faghihi, G., Andalib, F., & Asilian, A. (2009). The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. *European Journal of Dermatology.* 19(6). 586–587. Available at: https://doi.org/10.1684/ejd.2009.0766}}

As such, the verdict is still out on how effective latanoprost is at treating AGA and other hair loss conditions, with much more research required. Importantly, however, there are significant safety concerns associated with the drug. 

Long-term use of latanoprost in patients with glaucoma can cause changes in iris color. Clinical data suggest this affects around 10% of people after a year of use, though some studies indicate the incidence could be as high as 70%.{{Teus, M. A., Arranz-Marquez, E., & Lucea-Suescun, P. (2002). Incidence of iris colour change in latanoprost treated eyes. *British Journal of Ophthalmology.* 86(10). 1085–1088. Available at: https://doi.org/10.1136/bjo.86.10.1085}} Given the potential for systemic absorption of the drug when applied topically, or for the drug to enter the eyes when applied to the head, this could pose a risk for those using it as a hair loss cure. What’s more, hair loss treatments are typically taken consistently for many years, increasing lifetime exposure.

For glaucoma patients, the potential for changes in iris pigmentation is likely weighed against the benefits of a proven treatment for a debilitating condition. For those looking to treat hair loss, this risk is associated with a drug that is, so far, clinically unproven. In this context, the inclusion of latanoprost in hair-loss medications could be seen as irresponsible.

You can read our in-depth article about latanoprost here.

Concern #3: Propylene Glycol

The use of propylene glycol is a widespread problem in the hair growth industry. It’s used as an excipient, meaning it serves as an “inactive” ingredient that helps to stabilize the active drugs or increase their availability. For drugs like minoxidil, which is poorly water-soluble, propylene glycol helps keep the solution uniform and consistent. It can also enhance the penetration of drugs by affecting the barrier of the stratum corneum, the outermost layer of the skin.{{Carrer, V., Alonso, C., Pont, M., Zanuy, M., Córdoba, M., Espinosa, S., Barba, C., Oliver, M. A., Martí, M., & Coderch, L. (2020). Effect of propylene glycol on the skin penetration of drugs. *Archives of Dermatological Research.* 312(5). 337–352. Available at: https://doi.org/10.1007/s00403-019-02017-5}},{{Lessmann, H., Schnuch, A., Geier, J., Uter, W. (2005). Skin-sensitizing and irritant properties of propylene glycol. Contact Dermatitis. 53(5). 247-259. Available at: https://doi.org/10.1111/j.0105-1873.2005.00693.x.}}

Unfortunately, propylene glycol is also widely recognized as an irritant and a cause of contact dermatitis. This effect will only be compounded by once or twice daily application in topical formulations. One retrospective study found that 6.4% of minoxidil users experience some skin irritation, and many of these reactions will be the result of propylene glycol.{{Shadi, Z. (2023). Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia. Dermatology and Therapy (Heidelb). 13(5). 1157-1169. Available at: https://doi.org/10.1007/s13555-023-00919-x}}.

Skin irritation is a common reason for people to discontinue treatment with topical hair loss products. More careful formulation could lead to better adherence and, ultimately, better results. 

Concern #4: Corticosteroids

The use of irritants like propylene glycol leads us to our fourth concern: the use of corticosteroids. Daily application of irritants to the scalp can lead to significant inflammation, which is actively detrimental to hair growth. To combat this, telehealth companies have turned to corticosteroids like hydrocortisone and fluocinolone. These steroids mimic the activity of cortisol to suppress inflammation and local immune response.{{Stacey, S. K., & McEleney, M. (2021). Topical corticosteroids: choice and application. *American Family Physician.* 103(6). 337–343. Available at: https://pubmed.ncbi.nlm.nih.gov/33719380/}}

However, corticosteroids are designed for intermittent use when treating acute inflammation. They are not designed for twice-daily application over the course of many years. The steroids wear down the stratum corneum and epidermis, and can lead to long-term side effects like spider veins.{{Torok, H. M., Jones, T., Rich, P., Smith, S., & Tschen, E. (2005). Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. *Cutis.* 75(1). 57–62. Available at: https://pubmed.ncbi.nlm.nih.gov/15732437/}}

The corticosteroids used in hair growth products are typically low-potency, meaning they can be used for longer periods of time than high- or medium-potency products. Happy Head, for example, uses 1% hydrocortisone in its TopicalRx Finasteride & Minoxidil formulation. However, one study showed that after only 2 weeks, 1% hydrocortisone can lead to a significant reduction in epidermal thickness. Although the skin recovered after multiple weeks of use, , this was only after treatment was ended.{{Aschoff, R., Schmitt, J., Knuschke, P., Koch, E., Bräutigam, M., & Meurer, M. (2011). Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. *Experimental Dermatology.* 20(10). 832–836. Available at: https://doi.org/10.1111/j.1600-0625.2011.01335.x}}

In clinical trials, 1% hydrocortisone can lead to skin atrophy (thinning) after 6 to 12 months in a small percentage of patients.{{Guin, J. D. (1981). Complications of topical hydrocortisone. *Journal of the American Academy of Dermatology.* 4(4). 417–422. Available at: https://doi.org/10.1016/S0190-9622(81)70040-9}},{{Lenane, P., Macarthur, C., Parkin, P. C., Krafchik, B., DeGroot, J., Khambalia, A., & Pope, E. (2014). Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial. *JAMA Dermatology.* 150(1). 47–50. Available at: doi:10.1001/jamadermatol.2013.5764}} However, as we’ve already noted, hair loss products should be designed for daily application for many years. The unnecessary inclusion of potentially harmful ingredients, with no clear benefit, is a major concern.

Concern #5: Dutasteride Formulation

One of the most important factors for drug producers and telehealth companies to consider when formulating their products is bioavailability: the extent to which the active ingredient is absorbed and used in the body. For common drugs like minoxidil and finasteride, this is fairly straightforward, as they are bioavailable on their own without much chemical modification.

Dutasteride, on the other hand, is poorly soluble in water and needs to be formulated with lipids. This is why it’s typically sold as a soft-gel capsule rather than a pill. 

There are emerging concerns that some telehealth companies may be dispensing oral dutasteride in compounded capsule formulations that differ from the soft-gel, lipid-based versions used in clinical trials. When dutasteride is compounded as a powder and combined with other ingredients (such as oral minoxidil, vitamins, or biotin) into a single capsule, its absorption may be reduced.

To see if compounded dutasteride pills had reduced efficacy, we ran a small test. One participant took 3 pills of 0.5 mg powdered dutasteride (i.e., 1.5 mg total) and then checked changes in their blood DHT levels 12 hours later. Like finasteride, dutasteride works by reducing levels of DHT, and we’d normally expect to see around 80-90% reduction in serum DHT with only 1 mg of dutasteride, based on pharmacology data.{{Gisleskog, P. O., Hermann, D., Hammarlund‐Udenaes, M., & Karlsson, M. O. (1998). A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors GI198745 and finasteride. *Clinical Pharmacology & Therapeutics.* 64(6). 636–647. Available at: https://doi.org/10.1016/S0009-9236(98)90054-6}}

However, we saw a reduction of only 13.6%. It is safe to assume that this level of DHT reduction will lead to substantially lower effectiveness for the drug. While rigorous, peer-reviewed research is needed to confirm the extent of these differences, the findings are enough to raise serious concerns. 

Happy Head compounds its dutasteride with minoxidil and vitamin D3 in a “SuperCapsuleTM”. While these compounded pills are designed to make taking them daily easier, they may be blocking their hair growth capabilities. The lack of evidence for the efficacy of dutasteride when it’s compounded in this way makes it difficult to understand the benefits of combining the drugs rather than providing the tried-and-tested gel-form capsule.

Interested in Oral Dutasteride?

Oral Dutasteride Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Can Prescription Vendors Do Better?

It is possible to provide personalized hair loss treatment. Rather than using marketing buzzwords and expensive, unproven DNA testing, vendors and telehealth companies can focus on the type and extent of hair loss, the tolerability of side effects, and ongoing management. 

After years of advocating for better standards across the industry and pushing for improved formulations, we saw many telehealth brands move in the opposite direction. That experience ultimately led us to cofound Ulo, a telehealth company dedicated exclusively to hair growth, with the goal of fixing the problems we repeatedly observed and offering consumers treatment plans that are genuinely personalized and grounded in clinical evidence.

Ulo is built around three core principles: evidence, personalization, and consumer safety. Unlike some brands that rely heavily on unproven testing or trend-driven ingredients, Ulo states that it builds treatment plans around established therapies, physician oversight, and independently vetted formulations.

Ulo is committed to addressing several common industry practices highlighted in this article:

• Personalization and Customization: There’s no need for poorly evidenced genetic testing to find the right solution. Conversations with experts and examinations by clinical professionals are the best way to find the treatment regimen and management plan for you.
• Safer Topical Design: Ulo avoids propylene glycol and corticosteroids in its topical products, instead focusing on safe formulations and adjustable ingredient combinations.
• Avoidance of Trend-Driven Ingredients: They don’t include ingredients with limited safety data or unclear benefit unless there is a clear evidence-based rationale.
• Evidence-based Formulations: Rather than using mega-dosed or experimental combinations, Ulo emphasizes clinically supported concentrations and delivery formats. For example, it offers oral dutasteride in soft-gel form consistent with clinical trial formulations.

This model underscores what telehealth hair-loss providers could do differently: prioritize proven drug-delivery systems, avoid unnecessary or potentially harmful additives, provide genuine physician-led personalization, and set realistic expectations for outcomes.

Final Thoughts

The rise of telehealth hair-loss companies has made prescription treatments more accessible than ever, but accessibility does not always guarantee quality. While the concerns with Happy Head we’ve listed here raise serious questions about the brand and its products, they are not isolated to one company. Unfortunately, overstated claims, untested formulations, and unnecessary inclusion of risky components are common.

As this review highlights, differences in formulation, ingredient selection, and evidence standards can impact both safety and results. The takeaway is simple: effective hair-loss treatment is rarely about novelty or trendy new ingredients. Instead, prioritize providers that emphasize proven formulations, transparent evidence, and ongoing medical oversight.

Over the past few years, there has been a rapid rise in the use of GLP-1-based medications for obesity and metabolic health. It is estimated that 63.4 million GLP-1 prescriptions were dispensed in the United States between 2015 and 2020.{{Adhikari, R., Jha, K., Dardari, Z., Heyward, J., Blumenthal, R.S., Eckel, R.H., Alexander, G.C., Blaha, M.J., (2022). National Trends In Use Of Sodium-Glucose Cotransporter-2 Inhibitors And Glucagon-Like Peptide-1 Receptor Agonists By Cardiologists And Other Specialties, 2015 To 2020. Journal Of The American Heart Association. 11(9). e023811. Available at: https://doi.org/10.1161/JAHA.121.023811}} Ozempic, Wegovy, Mounjaro, and Zepbound represent just a few of these FDA-approved GLP-1 medications used to treat diabetes and chronic weight management.

With a rise in popularity, there is also a rise in users reporting side effects. Alongside well-known gastrointestinal effects, some users online report hair shedding or worsening hair loss with drugs like Zepbound, including new hair shedding, worsening of pattern hair loss (androgenic alopecia), and a “reversal” of prior hair regrowth!

But could this be true? In this article, we separate anecdotes from evidence. We’ll dive into the science behind Zepbound, the research discussing its association with hair loss, and discuss the ways you can monitor hair loss and reduce the risk of losing hair when you’re trying to lose weight.

Interested in Topical Minoxidil?

High-strength topical minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

What Is Zepbound?

Zepbound is one of the many GLP-1 medications FDA-approved for the treatment of chronic weight management. It is an injection, usually taken once weekly at a dosage of 2.5 mg to 5.0 mg.{{U.S. Food and Drug Administration. (2025). Tirzepatide Injection Label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf (Accessed: 04 March 2026)}}

Zepbound is a brand name. Chemically, it is the same as Mounjaro, with both containing the active ingredient tirzepatide, but Mounjaro is FDA-approved for the treatment of type 2 diabetes.

Tirzepatide mimics natural hormones found in the body – incretins (like GIP and GLP-1).{{Galindo, R.J., Cheng, A.Y.Y., Longuet, C. (2026). Insights Into The Mechanism Of Action Of Tirzepatide: A Narrative Review. Diabetes Therapy. 17. 19-40. Available at: https://doi.org/10.1007/s13300-025-01804-w}} By mimicking these incretins, tirzepatide has two key effects in the body:

• It’s a gastric inhibitory peptide (GIP) analog: It stimulates insulin secretion 
• It’s a GLP-1 receptor agonist: It activates GLP-1 receptors, causing reduced blood sugar, appetite, and energy intake.

How Do GLP-1–Based Therapies Work For Weight Loss?

Let’s look deeper into how GLP-1 therapies like Zepbound really function to support weight loss. 

As the title suggests, it’s the GLP-1 receptor agonist activity of these medications that makes these drugs suitable for weight management. GIP analog activity may enhance weight loss when combined with GLP-1 activity, but this action does not promote weight loss alone.

1st step: Activating the GLP-1 receptor

Tirzepatide mimics the incretin GLP-1 (found naturally in the body). By having the same shape and structure as GLP-1, tirzepatide can bind to GLP-1 receptors. Think of the GLP-1 receptors like a lock, and GLP-1 as the key. When they interact, GLP-1 (or tirzepatide, in this case) “unlocks” and activates GLP-1 receptors.

2nd step: Signalling

Activation of the GLP-1 receptors causes a series of effects in the body:

• It lowers blood glucose levels: GLP-1 receptor activation suppresses glucagon secretion (which normally stimulates the liver to release glucose into the bloodstream) and increases glucose-dependent insulin secretion, promoting the uptake of glucose from the bloodstream into tissues.{{Galindo, R.J., Cheng, A.Y.Y., Longuet, C. (2026). Insights Into The Mechanism Of Action Of Tirzepatide: A Narrative Review. Diabetes Therapy. 17. 19-40. Available at: https://doi.org/10.1007/s13300-025-01804-w}}
• It stimulates feelings of satiety: GLP-1 receptor activation contributes to gut-brain signaling that relaxes the stomach and slows emptying, both causing a feeling of “fullness”.{{Tack, J., Verbeure, W., Mori, H., Schol, J., Van den Houte, K., Huang, I.H., Balsiger, L., Broeders, B., Colomier, E., Scarpellini, E., Carbone, F. (2021). The Gastrointestinal Tract In Hunger And Satiety Signalling. United European Gastroenterology Journal. 9(6). 727-734. Available at: https://doi.org/10.1002/ueg2.12097}}

3rd step: Weight loss

Along with an appropriate diet and exercise, the increased satiety effects reduce food intake and promote higher energy expenditure than energy (calorie) intake. This leads to weight loss over time.

Types of Hair Loss: Telogen Effluvium and Androgenic Alopecia

Before we get into the how and why behind Zepbound and weight loss, let’s establish two of the main types of hair loss: telogen effluvium and androgenic alopecia.

Telogen effluvium
In the normal hair cycle, there are four phases: 

• The growth phase (anagen phase)
• The transition phase (catagen phase)
• The resting phase (telogen phase)
• The shedding phase (exogen phase)

Telogen effluvium is a condition where there are too many hairs in the telogen phase, causing diffuse premature hair shedding and a noticeable loss in hair density. 

There are many reasons why this might happen. Usually, it is caused by a “negative event”, like illness, stress, diet, surgical trauma, childbirth, or even starting and stopping medications. The time between exposure to a trigger and actual hair loss can be rather long – often, people will experience telogen effluvium 2 to 8 months after they experience a trigger.{{Malkud, S., (2015). Telogen Effluvium: A Review. Journal Of Clinical And Diagnostic Research. 9(9). WE01-WE03. Available at: https://doi.org/10.7860/JCDR/2015/15219.6492}},{{Hussain, N., Agarwala, P., Iqbal, K., et al. (2022). A Systematic Review Of Acute Telogen Effluvium, A Harrowing Post-COVID-19 Manifestation. J Med Virol. 94. 1391-1401. Available at: https://doi.org/10.1002/jmv.27534}},{{Bin Dayel, S., Hussein, R.S., Atia, T., Abahussein, O., Al Yahya, R.S., Elsayed, S.H. (2024). Is Thyroid Dysfunction A Common Cause Of Telogen Effluvium?: A Retrospective Study. Medicine. 103(1). e36803. Available at: https://doi.org/10.1097/MD.0000000000036803}},{{Kang, D.H., Kwon, S.H., Sim, W.Y., Lew, B.L. (2024). Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 36(6). 384-388. Available at: https://doi.org/10.5021/ad.24.043}}

Fortunately, telogen effluvium is not permanent in most cases. Once the “negative event” causing it has been removed, hair usually regrows after 2 to 8 months.{{Malkud, S., (2015). Telogen Effluvium: A Review. Journal Of Clinical And Diagnostic Research. 9(9). WE01-WE03. Available at: https://doi.org/10.7860/JCDR/2015/15219.6492}}

Androgenic alopecia
This is a progressive hair loss condition, where more and more hair loss occurs with time. It is the most common type of progressive hair loss, and affects up to 50% of men and 30% of women.

Androgenic alopecia is characterized by miniaturization of the hair follicle. This means that the hair follicle gets smaller over time. This causes long hairs that contribute to the cosmetic appearance of hair density (terminal hairs) to turn into “peach fuzz” hairs that do little to contribute to hair “fullness” (vellus hairs). 

This happens because of an alteration to the normal hair growth cycle where the duration of the anagen phase decreases, while the telogen phase increases. The anagen phase determines hair length, so as it shortens, so does the length of hair. As the hair cycle repeats, this leads to more and more hair miniaturization and, eventually, a balding appearance.

You can often tell telogen effluvium apart from androgenic alopecia by examining the hairline. Androgenic alopecia typically starts with a widening part and receding hairline, while there is more diffuse hair thinning in telogen effluvium. 

If you’d like to learn more about androgenic alopecia, read our article.

Research Deep Dive: Zepbound and Hair Loss

Prescribing information for Zepbound notes that common side effects include nausea, diarrhea, vomiting, and, interestingly, hair loss.{{U.S. Food and Drug Administration. (2025). Tirzepatide Injection Label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf (Accessed: 04 March 2026)}} There are only a few published clinical studies reporting the association between Zepbound and hair loss, so extensive evidence is limited. But let’s look deeper into the scientific evidence that we do have.

Randomized, Double-Blinded, Placebo-Controlled Trials 

Unfortunately, there are no studies examining the direct link between human hair loss and GLP-1 medications. However, trials and reports are showing that hair loss is sometimes reported in those taking GLP-1 medications. 

For example, there are two clinical trials reported in the FDA Zepbound documentation that have documented adverse reactions.{{U.S. Food and Drug Administration. (2025). Tirzepatide Injection Label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf (Accessed: 04 March 2026)}}

These trials included a total of 2,519 adults who were treated for up to 72 weeks with Zepbound (at 5 mg, 10 mg, or 15 mg), or a placebo. When pooling all the data of adverse reactions, we can see that:

• 1% of users on the placebo reported hair loss
• 5% of users on 5 mg Zepbound reported hair loss
• 4% of users on 10 mg Zepbound reported hair loss
• 5% of users on 15 mg Zepbound reported hair loss
• One participant receiving the placebo discontinued due to hair loss 
• No Zepound patients discontinued the study due to hair loss

While hair loss is noted as an adverse reaction, the documentation doesn’t provide further detail. For example, did these participants already have pre-existing hair loss, or did they develop new hair loss? Reports could reflect hair loss that would have worsened naturally, with or without treatment with Zepbound.

Does this show Zepbound causes hair loss?

No. There seems to be a higher incidence of hair loss in those receiving Zepbound. But we can’t know whether Zepbound is a cause of hair loss, or if it accelerates hair loss in those already susceptible.

2024 FAERS Study   

A 2024 study reported that alopecia is associated with the use of tirzepatide.{{Godfrey, H., Leibovit-Reiben, Z., Jedlowski, P., Thiede, R. (2025). Alopecia Associated With The Use Of Semaglutide And Tirzepatide: A Disproportionality Analysis Using The FDA Adverse Event Reporting System (FAERS) From 2022 To 2023. Journal Of The European Academy Of Dermatology And Venereology. 39. e153-e154. Available at: https://doi.org/10.1111/jdv.20197}}

The researchers searched the term “alopecia” in the FDA adverse reporting system (FAERS), which collects reports of side effects and adverse reactions from the use of FDA-approved drugs. They then isolated cases from 2022 to 2023 associated with GLP-1 agonist drugs.

They found that there were 179 reported cases of alopecia associated with tirzepatide, while semaglutide returned 199 cases. Other similar medications like liraglutide, dulaglutide, exenatide, and lixisenatide returned 0 to 65 cases. 

A disproportionality analysis was then performed. This is a type of statistical test that assesses whether effects are reported more often in people using a drug than would occur in the general population. They concluded that the reporting odds for semaglutide and tirzepatide were higher. 

But it’s important to remember that the FAERS is a public database where anyone can view and report adverse events – healthcare professionals as well as consumers, patients, and caregivers. That means reporting is vulnerable to:

• Media attention and amplification on social media
• Increased awareness leading to more reports 
• Missing clinical details that determine hair loss type, severity, and other factors that could contribute to hair loss (i.e., androgenic alopecia vs. alopecia areata, hair counts before and after treatment, weight loss rate, diet…)

This could inflate reports of hair loss for a particular drug. When we look at the numbers, we see that 84% of alopecia reports were from consumers, and only 16% were from healthcare professionals. So, how do we truly know that these reports of hair loss are clinically legitimate? The answer is that we can’t know for sure.

Does this show Zepbound causes hair loss?

No. What this study does show is that there could be an association between hair loss and Zepbound. It does not show that Zepbound is proven to cause alopecia; it simply signals that this association is worth investigating further. 

2025 Retrospective Studies

A retrospective study doesn’t generate new data; it looks back at old data (such as medical charts and databases) to identify patterns that weren’t previously seen. In 2025, two retrospective studies were conducted to find any association between hair loss and GLP-1 medications.{{Burke, O. (2025). Glucagon-Like Peptide-1 Receptor Agonist Medications And Hair Loss: A Retrospective Cohort Study. Journal Of The American Academy Of Dermatology. 92(5). 1141-1143. Available at: https://doi.org/10.1016/j.jaad.2025.01.046}},{{Akiska, Y.M., Vidal, S.I., Menta, N. (2025). Increased Incidence And Risk Of Hair Loss With Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study. EMJ. 13(1). 52-54. Available at: https://doi.org/10.33590/emjdermatol/TYEW1122}}

In the first study, the researchers focused on two hair loss conditions: androgenic alopecia and telogen effluvium. They collected data from 2021 to 2023, including 283 patients aged over 18 years, who were on GLP-1 medications and also seen in the dermatology department at the University of Miami Hospital.{{Burke, O. (2025). Glucagon-Like Peptide-1 Receptor Agonist Medications And Hair Loss: A Retrospective Cohort Study. Journal Of The American Academy Of Dermatology. 92(5). 1141-1143. Available at: https://doi.org/10.1016/j.jaad.2025.01.046}}

Of all the GLP-1 agonist users:

• 84.1% reported no hair loss
• 1.2% reported new hair loss

In GLP-1 agonist users with pre-existing hair loss (13% of users):

• 11.9% reported worsening of hair loss
• 0.4% reported resolved hair loss
• 0.8% reported stabilization of hair loss

Interestingly, tirzepatide was most associated with patients with telogen effluvium. Semaglutide was found to be most associated with androgenic alopecia. The fact that these two GLP-1 medications were flagged adds credibility to the 2024 FAERS study, where both of these drugs showed strong associations with reports of alopecia.

However, it should be noted that the association between tirzepatide and telogen effluvium was not found to be statistically significant. This means it could be down to chance! What’s more, the report of 1.2% of users experiencing new hair loss is approximately the same rate as would be expected in the general population over two years. So, this is not a strong indication that GLP-1 treatment caused hair loss.

In the second study, the researchers pooled electronic health records of over 100 million patients and searched for those on GLP-1 medications without a prior history of alopecia. Among the resulting 500,000 patients, it was found that after 12 months of GLP-1 use, there was a significantly elevated risk of users developing androgenic alopecia, telogen effluvium, and non-scarring hair loss.{{Akiska, Y.M., Vidal, S.I., Menta, N. (2025). Increased Incidence And Risk Of Hair Loss With Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study. EMJ. 13(1). 52-54. Available at: https://doi.org/10.33590/emjdermatol/TYEW1122}}

While retrospective data can be useful, we must consider that the design of these studies lacks some key components that allow us to make strong conclusions:

• It’s not randomized
• No untreated control group
• Hair outcomes were self-reported rather than objectively measured through hair counts 
• The duration of medication use was not clearly tracked or standardized

Without these parameters in place, it’s difficult to say whether the patients are reporting a worsening of hair loss due to GLP-1 medications or simply due to pre-existing hair loss conditions and susceptibilities that are naturally progressing with age while they are taking the medication.

Does this show Zepbound causes hair loss?

No. The studies raise a hypothesis and support further investigation, but do not demonstrate a cause-and-effect relationship between Zepbound and hair loss.

How Might Zepbound Contribute to Hair Loss?

From the studies, it seems there is no evidence to suggest that Zepbound causes hair loss, but there is evidence to support that there may be an association between Zepbound and hair loss in a small number of users. Because Zepbound often produces meaningful weight loss, it raises a key question: Is any hair loss due to the drug itself or due to the weight loss?

No single mechanism has been confirmed, but several possible explanations exist.{{Desai, D.D., Sikora, M., Nohria, A., Bordone, L., Caplan, A.S., Shapiro, J., Lo Sicco, K.I. (2024). GLP-1 Agonists And Hair Loss: A Call For Further Investigation. International Journal Of Dermatology. 63. 1128-1130. Available at: https://doi.org/10.1111/ijd.17246}}

Direct Action Against The Hair Cycle

In one animal study that predates the first FDA-approved GLP-1 drug, Byetta, it was found that  GLP-1 levels were heightened at the hair follicles within the skin of newborn mice.{{List, J.F., He, H., Habener, J.F. (2006). Glucagon-Like Peptide-1 Receptor And Proglucagon Expression In Mouse Skin. Regulatory Peptides. 134(2–3). 149-157. Available at: https://doi.org/10.1016/j.regpep.2006.02.007}} The study also found that, in skin cells, GLP-1 was found to activate the MAPK/ERK pathway, which is associated with cell proliferation.

The researchers conclude that GLP-1 could have a role in hair follicle development. Could this provide a potential link between GLP-1 medications and hair? If anything, the study shows that GLP-1 would contribute to hair growth, not decline. 

The study does not include any testing on humans – what happens in an animal does not always translate to what happens in humans. So what we can take from this study is that there could be some involvement of GLP-1 in the hair cycle of mice, but we can’t conclude whether GLP-1 could have the same involvement in humans nor whether this mechanism is a plausible cause of the Zepbound and hair loss association.

Rapid Weight Loss, Caloric Deficit, and Nutritional Deficiencies 

We know that telogen effluvium can be triggered by a variety of stressors, and one of the well-established triggers for telogen effluvium is rapid weight loss.{{Smolarczyk, K., Meczekalski, B., Rudnicka, E., Suchta, K., Szeliga, A. (2024). Association Of Obesity And Bariatric Surgery On Hair Health. Medicina. 60(2). 325. Available at: https://doi.org/10.3390/medicina60020325}}

For example, within the first three months after bariatric surgery (weight loss surgery), a case study of a 24-year-old woman noted the development of telogen effluvium.{{Cohen-Kurzrock, R.A., Cohen, P.R., (2021). Bariatric Surgery-Induced Telogen Effluvium (Bar SITE): Case Report And A Review Of Hair Loss Following Weight Loss Surgery. Cureus. 13(4). e14617. Available at: https://doi.org/10.7759/cureus.14617}}

This is not an isolated incident – hair loss has been noted in several cases following bariatric surgery.{{Rojas, P., Gosch, M., Basfi-Fer, K., (2011). Alopecia In Women With Severe And Morbid Obesity Who Undergo Bariatric Surgery. Nutricion Hospitalaria. 26(4). 856-862. Available at: https://doi.org/10.1590/s0212-16112011000400028}},{{Nadler, E.P., Youn, H.A., Ginsburg, H.B., Ren, C.J., Fielding, G.A., (2007). Short-Term Results In 53 US Obese Pediatric Patients Treated With Laparoscopic Adjustable Gastric Banding. Journal Of Pediatric Surgery. 42(1). 137-142. Available at: https://doi.org/10.1016/j.jpedsurg.2006.09.014}},{{Nadler, E.P., Youn, H.A., Ren, C.J., Fielding, G.A., (2008). An Update On 73 US Obese Pediatric Patients Treated With Laparoscopic Adjustable Gastric Banding: Comorbidity Resolution And Compliance Data. Journal Of Pediatric Surgery. 43(1). 141-146. Available at: https://doi.org/10.1016/j.jpedsurg.2007.09.035}}

The case study speculates that this hair loss may be the result of nutritional deficiencies, which can occur after bariatric surgery.{{Ruiz-Tovar, J., Oller, I., Llavero, C., Zubiaga, L., Diez, M., Arroyo, A., Calero, A., Calpena, R., (2014). Hair Loss In Females After Sleeve Gastrectomy: Predictive Value Of Serum Zinc And Iron Levels. The American Surgeon. 80(5). 466-471}},{{Almohanna, H.M., Ahmed, A.A., Tsatalis, J.P., Tosti, A., (2019). The Role Of Vitamins And Minerals In Hair Loss: A Review. Dermatology And Therapy. 9(1). 51-70. Available at: https://doi.org/10.1007/s13555-018-0278-6}} However, in this case, evaluation of her nutritional profile showed no deficiencies, and the hair loss was resolved within 14 months of surgery.

But it’s not just weight loss from bariatric surgery that can cause telogen effluvium. Those who have lost weight due to diet (calorie reduction) have also been shown to experience telogen effluvium.{{Kang, D.H., Kwon, S.H., Sim, W.Y., Lew, B.L., (2024). Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Annals Of Dermatology. 36(6). 384-388. Available at: https://doi.org/10.5021/ad.24.043}}

Why might this be? There isn’t one specified cause of telogen effluvium from weight loss and diet change, but a few potential contributors include:

• Sustained calorie restriction
• Reduced protein intake
• Iron, zinc, or other micronutrient insufficiencies
• Physiologic stress from rapid fat loss or surgery

Calories, proteins, and nutrients are needed to sustain hair follicle growth, and stress is a known driver of hair loss. So, it’s possible these factors associated with weight loss and diet changes could act to trigger telogen effluvium.

When taking a medication like Zepbound, appetite suppression for prolonged periods could inadvertently create very low caloric intake and result in nutrient deficiencies.  In line with this, studies have shown that GLP-1 users often do not eat adequate amounts of protein and have insufficient intake of multiple key nutrients.{{Johnson, B., Milstead, M., Thomas, O. (2025). Investigating Nutrient Intake During Use Of Glucagon-Like Peptide-1 Receptor Agonist: A Cross-Sectional Study. Frontiers In Nutrition. 12. 1566498. Available at: https://doi.org/10.3389/fnut.2025.1566498}} This may shift hairs prematurely into the telogen phase, increasing shedding and triggering telogen effluvium.

Telogen effluvium typically begins 2 to 4 months after the trigger and is often reversible, though regrowth can sometimes appear finer initially. The bad news is that telogen effluvium could also accelerate the onset or appearance of androgenic alopecia for susceptible individuals. 

If shedding is increased, this means that hair follicle miniaturization is also accelerated, since hair follicle miniaturization occurs with repeated hair cycles. In this way, weight loss and reduced calorie intake promoted by Zepbound may appear to worsen androgenic alopecia. This hasn’t been demonstrated in research, but it is a plausible scenario. 

Changes to Hormonal Pathways 

Zepbound may affect the hormonal pathways that regulate hair growth. Insulin is known to increase the production of hormones like IGF-1.{{Brismar, K., Fernqvist-Forbes, E., Wahren, J., Hall, K., (1994). Effect Of Insulin On The Hepatic Production Of Insulin-Like Growth Factor-Binding Protein-1 (IGFBP-1), IGFBP-3, And IGF-I In Insulin-Dependent Diabetes. Journal Of Clinical Endocrinology And Metabolism. 79(3). 872-878. Available at: https://doi.org/10.1210/jcem.79.3.7521354}} IGF-1 stimulates hair follicle proliferation, promotes movement into the anagen phase, and reduces cell death of hair follicles.{{Hsieh, W.J., Qiu, W.Y., Percec, I., Chang, T.M., (2025). Insulin-Like Growth Factor 1 (IGF-1) In Hair Regeneration: Mechanistic Pathways And Therapeutic Potential. Current Issues In Molecular Biology. 47(9). 773. Available at: https://doi.org/10.3390/cimb47090773}}

In support of this, a 2021 case report documented hair shedding in a 54-year-old woman with diabetes and hair loss, demonstrating that insulin therapy, but not minoxidil, led to hair growth and reduced hair shedding.{{Kant, R., Barnwal, S., Sharma, S.K., Thakur, K. (2021). Reversal Of Alopecia By Insulin Therapy In Uncontrolled Type 2 DM: A Case Report. Journal Of Diabetology. 12(4). 533-537. Available at: https://doi.org/10.4103/jod.jod_66_21}}

However, this is just a case report. Much like the retrospective study discussed earlier, a report like this lacks:

• Multiple participants
• Randomization
• An untreated control group
• Objective measures of hair counts from before and after treatment

This doesn’t discredit the findings, but it doesn’t allow the results to be applied to a general population, and it’s difficult to conclude causality. What we can take from this is that, in this case, there may be an association between insulin and hair growth. 

Why is this important?

Because we know that GLP-1 therapies increase glucose-dependent insulin secretion, promoting the uptake of glucose from the bloodstream into tissues. This means that when glucose is high (like after a meal), the insulin response is enhanced to rid the extra glucose. But with long-term use, the curbing of appetite, weight loss, and reduced food intake could reduce the amount of insulin produced by the body more than before treatment.{{{Jørgensen, S.W., Hjort, L., Gillberg, L., Justesen, L., Madsbad, S., Brøns, C., Vaag, A.A. (2021). Impact Of Prolonged Fasting On Insulin Secretion, Insulin Action, And Hepatic Versus Whole Body Insulin Secretion Disposition Indices In Healthy Young Males. American Journal Of Physiology Endocrinology And Metabolism. 320(2). E281-E290. Available at: https://doi.org/10.1152/ajpendo.00433.2020}},{{Alhowiti, A., Mirghani, H. (2025). The Effects Of GLP-1 Agonists On HbA1c And Insulin Dose Among Patients With Type 1 Diabetes. Frontiers In Endocrinology. 16. 1550938. Available at: https://doi.org/10.3389/fendo.2025.1550938}},{{Luo, Y., Yang, S., Zeng, H., Liu, S., Zhang, Y., Li, J.E., Liu, J. (2025). Both Subcutaneous Semaglutide And Calorie Restriction Improves Pancreatic Cell Hyperplasia And Gut Microbiota In High-Fat Diet-Induced Obese Mice. Nutrition And Metabolism. 22(1). 95. Available at: https://doi.org/10.1186/s12986-025-00987-0}} So, it’s possible GLP-1 medications like Zepbound may, in turn, inadvertently lower the activation of the pathways that insulin affects (like the IGF-1 pathway for hair follicle growth).

Insulin changes could also contribute to the onset of telogen effluvium. For those with a genetic susceptibility, this may trigger an earlier onset of androgenic alopecia, or just faster visibility of hair loss. However, it’s important to remember that this is just a theory for now – there’s no evidence to show that this does, in fact, happen.

Should You Be Concerned About Hair Loss If You’re Taking Zepbound?

If you’re taking Zepbound, you may be concerned about hair loss as a side effect. But the evidence suggests that, unless you already have pre-existing hair loss, you probably don’t have to worry. 

If you have no signs of hair loss

• Current evidence suggests the risk of new-onset hair loss is likely low
• Most users in clinical observational data report no hair loss

If you have androgenic alopecia

• You may be more likely to notice worsening during rapid weight loss
• A shed can reduce density and make pattern thinning more obvious
• Some people may benefit from starting androgenic alopecia treatment alongside weight loss therapy, especially if hair preservation is a priority

Considering treatments for androgenic alopecia? Take a look at our articles on the FDA-approved treatments for this condition, topical minoxidil and oral finasteride.

If you have early or unnoticed androgenic alopecia

• Shedding related to weight loss can make thinning suddenly noticeable
• This may feel like the medication “caused” hair loss, when it may have revealed an underlying pattern

If you have a family history of baldness or are worried you might have androgenic alopecia, you may want to consult your doctor before taking a medication like Zepbound for a scalp assessment and to understand your potential for hair loss. Age, smoking, and obesity are also risk factors for androgenic alopecia.{{Liu, L.P., Wariboko, M.A., Hu, X., Wang, Z.H., Wu, Q., Li, Y.M., (2024). Factors Associated With Early-Onset Androgenetic Alopecia: A Scoping Review. PLOS ONE. 19(3). e0299212. Available at: https://doi.org/10.1371/journal.pone.0299212}}

Interested in Oral Finasteride?

Oral finasteride & minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Practical Considerations While Taking Zepbound

If you have or suspect you may have androgenic alopecia, it doesn’t mean you have to avoid or stop using Zepbound. 

There are two clear strategies to reduce hair loss when using GLP-1 medications:

• Aim for slower, steadier weight loss when possible: Slowly increase dosage over time so that weight loss occurs gradually, as opposed to rapidly
• If you have androgenic alopecia, start a hair loss treatment: Hair loss can be minimized with FDA-approved treatments for androgenic alopecia, like topical minoxidil or oral finasteride, along with a plethora of other treatments that are effective for stabilizing hair loss and promoting hair regrowth

You can also make sure to prioritize adequate protein intake, ensure you are getting sufficient iron and key micronutrients, and avoid extreme calorie deficits for long periods.

If shedding occurs, don’t panic.

• Evaluate timing to assess whether it is telogen effluvium (often 2 to 4 months after rapid weight loss)
• Consider whether the pattern looks like telogen effluvium (diffuse thinning) or androgenic alopecia (typically starts with a widening part and receding hairline)
• Discuss your concerns with your doctor and determine the next steps

By doing this, you should be able to balance healthy weight loss with healthy hair outcomes.

Final Thoughts

Online anecdotes about Zepbound have amplified concern that this drug may cause hair loss, but the current clinical evidence does not establish this GLP-1 medication as a cause of hair loss. The answer likely isn’t the drug itself, but what the drug facilitates: weight loss. Weight loss is a known trigger of telogen effluvium, a temporary hair loss condition. 

For those with diagnosed, early, or undiagnosed androgenic alopecia, telogen effluvium may accelerate the onset or progression of hair miniaturization. So, for most people without underlying hair loss, significant or permanent thinning from Zepbound appears unlikely. But for those with androgenic alopecia, it’s possible the rapid weight loss associated with this drug could promote worsening of your current condition.

The good news is you don’t have to avoid or stop taking Zepbound if you have androgenic alopecia. Monitor hair loss, ramp up dosage slowly to avoid rapid weight loss, and incorporate some hair loss interventions into your routine to help reduce the chance that weight loss from Zepbound could make hair loss more noticeable.

We have seen a rapid rise in GLP-1 medications for weight loss and diabetes. These medications are highly effective as well as convenient, with treatments requiring just a once-daily or once-weekly injection.

There are many different GLP-1 medications on the market: liraglutide, semaglutide, dulaglutide, exenatide, liraglutide, tirzepatide. From 2018 to 2023, it was estimated that semaglutide medications (like Ozempic and Wegovy) accounted for 60% of prescribed GLP-1 drugs.{{Ukhanova, M., Wozny, J.S., Truong, C.N., Ghosh, L., Krause, T.M. (2025). Trends In Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns. Am J Manag Care. 31(8). e228-e234. Available at: https://doi.org/10.37765/ajmc.2025.89778}} While these treatments are effective, they are not without side effects. Common side effects include nausea, vomiting, and diarrhea, and more and more, there have been reports of hair loss.

Online discourse, as well as some published studies, report that semaglutide treatments like Ozempic and Wegovy are causing increased hair shedding, worsening of androgenic alopecia, and loss of prior hair regrowth.

But are these reports legitimate? Could semaglutide treatments really cause or influence hair loss? We dig deeper into the truth behind the anecdotes. In this article, we dissect the current evidence surrounding the relationship between Wegovy and hair loss. We discuss the plausibility of this association, how it might happen, and what you can do to minimize the risk of hair loss.

Interested in Topical Minoxidil?

High-strength topical minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

What Is Wegovy?

Wegovy is a brand name for the drug known as semaglutide. Wegovy is FDA-approved as a once-weekly injection for chronic weight management, and has also recently been approved as a daily oral pill for chronic weight management as well as to prevent adverse cardiovascular events. Ozempic is the same drug, but it is FDA-approved for the treatment of diabetes.

Wegovy works by acting as a GLP-1 receptor agonist. GLP-1 is a naturally occurring hormone found in the body, known as an incretin. “Agonist” is defined as: a substance that initiates a physiological response when combined with a receptor. So, as the name suggests, semaglutide activates GLP-1 receptors by mimicking GLP-1.

How Does Wegovy Work?

We’ve established that semaglutide mimics GLP-1, and this imitation allows semaglutide to activate GLP-1 receptors. How exactly does this lead to weight loss? 

The binding of GLP-1 (or semaglutide) to GLP-1 receptors activates several biological responses:

• Increased insulin secretion after food intake, which improves blood glucose levels
• Reduced glucagon secretion, which limits glucose in the blood and helps reduce spikes in blood sugar
• Slowed emptying of the stomach, which helps people feel less hungry during the day
• Suppressed appetite, which again helps with feelings of satiety

All of these factors promote sustained food (and therefore calorie) reduction, supporting weight loss with time.{{Kommu, S., Whitfield, P., (2025), Semaglutide. Available at: http://www.ncbi.nlm.nih.gov/books/NBK603723/ (Accessed: 27 February 2026)}}

Semaglutide is highly effective for weight loss, with 2.4 mg once weekly injections, alongside appropriate diet and exercise, reducing mean body weight by 16% after use for 68 weeks.{{Wadden, T.A., Bailey, T.S., Billings, L.K., Davies, M., Frias, J.P., Koroleva, A., Lingvay, I., O’Neil, P.M., Rubino, D.M., Skovgaard, D., Wallenstein, S.O.R., Garvey, W.T. (2021). Effect Of Subcutaneous Semaglutide Vs Placebo As An Adjunct To Intensive Behavioral Therapy On Body Weight In Adults With Overweight Or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 325(14). 1403-1413. Available at: https://doi.org/10.1001/jama.2021.1831}} It’s clear that a semaglutide like Wegovy can support rapid weight loss, but anecdotal reports suggest that Wegovy may also contribute to hair loss. The key question is this: Does semaglutide itself cause hair loss, or are hair changes related to rapid weight loss?

Different Types of Hair Loss

Before we discuss the association between Wegovy and hair loss, we will first establish what hair loss is and the conditions that can cause it.

In the normal hair growth cycle, there are four key stages:

• The growth phase (anagen phase)
• The involuting phase (catagen phase)
• The resting phase (telogen phase)
• The shedding phase (exogen phase)

Hair loss can happen when the cycling through these stages is disturbed or changed. There are three main conditions causing hair loss: androgenic alopecia, telogen effluvium, and alopecia areata. 

Androgenic Alopecia

What is it? Also known as pattern hair loss, this is a progressive hair loss condition. It is one of the most common, affecting up to 50% of men and 30% of women. It causes terminal hairs that contribute to the appearance of hair “fullness” to become vellus hairs (i.e., “peach fuzz” hairs), ultimately leading to hair thinning, a process known as hair follicle miniaturization.{{Oiwoh, S.O., Enitan, A.O., Adegbosin, O.T., Akinboro, A.O., Onayemi, E.O. (2024). Androgenetic Alopecia: A Review. Niger Postgrad Med J. 31(2). 85-92. Available at: https://doi.org/10.4103/npmj.npmj_47_24}} 

What does it look like? Hair thinning usually first appears as a receding hairline with a balding crown in men, or a widening part in women. Hair thinning occurs slowly over time, without scarring.

What causes it? There are several reasons hair follicle miniaturization can happen: genetics, age, and hormonal changes. The primary driver of androgenic alopecia is a change in dihydrotestosterone (DHT) levels at the scalp, which can cause the hair miniaturization process.

Telogen Effluvium

What is it? This is a temporary hair loss condition in which too many hairs enter the telogen phase of the hair cycle, causing premature and excessive shedding. It often resolves within 2 to 8 months after onset.{{Malkud, S., (2015). Telogen Effluvium: A Review. Journal Of Clinical And Diagnostic Research. 9(9). WE01-WE03. Available at: https://doi.org/10.7860/JCDR/2015/15219.6492}}

What does it look like? Sudden diffuse thinning across the entire scalp.

What causes it? A “negative event” often triggers telogen effluvium. There isn’t one single cause, and the cause can be different for everyone, whether it be illness, stress, diet, surgical trauma, childbirth, or starting and stopping medications. The time between exposure to a trigger and the onset of telogen effluvium can vary, roughly between 2 and 8 months, similar to the recovery time.

Alopecia Areata

What is it? This is an autoimmune condition in which the body begins to attack its own cells, specifically those of hair follicles. Research shows that there is an abnormally high number of hairs in the catagen phase with this condition, and hair follicles undergo miniaturization with time.{{Sibbald, C. (2023). Alopecia Areata: An Updated Review For 2023. J Cutan Med Surg. 27(3). 241-259. Available at: https://doi.org/10.1177/12034754231168839}}

What does it look like? Bald patches of hair that develop in a non-uniform fashion. Hair loss can sometimes extend beyond the scalp, and inflammation is often observed.

What causes it? Inflammation that is caused by genetics, environmental triggers (i.e., stress, infections, hormone fluctuations, nutrition), and/or loss of hair follicle immunity.

The Science: Does Wegovy Cause Hair Loss?

Wegovy has shown great success in helping people manage their weight. However, every medication comes with risks and potential side effects. With semaglutide medications like Wegovy, there have been several studies and reports documenting how these treatments are sometimes associated with hair loss.

Online discussions also provide anecdotal evidence that this drug may be causing hair loss. But is it true? We will look deeper into the scientific evidence that may indicate a link between Wegovy and hair loss.

Randomized, Double-Blinded, Placebo-Controlled Trials  

Clinical trials that are randomized, double-blinded, and placebo-controlled are the gold standard for testing the effectiveness of new treatments. We can see from the prescribing documentation for Wegovy that there were at least three randomized, double-blind, placebo-controlled trials with adults for this medication. Together, these trials included 3,377 adults with obesity or who were overweight. They were treated with either 2.4 mg Wegovy once weekly, or a placebo once weekly.{{U.S. Food and Drug Administration. (2025). Drug Label: 218316Orig1s000lbl. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf Accessed: 05 March 2026)}}

These trials don’t just test effectiveness; they also evaluate safety and adverse reactions. When pooling the results of all the trials, we can see that there were some common side effects, like nausea, diarrhea, and vomiting, but interestingly, 3% of those receiving the Wegovy injection also reported hair loss. In the placebo group, 1% of users reported hair loss.

We don’t know what kind of hair loss was reported (e.g., telogen effluvium, androgenic alopecia, alopecia areata) or whether the hair loss was clinically diagnosed or self-reported by the user. This makes it difficult to understand the validity of these results. However, it does bring up an important question: Is hair loss truly associated with Wegovy, or is there a natural progression of hair loss occurring while people are taking Wegovy, which they are attributing to the medication?

Overall conclusion: There may be an association between Wegovy and hair loss, but we don’t know whether Wegovy was the cause or what kind of hair loss it may have influenced.

2025 and 2026 Case Reports

Case reports describe the diagnosis, treatment, and follow-up of an individual patient. These types of reports are good for documenting rare or unexpected clinical outcomes. There are two recent case reports describing hair loss following treatment with semaglutide.

Before we get into the reports, let’s just discuss what we can and cannot take from case reports like these. Because they just follow one patient, the results aren’t generalizable to an entire population of people, and sometimes the lack of other study design parameters (like the use of controls, randomization) prevent strong conclusions on cause-and-effect to be made. However, we can use these reports to support the conclusion that there could be an association between the events described in the case.

2025 Case Report

This case report followed a 23-year-old obese female who had been using semaglutide for weight loss over the prior 4 months, injecting 0.25 mg once weekly for the first 2 months, and 0.5 mg once weekly for the remaining 2 months. As she entered her 3rd month of treatment, she noticed the sudden onset of hair loss, with multiple round patches of baldness appearing on the scalp.{{Alzahrani, W.S., Bahkali, S.A., Alharthy, R.F., Alsabban, A.S., (2025). Alopecia Areata Following Semaglutide Treatment For Weight Loss: A Case Report. JAAD Case Reports. 63. 44-46. Available at: https://doi.org/10.1016/j.jdcr.2025.06.012}}

Scalp analysis by a dermatologist revealed:

• Slight redness
• No scaling
• No noticeable changes in the scalp

The hair loss and hair examination were in line with a diagnosis of alopecia areata.

The patient was advised to stop semaglutide and to begin treatment for alopecia areata using a combination of intralesional corticosteroids, 2% ketoconazole shampoo, and 5% topical minoxidil. With the treatment, her hair regrew.

Overall conclusion: There may be an association between a semaglutide like Wegovy and alopecia areata, but there is no evidence that the semaglutide was the cause of alopecia areata.

2026 Case Report

This 2026 case report followed a 33-year-old male who was receiving a 2.4 mg dose of semaglutide weekly. After 2 days, he noticed a small patch of hair loss. After 6 weeks, hair loss was noticeable as a 5 cm2 patch on the left side of his head.{{Cheng, J.-R., Zheng, J., Li, Y., Shi, H., Yang, N., Lei, Y., Wan, Y.-F. (2026). Weight Loss-Associated Alopecia Areata. American Journal of Therapeutics. Available at: https://doi.org/10.1097/MJT.0000000000001851}} 

Semaglutide injections were stopped due to the diagnosis of alopecia areata, and the patient’s alopecia improved 2 months after discontinuing the injections.

Overall conclusion: There may be an association between a semaglutide like Wegovy and alopecia areata, but there is no evidence that the semaglutide was the cause of alopecia areata.

2024 FAERS Study

FAERS is the FDA Averse Event Reporting System, a publicly-accessible, searchable FDA system that collects reports of drug adverse events. 

In 2024, a group of researchers explored the relationship between GLP-1 medications and hair loss by searching reports between 2022 and 2023 related to GLP-1 medications and hair loss.{{Godfrey, H., Leibovit-Reiben, Z., Jedlowski, P., Thiede, R. (2025). Alopecia Associated With The Use Of Semaglutide And Tirzepatide: A Disproportionality Analysis Using The FDA Adverse Event Reporting System (FAERS) From 2022 To 2023. Journal Of The European Academy Of Dermatology And Venereology. 39. e153-e154. Available at: https://doi.org/10.1111/jdv.20197}} They then carried out a disproportionality analysis, a type of statistical test that assesses whether side effects are reported more often in people using a drug than would occur in the general population. What they found was surprising.

Increased reporting odds of hair loss for:

• Semaglutide (199 cases)
• Tirzepatide (179 cases)

No increased reporting odds of hair loss for:

• Liraglutide (20 cases)
• Dulaglutide (65 cases)
• Exenatide (6 cases)
• Lixisenatide (0 cases)

There are a substantial number of reported cases of hair loss with the use of semaglutide and tirzepatide GLP-1 medications. But we have to be aware that this type of analysis is not without several caveats. 

Caveat #1: Reports can be made by anyone

Reports to FAERS can be made by consumers (i.e., the general public) and healthcare professionals alike. That means you can have reports backed by clinical diagnosis, as well as subjective reports where there is no clinician-confirmed diagnosis of hair loss. The study reported that 84% of the reports were from consumers, and 16% were from healthcare professionals.

Caveat #2: Reports can be viewed by anyone

FAERS is publicly accessible. So, anyone can review the results, including the general public and the media. The public and the media may see reports of hair loss by some GLP-1 medications and then create social media posts or sensationalized headlines. This puts the concept of GLP-1 medications as a factor influencing hair loss into the public consciousness, which may increase self-diagnosed reports of hair loss. 

Caveat #3: Reports lack clinical detail

All we see from these reports is that some hair loss occurred. We don’t know what type of hair loss was diagnosed, whether any objective measurements were used to facilitate a clinical diagnosis (e.g., hair counts), or whether there are any other factors in the user’s life that could have influenced this happening (genetics, stress, etc.). All these factors matter when determining an association between GLP-1 medications and hair loss.

Because of these caveats, it’s difficult to build a clear picture of how exactly GLP-1 medications like semaglutide are contributing to reports of hair loss.

Overall conclusion: This FAERS study identifies potential safety signals but does not demonstrate that semaglutide medications are a cause of hair loss in these individuals.

2025 Retrospective Studies

A retrospective study looks back at existing data, usually at medical records, to investigate relationships between past exposures and outcomes. Much like case studies, these types of studies lack randomization and control groups that would permit a cause-and-effect relationship to be established, but we can still draw some conclusions from them.

Retrospective Study #1

The first retrospective study analyzed the medical records of 283 adult patients who were taking GLP-1 medications and had also visited the dermatology department for hair loss between 2021 and 2023.{{Burke, O. (2025). Glucagon-Like Peptide-1 Receptor Agonist Medications And Hair Loss: A Retrospective Cohort Study. Journal Of The American Academy Of Dermatology. 92(5). 1141-1143. Available at: https://doi.org/10.1016/j.jaad.2025.01.046}}

Findings:

• 84.1% of users reported no hair loss
• 1.2% of users with no prior history of hair loss reported new hair loss
• Over 90% of the users with pre-existing hair loss (approximately 13%) experienced worsening of their hair loss 

Let’s look at these numbers in more detail. 

Most of the users did not report any hair loss. This shows that instances of hair loss are not common among those receiving GLP-1 medications, and suggests that, for many, hair loss shouldn’t be a concern if they are prescribed this treatment.

Approximately 1% of users experienced new hair loss, without a prior history of this previously. This might sound bad, but in reality, this matches the rate of hair loss that is expected in the general population over two years. So, are these instances of new hair loss really down to the GLP-1, or down to natural hair loss?

Most of the users with pre-existing hair loss experienced worsening of their condition. Namely, semaglutide was most strongly associated with androgenic alopecia. This is similar to the FAERS study, where semaglutide was identified as having a strong correlation with hair loss reports.

Aside from the common limitations with retrospective studies, the researchers did not include medication duration in their analysis, and hair loss was self-reported by patients instead of being objectively measured, like through hair counts. The time medications were taken matters, because hair loss conditions like telogen effluvium often occur 2 to 8 months after a “trigger”, like when a new medication is taken. Also, with self-reports, we can’t know whether the patients were truly experiencing hair loss as would be defined by a clinician. 

Overall conclusion: These findings warrant further investigation into the relationship between semaglutide and hair loss, but do not demonstrate causation.

Retrospective Study #2

In this second retrospective study, the researchers searched health records of over 100 million patients. They isolated patients who had no prior history of hair loss, but were taking GLP-1 medications (liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or tirzepatide).{{Akiska, Y.M., Vidal, S.I., Menta, N. (2025). Increased Incidence And Risk Of Hair Loss With Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study. EMJ. 13(1). 52-54. Available at: https://doi.org/10.33590/emjdermatol/TYEW1122}} They identified over 500,000 people who met this criteria.

After 6 months of treatment, use of GLP-1 medications was associated with:

• Increased risk of androgenic alopecia
• Increased risk of non-scarring hair loss
• No significant change to the risk of telogen effluvium
• No significant change to the risk of alopecia areata

After 12 months of treatment, use of GLP-1 medications was associated with:

• Increased risk of androgenic alopecia
• Increased risk of non-scarring hair loss
• Increased risk of telogen effluvium
• No significant change to the risk of alopecia areata

Interestingly, no increased risk of alopecia areata was found, given that GLP-1 medications like semaglutide have been reported to be linked to this condition in case studies.

It is also interesting that telogen effluvium risk increased with use over 12 months, but not 6 months. With telogen effluvium, the onset of hair loss after experiencing a trigger can be between 2 and 8 months.{{Malkud, S., (2015). Telogen Effluvium: A Review. Journal Of Clinical And Diagnostic Research. 9(9). WE01-WE03. Available at: https://doi.org/10.7860/JCDR/2015/15219.6492}} These results would suggest that the onset of telogen effluvium was consistently greater than 6 months. 

However, the study design here does not allow us to say whether GLP-1 medications were the cause of hair loss in those instances.

Overall conclusion: These findings warrant further investigation into the relationship between semaglutide and hair loss, but do not demonstrate causation.

What Does It All Mean?

The clinical trials are robust in their design, but they did not further explore the cause of the hair loss reported by some users of Wegovy. 

Similarly, case reports are great for documenting rare events, and retrospective studies are useful for identifying patterns, but neither can establish a cause-and-effect relationship.

So, none of these studies suggest a cause-and-effect relationship between semaglutide medications and hair loss. But what they do show is that there may be an association between semaglutide medications and hair loss, and that this is an association worthy of further investigation.

How Might Wegovy Cause Hair Loss?

There is no evidence to suggest that a semaglutide like Wegovy is a cause of hair loss, but we have established that there could be some association between these two factors. What could cause this association? For now, we don’t know. But there are a few plausible biological explanations.{{Desai, D.D., Sikora, M., Nohria, A., Bordone, L., Caplan, A.S., Shapiro, J., Lo Sicco, K.I. (2024). GLP-1 Agonists And Hair Loss: A Call For Further Investigation. International Journal Of Dermatology. 63. 1128-1130. Available at: https://doi.org/10.1111/ijd.17246}}

Physiological Changes 

Rapid weight loss from using a treatment like Wegovy can have a number of physiological effects on the body, and also introduce some dietary changes. These include:

• Calorie restriction
• Nutritional deficiencies 
• Protein deficiences 
• Physiological stress

These changes are interlinked. For example, calorie restriction can cause physiological stress and may also lead to nutritional and protein deficiencies. All of these stressors are possible when people undergo rapid weight loss. In line with this, studies have shown that GLP-1 users with weight loss often do not have adequate nutritional intake.{{Johnson, B., Milstead, M., Thomas, O. (2025). Investigating Nutrient Intake During Use Of Glucagon-Like Peptide-1 Receptor Agonist: A Cross-Sectional Study. Frontiers In Nutrition. 12. 1566498. Available at: https://doi.org/10.3389/fnut.2025.1566498}} Nutritional deficiencies like these could be a clear cause of hair loss, since protein, iron, and zinc are essential for normal hair cycles and hair growth. You can learn more about the vitamin deficiencies that cause hair loss in our article here.

But there is also a more nuanced perspective. These stressors could trigger telogen effluvium or alopecia areata. 

Calorie restriction, nutritional deficiencies, protein deficiencies, and physiological stress can all be characterized as “negative events” or “environmental factors” that could trigger conditions like these because they disrupt the normal hair growth process. There is research to support this thought:

• Rapid weight loss is a well-known trigger for telogen effluvium. It is not unheard of that after patients have undergone bariatric surgery (weight loss surgery), they soon experience telogen effluvium.{{Cohen-Kurzrock, R.A., Cohen, P.R., (2021). Bariatric Surgery-Induced Telogen Effluvium (Bar SITE): Case Report And A Review Of Hair Loss Following Weight Loss Surgery. Cureus. 13(4). e14617. Available at: https://doi.org/10.7759/cureus.14617}},{{Rojas, P., Gosch, M., Basfi-Fer, K., (2011). Alopecia In Women With Severe And Morbid Obesity Who Undergo Bariatric Surgery. Nutricion Hospitalaria. 26(4). 856-862. Available at: https://doi.org/10.1590/s0212-16112011000400028}},{{Nadler, E.P., Youn, H.A., Ginsburg, H.B., Ren, C.J., Fielding, G.A., (2007). Short-Term Results In 53 US Obese Pediatric Patients Treated With Laparoscopic Adjustable Gastric Banding. Journal Of Pediatric Surgery. 42(1). 137-142. Available at: https://doi.org/10.1016/j.jpedsurg.2006.09.014}},{{Nadler, E.P., Youn, H.A., Ren, C.J., Fielding, G.A., (2008). An Update On 73 US Obese Pediatric Patients Treated With Laparoscopic Adjustable Gastric Banding: Comorbidity Resolution And Compliance Data. Journal Of Pediatric Surgery. 43(1). 141-146. Available at: https://doi.org/10.1016/j.jpedsurg.2007.09.035}}
• Telogen effluvium can be triggered by calorie deficit.{{Kang, D.H., Kwon, S.H., Sim, W.Y., Lew, B.L., (2024). Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Annals Of Dermatology. 36(6). 384-388. Available at: https://doi.org/10.5021/ad.24.043}}
• Alopecia areata has been associated with deficient dietary protein and vitamin D.{{Pham, C.T., Romero, K., Almohanna, H.M., Griggs, J., Ahmed, A., Tosti, A. (2020). The Role Of Diet As An Adjuvant Treatment In Scarring And Nonscarring Alopecia. Skin Appendage Disord. 6(2). 88-96. Available at: https://doi.org/10.1159/000504786}},{{Bhat, Y.J., Latif, I., Malik, R., Hassan, I., Sheikh, G., Lone, K.S., Majeed, S., Sajad, P. (2017). Vitamin D Level In Alopecia Areata. Indian Journal Of Dermatology. 62(4). 407-410. Available at: https://doi.org/10.4103/ijd.IJD_677_16}}

We should also consider that symptoms like diarrhea are common in those taking Wegovy. Diarrhea is a result of intestinal inflammation. Is it possible, then, that this inflammation event could trigger an inflammation event of the scalp, like one that might onset alopecia areata? For now, we don’t know. These are all plausible biological explanations, but there is a lack of clinical trials to show a direct link between Wegovy-associated physiological changes and hair loss.

One curious thing is the association between Wegovy and androgenic alopecia. Why might this happen? 

For those without underlying androgenic alopecia, hair loss from telogen effluvium may get better once the triggers (like rapid weight loss and dietary changes) are removed, and for those experiencing alopecia areata, hair regrowth may be initiated with the removal of triggers and intervention with autoimmune therapies. But, for those experiencing telogen effluvium combined with either androgenic alopecia or alopecia areata, the story might be a bit different. 

Since hair follicle miniaturization can occur after each hair cycle, enhanced shedding could accelerate this process. Therefore, telogen effluvium triggered by rapid weight loss may actually accelerate hair thinning in those who already have androgenic alopecia or alopecia areata. This could explain the connection between hair loss and Wegovy. 

All-Natural Hair Supplement

The top natural ingredients for hair growth, all in one supplement.

Take the next step in your hair growth journey with a world-class natural supplement. Ingredients, doses, & concentrations built by science.

Shop Supplements

Hormonal and Signaling Changes

In the normal growth cycle of hair follicles, hair growth is stimulated by a factor known as insulin-like growth factor 1 (IGF-1). IGF-1 not only stimulates hair follicle proliferation, but also inhibits hair follicle cell death, and stimulates the transition from the telogen phase to the anagen phase.{{Hsieh, W.J., Qiu, W.Y., Percec, I., Chang, T.M., (2025). Insulin-Like Growth Factor 1 (IGF-1) In Hair Regeneration: Mechanistic Pathways And Therapeutic Potential. Current Issues In Molecular Biology. 47(9). 773. Available at: https://doi.org/10.3390/cimb47090773}}

If an outside influence were to disrupt the IGF-1 pathway, it would follow that this outside influence could also disrupt hair growth, and maybe that’s what happens with Wegovy.

We know that semaglutide can change insulin synthesis after food intake. Prolonged energy deficit and weight loss often reduce circulating insulin levels, and similar reductions in insulin have been observed for GLP‑1 agonist users.{{{Jørgensen, S.W., Hjort, L., Gillberg, L., Justesen, L., Madsbad, S., Brøns, C., Vaag, A.A. (2021). Impact Of Prolonged Fasting On Insulin Secretion, Insulin Action, And Hepatic Versus Whole Body Insulin Secretion Disposition Indices In Healthy Young Males. American Journal Of Physiology Endocrinology And Metabolism. 320(2). E281-E290. Available at: https://doi.org/10.1152/ajpendo.00433.2020}},{{Alhowiti, A., Mirghani, H. (2025). The Effects Of GLP-1 Agonists On HbA1c And Insulin Dose Among Patients With Type 1 Diabetes. Frontiers In Endocrinology. 16. 1550938. Available at: https://doi.org/10.3389/fendo.2025.1550938}},{{Luo, Y., Yang, S., Zeng, H., Liu, S., Zhang, Y., Li, J.E., Liu, J. (2025). Both Subcutaneous Semaglutide And Calorie Restriction Improves Pancreatic Cell Hyperplasia And Gut Microbiota In High-Fat Diet-Induced Obese Mice. Nutrition And Metabolism. 22(1). 95. Available at: https://doi.org/10.1186/s12986-025-00987-0}}

How does this relate to IGF-1? Well, insulin is a primary factor modulating the availability of IGF-1 in the body.{{Brismar, K., Fernqvist-Forbes, E., Wahren, J., Hall, K., (1994). Effect Of Insulin On The Hepatic Production Of Insulin-Like Growth Factor-Binding Protein-1 (IGFBP-1), IGFBP-3, And IGF-I In Insulin-Dependent Diabetes. Journal Of Clinical Endocrinology And Metabolism. 79(3). 872-878. Available at: https://doi.org/10.1210/jcem.79.3.7521354}} It is possible that by affecting insulin levels in the body, a drug like Wegovy may inadvertently affect the normal hair growth cycle.

A case study with a 54-year-old woman experiencing hair loss showed that treatment with insulin therapies was associated with a reduction in hair shedding. Hair shedding was not improved with minoxidil, suggesting usual causes of hair loss were not the underlying problem here. Although cause-and-effect can not be established, the case supports the notion that insulin and hair growth are linked.{{Kant, R., Barnwal, S., Sharma, S.K., Thakur, K. (2021). Reversal Of Alopecia By Insulin Therapy In Uncontrolled Type 2 DM: A Case Report. Journal Of Diabetology. 12(4). 533-537. Available at: https://doi.org/10.4103/jod.jod_66_21}}

It is not without mention that changes to insulin could also be a trigger for alopecia areata or telogen effluvium. With the latter, this may accelerate hair thinning in those with androgenic alopecia, as we’ve discussed.

Hair Cycle Changes

A 2006 study in mice found high levels of the hormone GLP-1 in the hair follicles of newborn mice. The researchers also discovered that GLP-1 activated a signalling pathway in skin cells called MAPK/ERK, which is known to be involved in cell growth and division.{{List, J.F., He, H., Habener, J.F. (2006). Glucagon-Like Peptide-1 Receptor And Proglucagon Expression In Mouse Skin. Regulatory Peptides. 134(2–3). 149-157. Available at: https://doi.org/10.1016/j.regpep.2006.02.007}}

Based on these findings, the scientists suggested that GLP-1 may play a role in the development of hair follicles. This raises the question of whether GLP-1 medications could have any effects on the hair cycle, a possible link between Wegovy and hair biology.

However, it’s important to note that this research was conducted only in animals and did not include human participants. Results seen in animal studies do not always apply to people. So while the study suggests GLP-1 may influence the hair cycle in mice, it does not show that the same process happens in humans.

Distinguishing Between Androgenic Alopecia, Telogen Effluvium, and Alopecia Areata

Hair loss can be distressing. If you are using Wegovy and are troubled about hair loss, it’s important to first assess what kind of hair loss you might have. 

Gradual (over many years), patterned thinning, and possibly a family history of balding? The likely cause is androgenic alopecia.

Sudden diffuse hair shedding without thinning, that has onset 2 to 8 months after taking Wegovy, or follows another recent stressful event? The likely cause is telogen effluvium.

Sudden patchy hair loss with a smooth bald spot and hair thinning, possibly with previous similar episodes or a personal or family history of autoimmune disease? The likely cause is alopecia areata.

I’m Using Wegovy, Should I Be Concerned?

Signs	Should I be concerned?
I have no signs of hair loss or a family history of hair loss	No, probably not. The evidence suggests that people with these signs are at a very low risk of developing new hair loss from Wegovy.
I have signs of hair loss, and may or may not have a family history of hair loss	Maybe. The evidence suggests that medications like Wegovy could worsen existing hair loss by causing telogen effluvium, although there is no clinical evidence directly showing that this is the case.
I have early signs of hair loss, or haven’t noticed any ongoing hair loss, and may or may not have a family history of hair loss	Maybe. If you haven’t noticed any hair loss, but are predisposed to androgenic alopecia or alopecia areata, a medication like Wegovy may progress thinning to a point where it is noticeable if telogen effluvium occurs. Again, there is no clinical evidence to back this theory, but it is a plausible scenario.

What Can I Do To Prevent Hair Loss With Wegovy?

#1: Avoid rapid weight loss

When pursuing weight loss, it is important to avoid aggressive calorie restriction, as severe deficits can stress the body and contribute to unwanted side effects such as increased hair shedding. 

#2: Eat a balanced diet, or take supplements

Aim for a balanced approach that ensures adequate intake of essential nutrients. In particular, sufficient protein is critical because hair is primarily made of keratin, a protein that depends on dietary amino acids for growth and maintenance. 

Adequate micronutrients, including iron, zinc, vitamin D, and B vitamins, are also necessary to support healthy hair follicles and overall metabolic function.

#3: Monitor your hair

During periods of rapid weight loss, monitor for increased hair shedding, which can occur due to physiological stress or nutrient deficiencies. Tracking changes early can help identify problems before significant hair thinning develops. 

#4: Get an opinion before starting Wegovy, and consider hair loss treatments

For individuals planning weight loss with Wegovy, it may be beneficial to obtain a baseline scalp evaluation from a healthcare professional to see whether there is any ongoing hair loss or whether there might be potential for hair loss in the future.

If you have a known predisposition to hair loss, talk to your doctor about early intervention with appropriate hair loss treatments like topical minoxidil or oral finasteride. These may be able to help preserve hair density while weight loss progresses. You can learn more about minoxidil, the side effects, and how to minimize them in our article here.

Final Thoughts

Online discussions and patient reports have caused concern that weight loss treatments like Wegovy may cause hair loss. Unfortunately, the current clinical evidence remains limited. A small number of case reports suggest that alopecia areata can occur in some individuals taking semaglutide, and larger retrospective studies indicate that, while most users do not experience significant hair loss during treatment, some with underlying hair loss conditions, like androgenic alopecia, experience a worsening of their condition.  

We don’t know why or how this might happen. However, we can speculate that this may be caused by the onset of telogen effluvium. Rapid weight loss and nutrient deficiencies are well-established triggers for telogen effluvium, and are possible while taking a medication like Wegovy. So, the hair changes observed during Wegovy therapy are likely not a result of the drug itself, but rather the physiological effects of weight loss.

Large, randomized, and controlled clinical trials are needed to confirm the relationship between Wegovy and hair loss. But for now, we recommend that if you are considering Wegovy, consider evaluating your hair health first. Consult your doctor, and implement appropriate treatment routes, lifestyle changes, and hair loss treatments for the best chance to avoid sudden changes to your hair when you are trying to lose weight.

GLP-1 agonists, including tirzepatide, are the new “it drugs”, rapidly gaining popularity over the last few years. While other GLP-1 agonists have previously held market dominance, tirzepatide has emerged as the most prescribed GLP-1 drug in the U.S in 2025.{{Truveta Research, (2025), GLP-1 RA Prescription Trends: January 2018 – June 2025. Available at: https://www.truveta.com/blog/research/glp-1-ra-prescription-trends-january-2018-june-2025/ (Accessed: 13 March 2026)}} A survey completed in 2024 found that approximately one in eight adults had at some point used a GLP-1 agonist, with 6% taking the drugs at the time of the survey.{{Montero, A., Sparks, G., Presiado, M., Hamel, L., (2024), KFF Health Tracking Poll May 2024: The Public’s Use And Views Of GLP-1 Drugs. Available at: https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/ (Accessed: 27 February 2026)}} Numbers are likely to have risen even further since then, with tens of millions of people having taken the drugs.

However, the many positive reports of weight loss and blood sugar control on taking GLP-1 agonists have been accompanied by increasing reports of side effects. Gastrointestinal problems are the most well-established side effect, but reports of hair loss are emerging on social media and internet forums. These alarming stories are becoming more prevalent, but are they actually true?

Interested in Topical Minoxidil?

High-strength topical minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

In this article, we have searched through the clinical literature to find out whether these claims are supported by the science. We will cover what tirzepatide is and how it works, evidence supporting hair loss claims, and potential hair loss mechanisms influenced by tirzepatide.

What is Tirzepatide?

Tirzepatide is the active drug molecule used in brand-name medications such as Mounjaro and Zepbound. Originally produced for use in type 2 diabetes, tirzapetide is now widely used both for diabetes treatment and weight loss. It involves a once-weekly injection.

Unlike Ozempic (the other main GLP-1 agonist drug), tirzepatide binds to two hormone receptors: glucagon-like peptide-1 (GLP-1) receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors, making it a dual agonist.{{Farzam, K., Patel, P. (2024). Tirzepatide. StatPearls. Available at: http://www.ncbi.nlm.nih.gov/books/NBK585056/ (Accessed: 16 March 2026)}}

Initial clinical trials with tirzepatide found that the drug successfully controlled type 2 diabetes while simultaneously resulting in significant weight loss in many users.{{Coskun, T., Sloop, K.W., Loghin, C. (2018). LY3298176, A Novel Dual GIP And GLP-1 Receptor Agonist For The Treatment Of Type 2 Diabetes Mellitus: From Discovery To Clinical Proof Of Concept. Molecular Metabolism. 18. 3-14. Available at: https://doi.org/10.1016/j.molmet.2018.09.009}} Large-scale clinical trials further demonstrated the effectiveness of tirzepatide, showing an average of 15% weight loss by week 72 with 5 mg weekly injections.{{Jastreboff, A.M., Aronne, L.J., Ahmad, N.N. (2022). Tirzepatide Once Weekly For The Treatment Of Obesity. New England Journal Of Medicine. 387(3). 205-216. Available at: https://doi.org/10.1056/NEJMoa2206038}}

Tirzepatide is available either as Mounjaro (FDA-approved for the treatment of type 2 diabetes) or as Zepbound (FDA-approved for chronic weight management in obese adults). Other related GLP-1 agonists include Ozempic and Liraglutide, but these do not contain tirzepatide as their active ingredient, are not dual agonists, and use slightly different mechanisms.

How Does Tirzepatide Work?

GLP-1 and GIP are both peptides found naturally within the body. They are released into the bloodstream in response to food consumption and act to increase insulin secretion, improving blood glucose levels.{{Wolfe, M.M., Boylan, M.O., Chin, W.W. (2025). Glucose-Dependent Insulinotropic Polypeptide In Incretin Physiology: Role In Health And Disease. Endocrine Reviews. 46(4). 479-500. Available at: https://doi.org/10.1210/endrev/bnaf006}}

Tirzepatide is a synthetic peptide with the ability to mimic natural GIP and GLP-1, resulting in the activation of their receptors. This results in a combined effect of:{{Holst, J.J. (2007). The Physiology Of Glucagon-Like Peptide 1. Physiological Reviews. 87(4). 1409-1439. Available at: https://doi.org/10.1152/physrev.00034.2006}},{{Drucker, D.J. (2022). GLP-1 Physiology Informs The Pharmacotherapy Of Obesity. Molecular Metabolism. 57. 101351. Available at: https://doi.org/10.1016/j.molmet.2021.101351}},{{Jiang, Y., Zhu, H., Gong, F. (2024). Why Does GLP-1 Agonist Combined With GIP And/Or GCG Agonist Have Greater Weight Loss Effect Than GLP-1 Agonist Alone In Obese Adults Without Type 2 Diabetes? Diabetes, Obesity And Metabolism. 27(3). 1079-1095. Available at: https://doi.org/10.1111/dom.16106}}

• Increased insulin secretion after eating.
• Inhibited glucagon secretion to reduce spikes in blood sugar.
• Slowing stomach emptying to help people feel fuller for longer.
• Suppressed appetite, resulting in reduced food cravings and decreased calorie intake.

When both the GLP-1 and GIP receptors are stimulated, their effects are magnified further than the activation of only one receptor. As such, tirzepatide is thought to be more effective than semaglutide (Ozempic), both for blood sugar control and weight loss.{{Frías, J.P., Davies, M.J., Rosenstock, J. (2021). Tirzepatide Versus Semaglutide Once Weekly In Patients With Type 2 Diabetes. New England Journal Of Medicine. 385(6). 503-515. Available at: https://doi.org/10.1056/NEJMoa2107519}},{{Rodriguez, P.J., Goodwin Cartwright, B.M., Gratzl, S. (2024). Semaglutide Vs Tirzepatide For Weight Loss In Adults With Overweight Or Obesity. JAMA Internal Medicine. 184(9). 1056-1064. Available at: https://doi.org/10.1001/jamainternmed.2024.2525}}

Does Tirzepatide Cause Hair Loss?

Although tirzepatide and other GLP-1 agonists have been approved by the FDA, they have not been used by the general public for very long. As a result, the understanding of long-term effects and the comprehensive analysis of side effects remains limited. As the number of people using the drugs rapidly rises, reports of side effects are becoming more prominent. 

The most common side effects are gastrointestinal, including nausea, vomiting, and abdominal pain.{{Jastreboff, A.M., Aronne, L.J., Ahmad, N.N. (2022). Tirzepatide Once Weekly For The Treatment Of Obesity. New England Journal Of Medicine. 387(3). 205-216. Available at: https://doi.org/10.1056/NEJMoa2206038}} A small number of GLP-1 agonist users may experience serious side effects, including pancreatitis, gallbladder disease, or kidney injury.

Stories of hair thinning and hair loss as a result of taking GLP-1 agonists are gaining traction on social media and forums (such as Reddit). But are these accurate, or are they simply anecdotal reports? 

Clinical Evidence

The existing clinical data linking tirzepatide to hair loss are limited. Throughout the process of progressing a drug to the market, side effects are comprehensively assessed to ensure the safety of the product. These side effects are publicly reported, and enable researchers to decide whether the benefits of the drug outweigh the potential harm caused by side effects.

In early tirzepatide clinical trials assessing its efficacy for treating type 2 diabetes, gastrointestinal adverse events were often reported, but there were no reports of alopecia.{{Frías, J.P., Davies, M.J., Rosenstock, J. (2021). Tirzepatide Versus Semaglutide Once Weekly In Patients With Type 2 Diabetes. New England Journal Of Medicine. 385(6). 503-515. Available at: https://doi.org/10.1056/NEJMoa2107519}} However, some of the earliest trials using tirzepatide for obesity reported alopecia as an adverse event occurring within the tirzepatide treatment group. In one study, alopecia was reported in 5.1% of people taking 5 mg tirzepatide, compared to only 0.9% in the placebo group.{{Jastreboff, A.M., Aronne, L.J., Ahmad, N.N. (2022). Tirzepatide Once Weekly For The Treatment Of Obesity. New England Journal Of Medicine. 387(3). 205-216. Available at: https://doi.org/10.1056/NEJMoa2206038}}

The reason for this disparity is unclear, but it may be due to the diabetes trial being shorter (only 40 weeks compared to 72 weeks for the obesity trial) or due to less stringent adverse event reporting.

With the approval of tirzepatide for weight loss, the use of this drug saw a rapid rise. However, this coincided with increasing reports of hair loss, leading to the FDA issuing a warning in 2023 that GLP-1 receptor agonists (such as tizepatide) may increase the risk of alopecia.{{Center for Drug Evaluation and Research, (2024), July – September 2023 | Potential Signals Of Serious Risks/New Safety Information Identified By The FDA Adverse Event Reporting System (FAERS). Available at: https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse (Accessed: 16 March 2026)}} A small number of studies have investigated the link between tirzepatide and hair loss further.

Study #1

This study was conducted using the FDA Adverse Event Reporting System (FAERS), which collects reports of adverse drug events from consumers (i.e., the people taking the drug) and healthcare professionals. The study was published in 2025, but reported data from 2022-2023.{{Godfrey, H., Leibovit-Reiben, Z., Jedlowski, P., Thiede, R. (2025). Alopecia Associated With The Use Of Semaglutide And Tirzepatide: A Disproportionality Analysis Using The FDA Adverse Event Reporting System (FAERS) From 2022 To 2023. Journal Of The European Academy Of Dermatology And Venereology. 39(2). e153. Available at: https://doi.org/10.1111/jdv.20197}}

The researchers searched through the FAERS database to identify cases of alopecia linked to GLP-1 and GLP-1/GIP agonists. Within the time period assessed, 179 reports of alopecia were reported for tirzapetide, 199 reports for semaglutide (Ozempic), and fewer reports for other GLP-1 receptor agonists (GLP-1 RAs).

The researchers then carried out a statistical test on this data to assess whether alopecia was reported more often in people taking the GLP-1 RA than would normally occur in the FAERS database as a whole (this is known as a disproportionality analysis). 

They found that tirzapetide and semaglutide showed an increase in reporting odds, so alopecia was reported more often in people taking either of these GLP-1 RAs than would be expected in the whole FAERS population.

This report highlighted the possibility of an association between tirzepatide and hair loss, but how much can we read into these results? 

A few limitations exist within this study, which constrain our ability to make bold claims about tirzepatide and alopecia. These include:

• The methodology of this study and the disproportionality analysis used cannot prove a causal relationship.
• FAERS only uses voluntary reporting of adverse events, meaning that the data can be skewed by a heightened awareness of potential side effects (such as through attention in the news or reports on social media).
• 84% of the reports of alopecia made to FAERS were from consumers, and only 16% were from healthcare professionals, making it likely that users were self-diagnosing and had not received a clinician-confirmed report of alopecia.
• The type of hair loss was not reported.

Therefore, while this report contributes evidence supporting the association between tirzepatide and hair loss, it does not prove the connection. Additional studies must be carried out to determine whether tirzepatide (or other GLP-1 RAs) is directly causing hair loss.

Study #2

This study was conducted using a retrospective analysis of patients on GLP-1 RAs who had visited a dermatology department between 2021 and 2023. This consisted of 283 patients total, and used a real-world setting to assess reports of alopecia in GLP-1 RA users.{{Burke, O., Sa, B., Alvarez Cespedes, D., Sechi, A., & Tosti, A. (2025). Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. Journal of the American Academy of Dermatology. 92(5). 1141–1143. Available at: https://doi.org/10.1016/j.jaad.2025.01.046}}

Of the 283 patients on GLP-1 RAs who visited the dermatology clinic, the majority did not have hair loss (84.1%), but 35 presented with hair loss. Of these, only three (1.2%) were experiencing new hair loss (with no previous reports of hair loss). This is approximately in line with the rate that would be expected in the population as a whole over two years, so does not demonstrate any specific effects of GLP-1 RAs on new hair loss.

The results are more convincing for those with preexisting hair loss; of the 32 people presenting with preexisting hair loss (13%), 90% reported that their hair loss had worsened since using GLP-1 RA drugs. However, male pattern hair loss is a progressive condition, meaning that hair loss continues to worsen over time. The design of this trial (being retrospective) makes it impossible to distinguish between the effects that the drugs may be having on hair loss and the normal rate of hair loss that occurs with male pattern baldness.

Further analysis of the results from this trial failed to demonstrate any significant associations between GLP-1 RAs and hair loss, although a borderline significant value was found linking tirzepatide and a specific type of hair loss known as telogen effluvium, suggesting a potential contribution of tirzepatide to this condition.

While this study highlights a potential association between tirzepatide and hair loss, again, there are several limitations to the study, including:

• The work was retrospective, putting it at risk of selection bias, confounding variables, and missing data.
• There was no control group, meaning that a cause-and-effect relationship cannot be assessed, and it is not possible to separate the normal rate of hair loss from drug-induced hair loss.
• The length of time that patients were on GLP-1 RA medication was not recorded.
• There was no official alopecia diagnosis based on objective measures; instead, self-reported patient data was used.

Similar to the first study, a connection between tirzepatide and hair loss is possible based on the results of this work, but it cannot be conclusively proven.

Study #3

Another retrospective analysis study was carried out, this time using the TriNetX database. This is a data network of healthcare organizations around the world that pools patient data from anonymized electronic health records. It is a very large database, meaning that this study was able to look at the data of over 360,000 patients, of which ~60% had been prescribed GLP-1 RAs.{{Neubauer, Z., Ong, M.M., Singal, A., Lipner, S.R. (2025). Increased Risk Of Telogen Effluvium With Tirzepatide Compared To Other Weight Loss Medications: A Retrospective Cohort TriNetX Database Study. Journal Of The American Academy Of Dermatology. 93(6). 1612-1614. Available at: https://doi.org/10.1016/j.jaad.2025.08.033}}

This study was specifically investigating a type of hair loss known as telogen effluvium, not any other types of hair loss (such as male pattern baldness). Tirzepatide-treated patients were shown to have an increased risk of telogen effluvium, whereas other GLP-1 RAs did not show increased risk. The authors suggested that this was due to the superior weight loss effects of tirzepatide.

Again, this work suggests a link between tirzepatide and hair loss, but due to its retrospective nature, a cause-and-effect relationship cannot be established.

Study #4

This study was also conducted using the TriNetX database. They carried out two analyses, one of which was specifically using the TriNetX U.S. database (consisting only of healthcare organizations in the U.S.), and the second was a worldwide analysis. Similarly to the previous study, due to the large sizes of these databases, they were able to get over 500,000 matched patients in the U.S. analysis and over 600,000 in the worldwide analysis.{{Herrera, H.O., Bordeaux, J.S. (2026). Risk Of New-Onset Hair Loss With Semaglutide And Tirzepatide: A TriNetX Cohort Study. Journal Of The American Academy Of Dermatology. 0(0). Available at: https://doi.org/10.1016/j.jaad.2026.02.042}}

The researchers found that the use of tirzapetide and semaglutide was associated with an increased risk of hair loss, including androgenic alopecia and telogen effluvium. While promising, this study was limited by the lack of information on hair loss severity, the lack of an official hair loss diagnosis using imaging techniques, and its retrospective nature.

How Might Tirzepatide Contribute to Hair Loss?

While evidence is growing supporting an association between tirzepatide (and other GLP-1 RAs) and hair loss, the exact mechanisms through which this occurs are essentially all speculation at this point. They include:

Direct Effects on the Hair Cycle

It is possible that tirzepatide may directly influence the hair growth cycle. GLP-1 receptors have been found to be localized around hair follicles in the skin, although this has only been demonstrated in research animals so far. In one study, GLP-1 was shown to activate a signaling pathway in skin cells, leading to cell proliferation.{{List, J.F., He, H., Habener, J.F. (2006). Glucagon-Like Peptide-1 Receptor And Proglucagon Expression In Mouse Skin. Regulatory Peptides. 134(2). 149-157. Available at: https://pubmed.ncbi.nlm.nih.gov/16631262/}} This could have an impact on hair growth; however, this has not been proven in any animal or human studies so far.

Tirzepatide may also disrupt metabolic and hormonal signalling pathways involved in the hair cycle, such as the insulin/insulin-like growth factor-1 (IGF-1) pathway. Interference with such pathways may play a role in accelerating follicle shrinkage, the key mechanism in the development of AGA. This could then accelerate the onset or progression of hair loss in those predisposed to AGA.

Telogen Effluvium

Tirzepatide has been linked to hair loss in general, but has been specifically associated with telogen effluvium. Telogen effluvium is a form of alopecia where a physiological stress can cause excessive, diffuse shedding (i.e., hairs across the whole scalp are affected, not only those in certain areas).

The hair growth cycle consists of several phases, including anagen (the growth phase) and telogen (the resting phase). In a healthy scalp, approximately 85% of all of the hair on the head is in anagen, and 15% is in telogen.{{Hughes, E.C., Syed, H.A., Saleh, D., (2025), Telogen Effluvium. Available at: http://www.ncbi.nlm.nih.gov/books/NBK430848/ (Accessed: 16 March 2026)}}

When exposed to a physiological stress, many hairs abruptly and prematurely switch from anagen to telogen. Hair growth of these hairs ceases, and approximately three months later, the hairs are shed. 

Physiological triggers can include metabolic stress from rapid weight loss. Telogen effluvium has been shown to occur in response to multiple causes of weight loss, including crash dieting and bariatric surgery.{{Kang, D.H., Kwon, S.H., Sim, W.Y., Lew, B.L. (2024). Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Annals Of Dermatology. 36(6). 384-388. Available at: https://doi.org/10.5021/ad.24.043}},{{Zhang, W., Fan, M., Wang, C. (2021). Hair Loss After Metabolic And Bariatric Surgery: A Systematic Review And Meta-Analysis. Obesity Surgery. 31(6). 2649-2659. Available at: https://doi.org/10.1007/s11695-021-05311-2}}

Tirzepatide causes rapid weight loss in many users, with patients seeing as much as 25% weight reduction within 88 weeks.{{Aronne, L.J., Sattar, N., Horn, D.B. (2023). Continued Treatment With Tirzepatide For Maintenance Of Weight Reduction In Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 331(1). 38-48. Available at: https://doi.org/10.1001/jama.2023.24945}} This rapid weight loss and metabolic stress from long-term calorie deficit may be the root-cause of the hair loss seen in many individuals taking tirzepatide.

While other GLP-1 RAs may also result in telogen effluvium, the additional weight loss thought to occur with tirzepatide may explain why tirzepatide in particular has been associated with telogen effluvium.

Telogen effluvium is a reversible condition in the majority of cases. As such, the removal of the physiological stressor (i.e., the sudden, rapid weight loss) will slow hair shedding, and hair will return to its original density.

Nutritional Deficiencies

GLP-1 RAs cause a reduction in appetite and cravings, resulting in a notable decrease in the amount of food eaten. As a result, people on these medications must carefully plan their diet to ensure that they are taking in all of the vitamins and minerals that are essential for normal bodily function and remaining healthy. In addition, they must ensure that sufficient protein is being consumed to retain muscle mass.{{Ida, S., Kaneko, R., Imataka, K. (2021). Effects Of Antidiabetic Drugs On Muscle Mass In Type 2 Diabetes Mellitus. Current Diabetes Reviews. 17(3). 293-303. Available at: https://doi.org/10.2174/1573399816666200705210006}}

One study investigating nutrient intake in GLP-1 RA users found that they were significantly under the recommended daily intake for several important nutrients, including vitamin B2, vitamin D, and iron.{{Johnson, B., Milstead, M., Thomas, O. (2025). Investigating Nutrient Intake During Use Of Glucagon-Like Peptide-1 Receptor Agonist: A Cross-Sectional Study. Frontiers In Nutrition. 12. 1566498. Available at: https://doi.org/10.3389/fnut.2025.1566498}}

Severe deficiencies in several nutrients have been implicated in hair loss, including vitamin D, iron, and vitamin B2.{{Almohanna, H.M., Ahmed, A.A., Tsatalis, J.P., Tosti, A. (2018). The Role of Vitamins And Minerals In Hair Loss: A Review. Dermatology And Therapy. 9(1). 51-70. Available at: https://doi.org/10.1007/s13555-018-0278-6}} This may be contributing to hair loss seen on GLP-1 RA use, but more research is needed to provide direct evidence for this.

Telogen Effluvium vs Androgenetic Alopecia

The existing evidence for tirzepatide-induced hair loss is limited; however, the small amount of evidence available indicates that tirzepatide may be influencing telogen effluvium and AGA. Both of these hair loss mechanisms have overlapping symptoms, so if you are experiencing hair loss, how can you tell the difference?

1. Telogen effluvium occurs fairly quickly, about 3 months after a trigger (such as rapid weight loss). AGA occurs gradually over many years.
2. The hairs shed via telogen effluvium look like normal hairs, with a standard hair shaft thickness. Hairs shed via AGA are often thinner, vellus-like hairs due to the miniaturization of the hair follicle altering the hair structure.
3. Telogen effluvium causes hair shedding and reduced hair density across the whole scalp (diffuse shedding). AGA hair loss happens in a particular pattern, commonly a receding hairline and bald patch at the crown of the head.

It is possible that users of tirzepatide may experience either AGA or telogen effluvium, neither, or both simultaneously. The diffuse shedding of telogen effluvium may make AGA more obvious, and so it may seem that AGA has occurred very suddenly, when in fact it has been gradually progressing since before taking tirzepatide.

Should You Be Concerned?

If you have not experienced hair loss in the past, then there is probably little reason to be concerned. 

The existing evidence so far suggests that people who have not previously experienced hair loss are unlikely to see a sudden onset of hair loss in response to taking tirzepatide. It is possible that rapid weight loss may trigger telogen effluvium, but this is often only temporary, and full hair density will be restored once the physiological trigger is removed.

If you have AGA, then you may be slightly more concerned. The studies carried out so far have shown a worsening of existing hair loss in some people taking tirzepatide. However, no placebo-controlled trials investigating this have been carried out, meaning that the effects seen may just be the natural progression of AGA over time.

Rapid weight loss-induced telogen effluvium may reveal AGA hair thinning that was previously unnoticed. As such, people with a genetic predisposition to AGA and with the early signs of it may suddenly appear to have experienced a dramatic loss of hair, when in actual fact this had been slowly progressing for years and has only now become noticeable.

If you are starting on tirzepatide:

• Avoid extreme calorie restriction.
• Ensure that you are taking in sufficient nutrients, including protein, vitamins, and minerals.
• Monitor your hair from the start, noting if you already have thinning areas, and tracking hair shedding (particularly considering the timing, as this could indicate telogen effluvium).
• If you already have AGA or know that you are likely predisposed to AGA, consider addressing hair loss early, such as through the use of hair loss treatments.

Hair loss treatments can be safely used alongside weight-loss treatments to reduce visible hair loss, maintain hair density, and give you peace of mind. Topical minoxidil, finasteride, and dutasteride are all viable options for encouraging hair growth. You should discuss with your provider which of these is most appropriate for you, as some may have additional safety concerns.

FAQs

Q: Does Mounjaro Cause Hair Loss?

A: Mounjaro is the brand name for tirzepatide. The data discussed in this article will apply to both Mounjaro and tirzepatide.

Q: Does Zepbound Cause Hair Loss?

A: Zepbound is another brand name for tirzepatide, and so the data discussed in this article can apply to Zepbound as well as tirzepatide.

Q: If I notice hair thinning while taking tirzepatide, what should I do?

A: You should monitor your hair shedding and speak to your doctor. You may be able to start on hair loss treatments alongside tirzepatide to reduce hair loss.

Q: If I lose weight quickly, will I experience hair loss?

Tirzepatide often causes rapid weight loss, potentially even more dramatic than that seen with Ozempic. Rapid weight loss may result in telogen effluvium and temporary hair shedding.

Final Thoughts

Tirzepatide and other GLP-1 RAs provide significant benefits for weight loss and type 2 diabetes treatment, but concerns about side effects – including hair loss – are still under investigation. The evidence so far does not prove a direct causal link between tirzepatide and hair loss, but there is a degree of evidence supporting the association, particularly in those genetically predisposed to male pattern hair loss.

Shedding may be temporary and linked to rapid weight loss-induced telogen effluvium; the extreme weight loss seen on tirzepatide treatment compared to other GLP-1 RAs may further implicate it in this mechanism of hair loss. Nutrient deficiencies and the natural progression of AGA are also likely mechanisms.

More long-term research into the side effects of tirzepatine is needed for definite conclusions to be drawn, but for the time being, the benefits of tirzepatide appear to outweigh the potential risk of hair loss.

Female hair loss remains a widely misunderstood and often under-treated condition, affecting nearly one-third of all women at some point in their lives and up to two-thirds after menopause. Unlike male pattern hair loss, research and treatment options for women have historically lagged, resulting in limited specialized solutions and significant emotional distress for those afflicted.

Minoxidil stands as the only FDA-approved medication for female pattern hair loss. Its efficacy is supported by robust data, particularly at the 2 and 5% concentrations for women. In this guide, we will showcase the six best minoxidil products for women, including the best overall, best value, and top specialized choices. 

Quick Look: Top 7 Minoxidil Brands for Women 2026

Product	Strength	Format	Customization	Price	Best
Ulo Women’s Rx Minoxidil	7%	Solution	High	$41.65	Overall Topical
Ulo Minoxidil Dissolving Chews	1.25 mg or 2.25 mg	Chewable rapid dissolve tablet	High	From $39	Overall Oral
Musely	8%	Solution	High	$99	Strength
Rogaine Women’s Foam	5%	Foam	None	$49.97	Sensitivity
Hers	2%-5%	Solution/Foam	None	$30	Value
Happy Head (Women’s Formula)	6%	Solution	High	$79	Alternative
Winona	7%	Solution	None	$150	Woman-centered care

Before we get into our list, let’s first take a look at what female pattern hair loss is and how minoxidil works for women.

Interested in Topical Minoxidil?

High-strength topical minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

What is Female Pattern Hair Loss?

Female pattern hair loss (FPHL) is a chronic, non-scarring alopecia where genetically susceptible follicles on the central scalp progressively minaturize, leading to reduced hair density over time. Clinically, women usually show diffuse thinning over the crown and midline part with relative preservation of the frontal hairline rather than “bald patches”.{{Bhat, Y.J., Saqib, N-U., Latif, I., Hassan, I. (2020). Female Pattern Hair Loss – An Update. Indian Dermatology Online Journal. 11(4). 493-501. Available at: https://doi.org/10.4103/idoj.IDOJ_334_19}} 

The Ludwig scale grades this pattern from I-III: mild central thinning (I), moderate widening of the part and density loss (II), and advanced, see-through vertex thinning (III). Trichoscopy and histology show increased hair shaft diameter variability and replacement of terminal hairs by finer, vellus-like hairs.{{Kothari, C.R., Shivakumar, P. (2024). Trichoscopic Features in Female Pattern Hair Loss: 1-Year Hospital-Based Cross-Sectional Study. Clinical Dermatology Review. 8(2). 95-101. Available at: https://doi.org/10.4103/cdr.cdr_123_21}} 

FPHL arises from a mix of genetics, hormones, low-grade inflammation, oxidative stress, and microvascular and aging-related changes around the follicle. Unlike classic male pattern hair loss, many women have normal serum androgens, suggesting that local androgen sensitivity and non-androgen mechanisms both contribute.{{Ramos, P.M., Miot, H.A. (2015). Female Pattern Hair Loss: a clinical and pathophysiological review. Anais Brasileiros de Dermatologia. 90(4). 529-543. Available at: https://doi.org/10.1590/abd1806-4841.20153370}} 

How Minoxidil Works

Minoxidil functions as a potassium channel opener that promotes vasodilation, increasing blood flow and improving microcirculation around hair follicles.{{Hussein, R.S., Dayel, S.B., Abahussein, O., El-Sherbiny, A.A. (2024). Applications and efficacy of minoxidil in dermatology. Skin Health and Disease. 4(6). E472. Available at: https://doi.org/10.1002/ski2.472}}

 It is also a prodrug that must be converted by the sulfotransferase enzyme into its active form, minoxidil sulfate. This conversion helps extend the anagen (growth) phase while shortening the telogen (resting) phase, thereby shifting a greater number of follicles into active growth cycles.{{Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Advances in Dermatology and Allergology. 39(3). 472-478. Available at: https://doi.org/10.5114/ada.2020.99947}}

Additional evidence indicates that minoxidil stimulates the expression of growth-promoting factors, such as vascular endothelial growth factor (VEGF), and activates the Wnt/β-catenin signaling pathway, both of which further support hair regrowth.{{Gupta, A.K., Talukder, M., Shemer, A., Piraccini, B.M., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: https://doi.org/10.1159/0000531890}}

While minoxidil does not directly address dihydrotestosterone (DHT), it can enhance the effectiveness of other therapies by targeting different biological pathways involved in hair loss. When used alongside anti-DHT treatments such as finasteride, which reduces the underlying hormonal driver of androgenic alopecia, minoxidil offers a complementary, non-hormonal mechanism of action. Clinical research demonstrates that the combined use of topical finasteride and minoxidil produces greater improvements in hair density in men compared to minoxidil alone.{{Asad, N., Naseer, M., Ghafoor, R. (2024). Efficacy of Topical Finasteride 0.25% with Minoxidil 5% versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of Drugs in Dermatology. 23(11). 1003-1008. Available at: https://doi.org/10.36849/JDD.7826}}

Why Women Respond Differently

In women, pattern hair loss is generally less strictly DHT-driven than in men, so microcirculation, oxidative stress, and local inflammatory pathways play a proportionately greater role.{{Fabbrocini, G., Cantelli, M., Masara, A., Annunziata, M.C., Marasca, C., Cacciapuoti, S. (2018). Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. International Journal of Women’s Dermatology. 4(4). 203-211. Available at: https://doi.org/10.1016/j.ijwd.2018.05.001}} This helps explain why a vasodilatory, pro-anagen agent like minoxidil is often effective even when anti-androgens alone are insufficient.

Hormonal transitions like perimenopause/menopause, thyroid dysfunction, and polycystic ovary syndrome (PCOS) commonly unmask or accelerate FPHL by altering estrogen-androgen balance and cycling dynamics.{{Aksenenko, M., Palkina, N., Komina, A., Ruksha, T. (2019). MiR-92a-1-5p and miR-328-3p Are Up-Regulated in Skin of Female Pattern Hair Loss Patients. Annals of Dermatology. 31(2). 256-259. Available at: https://doi.org/10.5021/ad.2019.31.2.256}} 

OTC vs Prescription Minoxidil for Women

Over-the-counter (OTC) minoxidil for women typically comes at 2-5% concentrations, while prescription or compounded products may use 5-8% or higher strengths in customized products.

2% minoxidil is the classic, label-approved strength for women, with clear evidence of a benefit versus placebo.{{van Zuuren, E.J., Fedorowicz, Z., Schoones, J. (2016). Interventions for female pattern hair loss. Cochrane Database of Systematic Reviews. 2016(5). CD007628. Available at: https://doi.org/10.1002/14651858.CD007628.pub4}} 

Compounded “high-strength” minoxidil (5-8%+) is prescription only and relies in part on carrier agent formulation.{{Sattur, S.S., Sattur, I.S. (2021). Pharmacological Management of Pattern Hair Loss. Indian Journal of Plastic Surgery. 54(4). 422-434. Available at: https://doi.org/10.1055/s-0041-1739254}} Simply raising the percentage does not guarantee better results and may raise the risk of irritation, hypertrichosis, or systemic absorption of the drug.{{Ghonemy, S., Alarawi, A., Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. Journal of Dermatological Treatment. 32(2). 236-241. Available at: https://doi.org/10.1080/09546634.2019.1654070}}

So, with that in mind, let’s take a look at our top seven minoxidil brands of 2026.

Best Minoxidil Brands for Women

#1 Best Overall: Ulo Women’s Rx Minoxidil (7%)

Pros:	Cons:
✓ Prescription-only 7% minoxidil, higher than standard OTC strengths	✗Prescription products are only available in the USA
✓ Optional evidence-based add-ons
✓ Quality-tested ingredients free of irritants
✓ Includes medical consultation and ongoing monitoring

Ulo Women’s Rx Minoxidil+ is our go-to product for topical minoxidil treatment. It is designed for those who want more than “pink-labeled” 2-5% solutions and are comfortable with a prescription approach guided by specialists. The 7% concentrated and layered actives (including cetirizine 1%, tretinoin 0.01%, melatonin 0.01%, and caffeine 0.2%) target multiple facets of hair loss with a level of customization that goes beyond typical off-the-shelf products.

Bottom Line: Ulo offers the most precise, clinically guided minoxidil-based treatment for women in 2026, combining higher-strength therapy with thoughtful formulation and ongoing medical oversight.

#2 Best for Overall Oral: Ulo Minoxidil Dissolving Chews

Pros:	Cons:
✓ Convenient, rapidly dissolving oral minoxidil	✗ Premium pricing
✓ Orange-flavored chewable tablet that requires no water	✗ Only available in the USA
✓ Available in 1.25 mg and 2.5 mg minoxidil strengths
✓ No scalp application or disruption to hair styling
✓ Online medical consultation and ongoing provider support

Ulo’s Dissolving Chews offer a minoxidil alternative for women who are interested in oral minoxidil but would prefer not to take traditional pills. The orange-flavored chews dissolve rapidly in the mouth, allowing users to take their daily treatment without water or the need for topical application.

This may be particularly beneficial for women with longer hair, sensitive scalps, or styling routines that make topical minoxidil difficult to apply consistently. The two available minoxidil strengths, 1.25 mg and 2.5 mg, also provide ample flexibility when selecting an appropriate dose.

Bottom Line: Ulo Dissolving Chews offer a convenient, pill-free way to take prescription oral minoxidil, particularly for women who find topical treatments difficult to incorporate into their daily hair care routine.

Minoxidil Dissolving Chews

A rapidly-dissolving chewable tablet with minoxidil.

For maximum convenience, in a delicious orange flavor. Available in 1.25 mg and 2.5 mg doses.

Shop Minoxidil Dissolving Chews

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

#3 Best for Strength: Musely The Hair Topical Solution-Classic

Pros:	Cons:
✓ High-strength 8% prescription minoxidil.	✗ Use of corticosteroids increases the risk of skin thinning.
✓ Optional evidence-based add-ons like dutasteride and spironolactone for hormonal control.	✗ Propylene glycol and ethyl alcohol base, which can sting or dry out sensitive scalps.
✓ Additional scalp-supporting actives like tretinoin, ketoconazole, caffeine, and melatonin.	✗ More expensive than simpler OTC or lower-strength prescription options.
✓ Includes periodic medical follow-up.

Musely’s 8% “Classic” Hair Topical is designed for women with advanced thinning or those who have plateaued on conventional strengths, combining high-dose minoxidil with potent anti-androgens and supportive ingredients in a single solution, including optional add-ons such as dutasteride 0.3%, spironolactone 0.075%, tretinoin 0.01%, ketoconazole 2%, hydrocortisone 1%, plus adjuncts like caffeine and melatonin. 

It functions more as an intensive, prescription-only protocol than a starter product, and is best reserved for users willing to tolerate a stronger propylene glycol/ethyl alcohol vehicle, and possible skin thinning if using long-term due to the addition of corticosteroids.

Bottom line: For women with stubborn, progressive hair loss who have outgrown basic 5% formulas, Musely’s high-strength, multi-active topical offers one of the most powerful at-home options, provided they are comfortable with higher cost and higher irritation risk.

#4 Best for Sensitivity: Rogaine Women’s Foam

Pros:	Cons:
✓ Propylene-glycol-free foam vehicle, often better tolerated on sensitive or irritated scalps.	✗No medical consultation or follow-up after buying
✓ Widely available OTC	✗ No customization.

Rogaine Women’s Foam is a classic choice for those looking for a gentle-on-the-scalp option of minoxidil. The propylene-glycol-free foam base, robust clinical evidence, and once-daily 5% option make it a gentle yet effective starting point for treating female pattern thinning. It should be noted that if you wanted to try the lower dose option (2%), you need to buy the solution, which contains propylene glycol, and so may not be as beneficial for those with sensitive skin. 

Bottom Line: Get the foam if you have a sensitive scalp or are a beginner, wanting a low-irritant minoxidil option. 

#5 Best Value: Hers Minoxidil Foam and Solution

Pros:	Cons:
✓ Budget-friendly option at around $30 for a 2-month supply.	✗No advanced customization available.
✓ Offers both 2% and 5% strengths at the same price.
✓ Available in solution and foam formats.

Hers Minoxidil is designed for women who want a clinically supported minoxidil treatment without paying premium prices for branding or heavy telehealth layering. With standard 2 and 5% options in familiar vehicles, it delivers an approachable, budget-conscious package for those comfortable managing a simple daily routine themselves.

Bottom Line: For cost-conscious women who want an easy, no-frills entry into proven minoxidil therapy, Hers Minoxidil offers standard concentrations with good value.

#6 Best Alternative: Happy Head Minoxidil and Spironolactone for Women

Pros:	Cons:
✓ Prescription-strength 6% minoxidil, higher than standard OTC options but below ultra-high-dose protocols.	✗ Uses a propylene glycol-containing vehicle, which can increase irritation, dryness, or stinging on sensitive scalps.
✓  Customizable blends that include spironolactone, tretinoin, and hydrocortisone	✗ Inclusion of topical corticosteroids carries a risk of skin thinning and barrier damage if used long-term.
✓ Strong telehealth model with online prescribing and adjustments to treatments over time.	✗ More expensive than generic 5% minoxidil and some standard telehealth offerings.
✓ Good fit for women who need more than basic 2-5% formulas but do not want to jump straight to 8%+ multi-drug cocktails.

Happy Head’s 6% formulas are aimed at women who want a personalized, prescription-only topical that goes beyond standard strengths while still staying below the most aggressive high-dose regimens. By combining minoxidil with spironolactone, retinoic acid, and short-term hydrocortisone in a single bottle, it offers a modular approach that can be tuned to individual tolerance and response rather than a one-size-fits-all solution. It should be noted that Happy Head uses corticosteroids in their topicals to offset the potential irritation from propylene glycol usage. However, this can cause skin thinning with long-term use.

Bottom line: For women who need a tailored, mid-high-strength minoxidil blend with added anti-androgens and supportive ingredients, but prefer not to escalate to ultra-high-dose, steroid-heavy cocktails, Happy Head provides a strong option.

#7 Best for Woman-Centered Care: Winona 7% Minoxidil

Pros:	Cons:
✓ Women-focused clinic model that addresses broader menopausal health alongside hair loss.	✗ Uses a propylene glycol-containing vehicle, which can increase irritation, dryness, or stinging on sensitive scalps.
✓  Prescription-strength 7% minoxidil specifically targeted to menopausal and perimenopausal thinning.	✗ No customization
✓ Guided supportive care pathway, with structured programs, check-ins, and follow-up.	✗ Premium pricing at around $150 for a 3-month supply.
✓ Treatment plans that can integrate other menopause therapies where appropriate

Winona’s 7% minoxidil is designed for women who want more than a stand-alone bottle and value a structured, woman-centered approach that fits into a broader menopause-care framework. The higher-strength prescription formula, combined with clear guidance, follow-up, and attention to hormonal context, makes it particularly suited to postmenopausal and perimenopausal hair loss rather than general early thinning. However, it should be noted that its carrier agent, propylene glycol, may be irritating for sensitive scalps.

Bottom line: For women seeking a guided, menopause-focused program built around prescription-strength minoxidil, Winona offers a structured, woman-centered care pathway, albeit at a higher price and with a more irritant-prone vehicle.

Regrowth Timeline

Setting realistic expectations is essential when beginning topical minoxidil for female pattern hair loss. Unlike quick cosmetic fixes, minoxidil works by gradually altering the hair growth cycle, and visible changes take time to develop.

Timeframe	What to Expect	Clinical Evidence
Months 0-3	An initial increase in shedding may occur as follicles shift out of the resting (telogen) phase and re-enter growth. This temporary “dread shed” phase typically improves within 4–8 weeks and is considered a normal response to treatment initiation.	{{Nohria, A., Desai, D., Sikora, M., Mandal, S., Shapiro, J., Lo Sicco, K. (2024). Combating “dread shed”: The impact of overlapping topical and oral minoxidil on temporary hair shedding during oral minoxidil initiation. JAAD International. 15. 220-224. Available at: https://doi.org/10.1016/j.jdin.2024.03.005}}
Months 3-6	Early visible signs of improvement may appear, including reduced shedding and the emergence of fine, new hairs (vellus to terminal transformation), particularly along the part line and crown.	{{Amit, K., Mansukh, G., Satyaprakash, M., Dhiraj, D., Hanmant, B. (2023). Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus. 15(7). E41681. Available at: https://doi.org/10.7759/cureus.41681}}
Months 6-12	More noticeable cosmetic improvements are typically seen, including increased overall density, thickening of existing strands, and improved scalp coverage in areas of diffuse thinning. For many women, this is the point at which changes become easily visible in the mirror and in photos.	{{Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available at: https://doi.org/10.1016/s0190-9622(87)70092-9}}
Months 12+	Hair density gains typically plateau. At this point, continued use is required to maintain results and prevent gradual regression back toward baseline. Stopping treatment may allow thinning to resume over time.	{{Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available at: https://doi.org/10.1016/s0190-9622(87)70092-9}}

Why Do I Need to Stay Consistent When Using Minoxidil?

Topical minoxidil works by extending the anagen (growth) phase of the hair cycle and shortening the telogen (resting) phase, thereby increasing the amount of time that follicles spend actively producing hair. Maintaining this effect requires regular, consistent application. When doses are frequently missed, follicles spend less cumulative time in a growth-biased state, which reduces the likelihood of noticeable improvement.{{Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2(1). 186-194. Available at: https://doi.org/https://doi.org/10.1111/j.1365-2133.2004.05785.x}}

This principle is especially important in women, whose hair loss is often more diffuse and gradual, making subtle changes harder to notice in the early months. Because the human scalp hair cycle progresses slowly, with the anagen phase potentially lasting several years, many follicles need prolonged, uninterrupted exposure to minoxidil before visible gains in density and coverage can be achieved.{{Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499948/ (Accessed: November 2025)}}

For this reason, most clinical guidance advises committing to at least six months of daily, consistent use before evaluating the effectiveness of treatment, with continued use required to sustain and build upon results.

What Minoxidil Formulations Are Available?

You can find topical minoxidil in several different delivery vehicles, each with its own advantages in terms of scalp tolerability, ease of use, and fit for a woman’s lifestyle and hair type. In most cases, the “best” option is not defined by pure strength alone, but by how well the formula matches skin sensitivity, styling habits, and consistency of application.

Foam – Best for Sensitive Skin

Propylene glycol–free foam formulations were developed to reduce the risk of contact dermatitis, itching, and dryness that can occur with traditional liquid solutions. Clinical observations suggest that foam is generally better tolerated and faster-drying, making it a strong choice for women with sensitive scalps or those who wash and style their hair frequently.{{Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714}}

Liquid – Best for Cost and Precision

Classic liquid solutions, usually formulated with alcohol and propylene glycol, remain widely available and affordable. While effective, they may cause itching, dryness, or flaking in some women. These solutions can work well for individuals without scalp sensitivity who prefer a more targeted, dropper-based application, especially along the part line.

Spray – Best for Quick, Even Coverage

Spray or mist-style applicators make it easier to cover larger areas of diffuse thinning, such as along the crown or upper scalp. However, they can be less precise, with some product landing on the hair shafts or surrounding skin rather than directly on the scalp.

Gel – Best for Targeted Areas

Gel or cream-gel formulations tend to stay in place, minimizing runoff and improving control. These are helpful for women treating specific areas of thinning, such as the temples, frontal hairline, or post-partum thinning zones.

Liposomal Delivery

Some prescription and premium products use liposomal or phospholipid-based carriers that are designed to improve follicular penetration while reducing irritation and systemic absorption. These advanced bases may be especially attractive for women who need stronger formulations but have experienced irritation with traditional vehicles.

How Safe is Minoxidil?

Topical minoxidil is generally well tolerated by women, but like any active medication, it can produce local scalp irritation, a brief increase in shedding during the early treatment phase, and, in very rare cases, systemic side effects, particularly in individuals with underlying skin or cardiovascular conditions.

Common local reactions may include:

• Mild itching
• Flaking or dryness
• Redness
• Burning or stinging
• Temporary increase in shedding

These symptoms are typically mild, tend to improve as the scalp adapts, and can often be reduced by switching to a foam-based formula, lowering concentration, or using a gentler vehicle.

Systemic and heart-related reactions are extremely uncommon with proper topical use. However, isolated case reports and safety data recommend seeking medical attention if symptoms such as chest tightness, heart palpitations, lightheadedness, dizziness, or unexplained swelling develop, as these could indicate increased systemic absorption or accidental ingestion. The risk of cardiovascular effects is significantly higher with oral minoxidil or improper dosing, where hypotension, tachycardia, and even heart failure have been reported.{{Tripathee, S., Benyovszky, A., Devbhandari, R., Quiza, K., Boris, J. (2024). A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure. Cureus. 16(8). E66039. Available at: https://doi.org/10.7759/cureus.66039}}

To minimize the risk of side effects, many clinicians recommend starting with once-daily application, gradually increasing only if tolerated. Women with reactive skin often benefit from foam formulations, lower-alcohol bases, or liposomal delivery systems, which can reduce irritation and improve comfort during long-term use.

Individuals with active inflammatory scalp conditions, such as psoriasis, eczema, or severe seborrheic dermatitis, are generally advised to first address the underlying condition before beginning minoxidil therapy. Applying treatment to an inflamed or compromised skin barrier can increase irritation, worsen symptoms, and lead to unpredictable absorption patterns.{{Junge, A., Jic-Hoesli, S.R., Bossart, S., Simon, D., de Viragh, P., Hunger, R.E., Heidemeye, K., Seyed Jafari, S.M. (2025). Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation. Acta Dermato-Venereologica. 105. 42401. Available at: https://doi.org/10.2340/actadv.v105.42401}}

Although topical minoxidil has lower systemic absorption than oral formulations, it is generally not recommended during pregnancy or while breastfeeding unless specifically advised by a healthcare provider. Women who are pregnant, trying to conceive, or nursing should consult a qualified medical professional to fully review potential risks and alternative treatment options.

Final Verdict

A range of minoxidil-based options is available to support different needs among women experiencing hair thinning, from strength-focused prescriptions to gentle, sensitivity-friendly alternatives and highly customized compounded formulas. While each product relies on the same core ingredient, differences in concentration, delivery vehicle, add-on actives, and level of medical support can significantly influence both tolerability and long-term adherence.

Whichever option you choose, consistent use of minoxidil remains one of the most evidence-backed ways to slow progression and improve hair density in women with pattern hair loss. With today’s expanded access to prescription platforms, foam-based formulations, and individualized treatment models, it is now easier than ever to find an approach that aligns with your scalp sensitivity, stage of hair loss, and lifestyle needs.

Finding the right hair loss treatment can feel overwhelming, and expert guidance is essential to identify the best formula for your needs. The PhD-led team at Perfect Hair Health leverages emerging research and close collaborations with top innovators to provide readers with the most accurate and actionable reviews of hair restoration offerings. Topical finasteride is one of the most sought-after treatments on the market, boasting clinical support, targeted results, and easy application. 

This comprehensive guide to the top-rated topical finasteride products is based on extensive research, expert recommendations, and the latest consumer feedback. Whether you’re just beginning your hair health journey or searching for better hair loss solutions, this article provides valuable information on safe and effective treatment options. Our recent partnership with Ulo enhances this guide with privileged insights on clinical findings and state-of-the-art protocols.  

Read on for specialized guidance, insightful reviews, and proven recommendations of topical finasteride preparations from today’s leading brands. 

Interested in Topical Finasteride?

Low-dose & full-strength finasteride available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Quick Look: 5 Best Topical Finasteride Products

Here’s a side-by-side comparison of our top recommended topical finasteride treatments. Read on for more details on each of these excellent products. 

Product	Price	Finasteride %	Customization	Application
Ulo	$64+/month	0.005% – 0.2%	High	Solution
Strut Health	$59	0.1-0.25%	Medium	Solution/Gel
Happy Head	$59-99/month	0.3%	Medium	Liposomal Gel
Roman	$50/month	0.3%	Low	Spray
Hims	$35+/month	0.3%	Low	Spray

Topical Finasteride: What It Is & Why It’s Better 

First, we will briefly explore the science behind topical finasteride, including its mechanism of action in treating hair loss and the advantages of topical formulations. 

What Is Topical Finasteride?

Topical finasteride is a clinically proven treatment for androgenic alopecia (AGA), a type of hair loss that affects more than 50% of men by the age of 50.{{Jang, W.S., Son, I.P., Yeo, I.K., Park, K.Y., Li, K., Kim, B.J., Seo, S.J., Kim, M.N., Hong, C.K. (2013). The Annual Changes of Clinical Manifestation of Androgenetic Alopecia Clinic in Korean Males and Females: A Outpatient-Based Study. Annals of Dermatology. 25(2). 181-188. Available at: https://doi.org/10.5021/ad.2013.25.2.181}} AGA is caused by dihydrotestosterone (DHT), a testosterone-derived hormone that damages hair follicles, causing them to shrink and produce thinner hair. Finasteride reduces DHT levels by inhibiting the enzyme 5-alpha-reductase, protecting the hair follicles to stop hair loss and encourage new growth.{{Duran, R, C-D., Martinez-Ledesma, E., Garcia-Garcia, M., Gauzin, D.B., Sarro-Ramirez, A., Gonzalez-Carillo, C., Rodriguez-Sardin, D., Fuentes, A., Cardenas-Lopez. (2024). The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia. International Journal of Molecular Sciences. 25(5). 2542. Available at: https://doi.org/10.3390/ijms25052542}} 

While orally administered finasteride has been in use since 1997, topical formulations are a relatively new development. When applied to the scalp, finasteride provides targeted treatment with a reduced risk of systemic side effects associated with oral preparations. Topical finasteride is shown to reduce DHT levels on the scalp for greater hair count and density with comparable effectiveness to oral finasteride.{{Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018).  A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in Dermatology. 17(4). 457-463. Available at: PMID: 29601622}}

Numerous studies confirm that topical finasteride slows and reverses hair loss by boosting hair thickness, density, and growth cycles. These results are enhanced when combined with other topical treatments like minoxidil. Due to minimal systemic absorption and attendant side effects, topical formulas are considered a safer choice for prolonged use. Overall, topical finasteride is prized among clinicians and patients as a safe, effective, and convenient solution to pattern hair loss.{{Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018).  A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in Dermatology. 17(4). 457-463. Available at: PMID: 29601622}},{{Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 36(2). 286-294. Available at: https://doi.org/10.1111/jdv.17738}}

Why Choose Topical Over Oral?

Because topical finasteride is applied directly to the scalp, it offers localized therapy and avoids the side effects associated with oral finasteride’s systemic exposure. Here is a brief overview of this and other primary advantages of topical formulas:

• Better Safety Profile: Oral finasteride is absorbed into the bloodstream and can have global side effects like sexual dysfunction, hormone disruption, and mood swings. In contrast, topical formulas target the scalp directly and minimally affect plasma levels. Topicals are consistently shown to have fewer systemic side effects. If present, side effects tend to be mild and temporary, such as scalp irritation.

• Individualized Dosing: While the oral finasteride dose is a standardized 1 mg, topical formulas enable tailored dosages and greater precision through potency titration. This is especially important given the dose-dependent outcomes of finasteride treatment. The finasteride concentration in topicals can range from a maintenance dose of 0.005% to a more aggressive protocol of 2.5%.

• Greater Customization: Topical formulas often combine other proven treatments, such as tretinoin, minoxidil, and caffeine. Studies demonstrate that finasteride-minoxidil combinations deliver superior results compared to single-agent treatments. Plus, the range of available delivery methods (e.g., solutions, sprays, gels) can improve convenience, satisfaction, and adherence. 

• Long-Term Use: With a better safety profile and lower systemic impact, topical finasteride is more suitable for prolonged use, which is often necessary to maintain the benefits of hair loss treatment. 

In short, research data indicate that topical finasteride yields comparable results with a more favorable safety profile than oral finasteride, making it a better option for long-term treatment. Further benefits of topical formulations include greater dose precision, synergistic adjuvants like minoxidil, and a range of delivery methods to support compliance.{{Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018).  A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in Dermatology. 17(4). 457-463. Available at: PMID: 29601622}},{{Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 36(2). 286-294. Available at: https://doi.org/10.1111/jdv.17738}}

Evaluation Criteria: What Makes the Best?

When selecting the best topical finasteride products, we adhered to the following evaluation criteria, which are thoroughly supported by clinical findings and customer feedback.{{Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 36(2). 286-294. Available at: https://doi.org/10.1111/jdv.17738}},{{Suchonwanit, P., Iamsumang, W., Leerunyakul, K. (2020). Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. Journal of Dermatological Treatment, 33(2), 643–648. Available at: https://doi.org/10.1080/09546634.2020.1782324}}

✓ Effectiveness

We assessed scientific data, DHT decrease rates, and real-world testimonies of hair count increases. The top products deliver measurable results in 3-6 months with continuous improvements in hair density throughout the first year and beyond.

✓ Safety

Because finasteride is a prescription-only treatment, we verified that providers adhere to all safety regulations, including proper prescribing and monitoring protocols. Leading suppliers also provide full ingredient transparency to help assess potential side effects.

✓ Customization

Premium brands offer treatment customization options tailored to patients’ needs and preferences, maximizing outcomes beyond those achieved with traditional, standardized approaches. These include concentration adjustments, synergistic add-on ingredients such as minoxidil, and various delivery methods. 

✓ Convenience

Successful treatment outcomes depend on long-term compliance and a positive user experience. Factors such as ease of application, clear instructions, manageable dose frequency, and responsive support help ensure uninterrupted treatment.

✓ Value

The best providers balance superior quality with transparent and affordable pricing models that cover doctor consultations, prescriptions, and follow-up care. These are especially important concerns in the telehealth landscape, where many subpar platforms employ opaque billing practices to stack on hidden fees and unexpected charges.  

How to Choose the Right Product for Your Needs 

When choosing the product that best meets your hair loss treatment needs, consider the extent of your hair loss and treatment aims, such as basic upkeep or intensive restoration. Also account for your preferred delivery method (i.e., gel, solution, or spray), desired add-ons, medical support requirements, and budget. 

Reviewing the Best Topical Finasteride Products

With the above key factors in mind, let’s turn now to our top recommended options that each offer unique advantages sure to satisfy. 

#1: Ulo Finasteride + Minoxidil Plus Rx

Pros:	Cons:
✓ Clinically-proven combination therapy	✗ Prescription products are only available in the USA
✓ True personalization with custom concentrations and medical consultations
✓ PhD-scientist formulated
✓ Ongoing medical monitoring and a user-friendly platform
✓ Quality-tested ingredients free of irritants

Ulo’s combination formula of high-strength finasteride with prescription-grade minoxidil takes the top spot, reflecting the platform’s commitment to providing safe, scientifically proven hair loss treatments tailored to meet individual needs. Every Ulo product is developed by a team of PhD scientists who deliver innovative interventions in hair restoration.

Their advanced finasteride and minoxidil solution blocks DHT and stimulates new growth in a targeted dual treatment that is proven superior to monotherapies in clinical trials. Ulo’s finasteride formulas are uniquely customizable and available in different concentrations (0.005% for maintenance and 0.2% for stronger protocols), with a series of synergistic add-ons like caffeine to boost circulation, tretinoin for better absorption, and melatonin for antioxidant protection.

The deluxe treatment begins at $64 per month, which includes an onboarding medical consultation to assess each client’s needs, a physician-crafted treatment plan, and continued dermatologist oversight. All Ulo products are strictly sourced from pharmacies that adhere to safety and quality regulations. The clinic’s licensed dermatologists provide customized treatment regimens with free home prescription deliveries and ongoing support.

Bottom Line: Ulo’s individualized hybrid treatment is the ultimate in advanced hair restoration technology. With precise formulation and continuous medical supervision, this tailored solution delivers exceptional results for a low monthly subscription fee starting at $64. Ulo’s guiding dedication to safety and efficacy makes this full-service platform the best option for those who are serious about combating hair loss.

#2 Strut Finasteride Hair Loss Formula

Pros:	Cons:
✓ Custom-compounded topical finasteride formulas (with optional add-ons)	✗ Not available internationally, and currently cannot ship to Arkansas
✓ Online consult and prescriptions from U.S. board-certified physicians	✗ Auto-refills by default; some reviews report difficulty canceling and customer service gaps
✓ Multiple formulation options (gel or solution; adjustable finasteride strength)
✓ Convenient telehealth model with free, discreet shipping in most U.S. states.

Strut Health is a U.S.-based telehealth provider offering customized topical finasteride for AGA. After an online questionnaire and photo-based evaluation, a board-certified clinician designs a compounded formula that may contain finasteride alone or in combination with other actives like minoxidil, tretinoin, fluocinolone, or biotin. The company’s finasteride hair-loss formulas typically use 0.1-0.25% topical finasteride, with optional minoxidil concentrations up to 7.5% and tretinoin in a gel or solution base, giving flexibility to tailor potency and tolerability.

Our in-house lab testing showed that Strut Health’s finasteride product contained the correct concentrations of ingredients (finasteride, minoxidil, and tretinoin), indicating that they can be trusted to provide a quality product.

However, there are trade-offs. Strut does not accept insurance, and pricing for topical finasteride (often around the mid-range of the telehealth market) may add up for long-term use. The company currently ships to nearly all U.S. states but cannot ship to Arkansas, and there is no international service. Public reviews highlight convenience for many users but also recurring concerns about auto-refills and difficulty canceling, as well as frustration with customer support responsiveness and refund policies. 

Bottom Line: Strut Health’s topical finasteride offers a flexible, telehealth-delivered alternative for patients who want DHT-targeted treatment without taking a daily pill, with customizable formulas that can include or exclude minoxidil and other actives. Its convenience, physician oversight, and compounding flexibility are strong advantages, but subscription-based pricing and mixed customer service reviews may give more budget-conscious patients pause.

#3 Happy Head Topical Super Solution: Finasteride, Minoxidil & Liposomal

Pros:	Cons:
✓ Medical oversight by board-certified dermatologists	✗ Price rises from $59 to $99 after the first six months
✓ Higher concentrations of 0.3% finasteride + 8% minoxidil	✗ Higher concentrations may increase side effect risk
✓ Made with a delayed-release liposomal base	✗ Gel formula cannot be customized
✓ User-friendly platform and follow-up care	✗ May irritate sensitive skin
✓ Affiliate programs available	✗ Possible shipping and customer service concerns

Our next selection is from Happy Head, known for unique formulations and dermatologist oversight. The Topical Super Solution features a more concentrated combination of 0.3% finasteride with 8% minoxidil for targeted hair restoration. 

Available in a mess-free pump dispenser, this gel is made with the brand’s proprietary liposomal delivery base that boosts scalp penetration with timed medication release and once-daily application. This helps minimize bloodstream absorption, reducing potential side effects, and is a notable safety feature for higher finasteride doses. That said, some ingredients in the carrier base should not be used on sensitive skin. Other products from the brand are more customizable and can be adapted to sensitive skin.

The starting price of Happy Head’s treatment is competitive at $59 for a monthly subscription that covers dermatologist oversight and prescription deliveries. However, the price increases to $99 after the first six months. Some reviews cite a lack of transparency regarding potential side effects, as well as intermittent shipping delays and inconsistent customer service. 

Bottom Line: Happy Head’s potent dual therapy is a useful option for patients with intermediate to severe hair loss and normal skin. The delayed-release gel base increases medication absorption for more targeted treatment while decreasing systemic side effects and requires application only once a day. Advantages include dermatologist support and attractive pricing, but patients should be aware of reviews citing shipping and customer service issues. 

#4: Roman (Ro) Hair Solution Rx

Pros:	Cons:
✓ Transparent and competitive price of $50 per month	✗ Contains potential irritants not suitable for sensitive skin
✓ High finasteride concentration (0.3%) for aggressive treatment	✗ High fixed concentration with a greater risk of side effects
✓ Includes minoxidil and tretinoin for synergistic effects	✗ Limited customization options
✓  Convenient once-daily application	✗ Standard delivery system lacks advanced features
✓ Established telehealth provider with medical supervision

Roman offers a simple topical finasteride formula designed for convenient, once-daily use and focused intervention. The spray contains three active ingredients: high-dose 0.3% finasteride with 6% minoxidil and tretinoin to enhance absorption. This product delivers a potent dose of finasteride on par with premium rivals through a no-frills spray system.

While tretinoin may improve minoxidil absorption, Roman’s spray has some drawbacks for users with sensitive skin or systemic side effect concerns. The 0.3% finasteride concentration cannot be tailored to individual response, and the standard delivery system does not have delayed-release technology to offset the risk of systemic absorption as seen in Happy Head’s liposomal gel. Inactive ingredients like ethyl alcohol and propylene glycol are also known irritants.

Roman is an accessible option for many users. The transparent and fixed monthly fee of $50 covers doctor consultations, prescription deliveries, and unlimited follow-ups. However, users with sensitive skin or more complex treatment needs may find Roman’s standardized and less gentle formulation to be unsuitable for long-term compliance.

Bottom Line: Roman offers a potent and affordable dual finasteride therapy with telehealth support features. Although it is not customizable like leading alternatives, this spray is a convenient choice for individuals with moderate to severe hair loss who can tolerate high dosages and potential irritants.

#5: Hims Topical Finasteride & Minoxidil Spray

Pros:	Cons:
✓ Lowest starting rate of $35+/month	✗ Standardized approach that lacks customization
✓ Well-known brand with recognized platform	✗ Minimal ongoing medical support
✓ Simple ordering process and rapid shipping	✗ Contains irritants not suitable for sensitive skin and fixed high dose
✓ No lengthy consultations required	✗ Basic telehealth features without specialist care
✓ High-dose dual treatment	✗ Concerns about the price transparency of subscription tiers

Hims is a well-known brand that offers topical finasteride through its streamlined telemedicine platform. Their fixed-dose spray of 0.3% finasteride and 6% minoxidil is a convenient and affordable option without the customization features of premium competitors, appealing to those who value simplicity over tailored care. 

Like similar high-dose sprays, this standardized formula from Hims is not suitable for patients with sensitive skin, complex treatment needs, or those requiring a lower maintenance dose.

This provider’s appeal is its wide accessibility. With low prices starting at just $35 per month, quick doctor consultations, and shipping in all 50 states, Hims is a gateway brand for many new hair loss patients. However, this entry-level approach lacks the treatment personalization and close medical supervision of established specialty providers. 

Bottom Line: Hims’ topical finasteride spray is an affordable and easily accessible option backed by a recognized brand name. Although Hims fails to offer the precision treatment and close medical oversight of premium alternatives, it is a mainstay for patients who prioritize low costs and convenience.

Final Verdict: Our Topical Finasteride Picks

After a comprehensive evaluation, Ulo emerges as our top choice for topical finasteride in 2026. Their genuine customization, science-backed formulations, and ongoing dermatologist supervision set the gold standard for personalized hair restoration.

While competitors offer standardized protocols or unproven technologies, Ulo delivers verified results through precision medicine tailored to individual needs. For patients seeking the highest quality care, Ulo’s scientific rigor and safety-first approach make it the clear winner.

What to Expect: Timeline and Results 

Realistic treatment expectations facilitate long-term compliance and successful outcomes. Medical research has established the following evidence-based benchmarks of expected improvements with topical finasteride use as prescribed to treat androgenetic alopecia.

Clinical Timeline for Topical Finasteride Results

Timeframe	What to Expect	Clinical Evidence
3 Months	Terminal hair count starts to improve; increases in total hair count may not yet be observable	{{​​B. Piraccini et al. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology, 36: 286 – 294. https://doi.org/10.1111/jdv.17738}},{{Cheng Zhou et al. (2025). Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study. Chinese medical journal. Available at: https://doi.org/10.1097/CM9.0000000000003495}}
6 Months	Noteworthy increases in hair counts (total and terminal); visible increase in vertex hair growth	{{​​B. Piraccini et al. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology, 36: 286 – 294. https://doi.org/10.1111/jdv.17738}},{{Cheng Zhou et al. (2025). Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study. Chinese medical journal. Available at: https://doi.org/10.1097/CM9.0000000000003495}},{{A. Rossi et al.  (2020). Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients. Dermatology Practical & Conceptual, 10 (2020). https://doi.org/10.5826/dpc.1002a39}}
12-18 Months	Maximum improvement is typically observed; continuous improvements in hair coverage and density	{{A. Rossi et al.  (2020). Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients. Dermatology Practical & Conceptual, 10 (2020). https://doi.org/10.5826/dpc.1002a39}}

• Early Treatment Phase (Months 1-3): During early treatment, visible changes are minimal, which may be disappointing for new patients. The therapy begins to suppress scalp DHT levels, creating shifts that are not yet cosmetically evident. Studies show that improvements in terminal hair count begin around 3 months, though total hair count is not yet typically impacted. 

In the first 6-8 weeks, some experience a temporary increase in shedding as finasteride prompts new growth cycles to start. This is expected and is an encouraging indication that the treatment is taking effect. 

• Visible Improvement Phase (Months 3-6): Visible results begin to appear during this period. Studies show notable increases in hair counts and density by 6 months. Patients tend to note particular improvements in the crown or vertex region.
  
• Optimization Phase (Months 6-18): The most significant benefits occur during this phase. Research indicates that maximum improvements arise around 12 months of continued treatment, as hair density and new growth quality increase.
  
• Long-Term Maintenance: According to clinical data, benefits stabilize around 18-24 months, and treatment transitions from active regrowth to maintenance. Because treatment cessation can lead to the gradual return of hair loss within 6-12 months, continued daily compliance is essential to maintain long-term therapeutic outcomes. 

Topical Delivery Formats

There are several different topical finasteride delivery formats that each offer unique advantages to suit individual needs and preferences, as follows:

• Solutions are liquid formulas typically applied using a dropper for targeted administration on desired scalp areas. These lightweight preparations are valued for their excellent absorption and residue-free finish. Because solutions may contain irritating excipients such as propylene glycol, sensitive patients should opt for gentle blends like Ulo’s prescription topicals. 
• Sprays are a lighter, more fluid type of solution applied using an aerosol or pump. This form enables misting over larger or difficult-to-reach scalp areas. However, sprays are not as precise as droppers, as the liquid may run off and fail to effectively reach the hair follicles.
• Gels offer a more controlled application with a thicker consistency than solutions. They often include advanced delivery bases such as liposome carriers with delayed-release technology, designed to enhance penetration and reduce systemic absorption. However, customization options are typically limited due to compounding practices. Additionally, gel formulas can leave a sticky residue that some users find undesirable.
• Foams may be beneficial for patients with sensitive skin, as they dry quickly and generally lack harsh additives. However, their capacity for targeted application is limited compared to other formulations. 
• Creams and lotions are appropriate for sensitive or dry scalps, featuring thick, emollient-laden bases with moisturizing benefits. Lotions are generally faster-absorbing, more spreadable, and lighter than creams.

The best formulation choice depends on hair and skin type, lifestyle, and personal preferences. Patients are encouraged to consult a doctor to determine the ideal format for their individual needs. 

Safety and Side Effects 

Topical finasteride is noted for its favorable safety profile, especially in contrast to oral formulations; however, understanding potential risks and proper monitoring practices is recommended.

• Common Mild Side Effects: The most common side effects are transient and mild scalp irritation or dryness. Though these reactions often resolve on their own, they also respond well to dose adjustment or calming adjunctive treatments. Patients with sensitive skin should avoid formulas containing irritants like propylene glycol or parabens.{{Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018).  A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in Dermatology. 17(4). 457-463. Available at: PMID: 29601622}},{{Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 36(2). 286-294. Available at: https://doi.org/10.1111/jdv.17738}} 
• When to Contact Your Doctor: More serious side effects or reactions are rare but possible and require prompt medical intervention. These include severe scalp irritation, allergic reactions (blistering, swelling, and redness), and systemic effects like mood changes, sexual dysfunction, or gynecomastia.{{Suchonwanit, P., Iamsumang, W., Leerunyakul, K. (2020). Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. Journal of Dermatological Treatment, 33(2), 643–648. Available at: https://doi.org/10.1080/09546634.2020.1782324}},{{Cheng Zhou et al. (2025). Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study. Chinese medical journal. Available at: https://doi.org/10.1097/CM9.0000000000003495}}
  
• Topical vs. Oral Finasteride Safety: Clinical data show that topical finasteride has a significantly lower risk of sexual side effects, typically less than 2% compared to 8-15% with oral formulations. This is attributed to the targeted delivery of topical preparations that limit systemic exposure while providing localized scalp treatment.{{Mysore, V. (2012). Finasteride and sexual side effects. Indian Dermatology Online Journal, 3(1), 62. https://doi.org/10.4103/2229-5178.93496.}}
  
• Who Should Avoid Topical Finasteride: Topical finasteride is not suitable for women who are pregnant or nursing due to the risk of birth defects or infant harm. Additionally, individuals with known sensitivity, scalp infections, or certain autoimmune diseases may be ineligible for use. Consult with a doctor before beginning treatment. 

Closing Thoughts 

Topical finasteride is an important development in hair loss therapeutics, providing comparable results with a superior safety profile to oral medications. In today’s market, Ulo’s individualized, clinically rigorous approach sets a benchmark for comprehensive care, outperforming competitors primarily focused on budget or convenience factors.

Successful treatment with topical finasteride requires patience and persistence. Advances in hair restoration technology suggest that tailored medicine, rather than standardized approaches, represents the future. Ready to begin your own journey toward hair restoration? 

Visit Ulo today to see how customized topical finasteride can enhance your results.

Frequently Asked Questions

Do I need a prescription for topical finasteride?

Yes, topical finasteride is a prescription-only medication in the USA. This ensures proper diagnosis, medical supervision, dosage, and quality control. Reputable telehealth providers like Ulo make the prescription process quick and easy via video consultations with licensed doctors specialized in hair restoration therapies. These elite platforms also offer ongoing medical supervision to monitor side effects and adjust treatment for optimization.

Avoid online platforms that market finasteride products without a prescription or those that fail to perform a proper medical consultation before prescribing treatment. Reputable platforms employ board-certified doctors licensed to practice in your state of residence with credentials clearly displayed or offered upon request. Sourcing topical finasteride products from unauthorized vendors without a prescription risks hazardous side effects and ineffectiveness.

Can topical finasteride be used with other hair loss treatments?

Yes, topical finasteride can be beneficially combined with treatments like minoxidil, a popular additive in many available products. These formulas often pair finasteride with additional synergistic ingredients such as antioxidants, vasodilators, antifungals, and absorption enhancers. 

Topical finasteride can also be safely used in conjunction with most non-prescription hair products, hair transplants, and low-level laser treatments. However, it should not be combined with oral DHT blockers (i.e., oral finasteride or dutasteride) due to the risk of systemic side effects. Medical approval is necessary before starting new treatments. 

When will I see results with topical finasteride?

Most patients report stabilization of hair loss after 3-4 months, with notable regrowth in 6-12 months. Shedding within the first 6-8 weeks of starting treatment is considered normal and indicative of the treatment’s efficacy. Because DHT suppression takes time to significantly impact hair growth cycles, consistency and patience are essential for optimal treatment outcomes.

Treatment outcomes can vary between individuals. Consult a doctor to discuss influencing factors and form realistic treatment expectations. This grounded approach facilitates better long-term adherence and more desirable results.  

Is topical finasteride suitable for women?

Although the FDA has not yet authorized topical finasteride to treat AGA in women, it is occasionally prescribed for off-label use in postmenopausal patients with female pattern hair loss (FPHL). Because topical finasteride risks fewer hormonal adverse effects than oral finasteride, it is considered a safer option in these cases. 

However, women of reproductive age are often recommended to completely avoid finasteride due to the risk of severe birth defects from exposure while pregnant. Non-pregnant women who may plan for pregnancy in the future should abstain from finasteride use unless under strict medical supervision with suitable contraception established. Newer low-dose formulations designed for women show promise, although more study is needed to verify long-term viability.

Ultimately, women considering finasteride therapy should speak with an experienced clinician to go over their medical history, weigh the benefits and risks, and review alternative treatment options, such as FDA-approved topical minoxidil.

What is the cost of topical finasteride without insurance? 

The average monthly cost of topical finasteride without insurance can vary from $35 to $90, depending on the source, formulation, and services rendered. Direct-pay telehealth providers tend to offer lower rates than conventional in-person dermatology clinics with combined pharmacy fees. Bespoke formulas with advanced excipients can command higher prices. Patients should account for continued costs to budget for long-term treatment, which is often required for beneficial outcomes. 

What will happen if I stop using topical finasteride? 

If regular topical finasteride treatment is discontinued, hair loss is expected to return gradually within 2-3 months of cessation. Most patients report a rebound to their baseline hair loss level within 6-12 months. Because this regression is gradual, patients have some flexibility regarding therapy breaks or medication transitions if needed. 

Does topical finasteride have any drug interactions?

Compared to oral finasteride, topical formulations have few contraindications due to lower systemic absorption rates. For your safety, inform your prescribing doctor of all current medications, especially blood thinners and other hormonal drugs. While topical finasteride is often safely combined with common medications, there may be exclusions. 

How do I store topical finasteride? 

Topical finasteride should be kept at room temperature out of direct light, moisture, and heat. With proper storage, most products maintain stability for 12-24 months. While refrigeration isn’t required, it may boost shelf life in temperate climates. Be sure to check expiration dates and safely dispose of expired products. 

Can I travel while on topical finasteride? 

Yes, prescribed topical finasteride may be stored in carry-on luggage during domestic travel. When traveling internationally, it is recommended to bring the original prescription and label. Be mindful of TSA restrictions on liquid volumes over 3.4 oz.

How is topical finasteride applied?

Topical finasteride is applied directly to a clean and dry scalp with the product applicator. While specific instructions vary with delivery method, in general, the hair should be parted to expose the scalp and allow targeted application to the desired areas. Patients should consult product instructions for precise indications and dosing protocols. Avoid wetting hair for several hours after application, and thoroughly wash hands after use.

Millions worldwide experience hair loss, with androgenic alopecia (AGA) as the leading cause. Also known as male- or female-pattern hair loss, AGA becomes more prevalent with age. It affects a majority of men over the age of 50 and a substantial number of postmenopausal women. Hair thinning and balding due to AGA is not just a cosmetic concern but can significantly detract from self-esteem and overall quality of life. 

Among popular hair restoration treatments, topical dutasteride is a breakthrough solution to the serious side effects and plateaued results many experience. This potent DHT blocker offers more targeted therapeutic benefits with minimal systemic exposure and reduced risk. However, not all topical dutasteride products meet quality standards, so specialized guidance is key to selecting the right formula. 

The PhD-directed board of experts at Perfect Hair Health draws from the latest clinical data and verified customer feedback to deliver this comprehensive guide to the best topical dutasteride products available in 2026. Through our research collaboration with leading innovators in the field, including our partnership with Ulo, we provide unique insights into the most advanced hair restoration protocols.

Read on for our detailed analysis and evidence-based product recommendations. 

Interested in Topical Dutasteride?

Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Quick View: 8 Best Topical Dutasteride Products

Here’s a brief comparison of our most highly recommended topical dutasteride products. Continue reading for in-depth reviews. 

Product	Price	Dutasteride %	Delivery Method	Key Feature
Ulo	$84+/month	0.02%-0.2%	Solution	PhD-developed extensive customization
XYON Health	$129+/month	2%	Gel	Patented controlled-release technology
Strut Health	$69/month	Up to 0.1%	Gel	Alcohol-free and customizable
Blends	~$45/month (90-day supply)	0.3%	Gel	Proprietary hydrating formula
Happy Head	$59-89+/month	Up to 0.3%	Solution	Potency and customization
Maximus	$54.99	0.1%	Gel	Customizability, including the addition of antihistamines
Miiskin	$30-59 + Rx cost	Variable, custom	Solution	No subscription required
Musely	$33/month	0.3%	Solution	Lowest cost option

Science and Benefits of Topical Dutasteride

To begin, we will briefly explore the scientific background of topical dutasteride, including how it works to treat AGA and the distinct benefits of topical preparations.

Mechanism of Action 

Topical dutasteride is valued as a breakthrough treatment for AGA due to its powerful and targeted effects on the molecular levels of hair loss. The root cause of AGA is the testosterone-derived hormone dihydrotestosterone (DHT), which adheres to hair follicles and leads to follicular degeneration and hair loss over time. Dutasteride is classified as a DHT blocker, reducing DHT levels on the scalp to combat hair loss.{{R. Cuevas-Díaz Durán., Martinez-Ledesma, E., Garcia-Garcia, M., Gauzin, D.B., Sarro-Ramirez, A., Gonzalez-Carrillo, C., Rodriguez-Sardin, D., Fuentes, A., Cardenas-Lopez, A. (2024) The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia. International Journal of Molecular Sciences, 25. Available at: https://doi.org/10.3390/ijms25052542.}},{{Dhurat, R., Sharma, A., Rudnicka, L., Kroumpouzos, G., Kassir, M., Galadari, H., Wollina, U., Lotti, T., Golubović, M., Binic, I., Grabbe, S., & Goldust, M. (2020). 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dermatologic Therapy, 33. Available at: https://doi.org/10.1111/dth.13379.}}

Among DHT-blocking treatments, dutasteride is considered the most potent due to its dual enzyme activity. Testosterone is converted into DHT through two forms of 5α-reductase enzymes: Type I is located in the skin and sebaceous glands, and Type II is in the hair follicles. Finasteride inhibits only Type II for about 70% DHT reduction, while dutasteride inhibits both types to elicit greater DHT suppression (up to 93% in the skin and 99% in the follicles).{{Arif, T., Dorjay, K., Adil, M., & Sami, M. (2017). Dutasteride in Androgenetic Alopecia: An Update.. Current clinical pharmacology, 12 1, 31-35. Available at: https://doi.org/10.2174/1574884712666170310111125.}}

Dutasteride’s powerful DHT inhibition leads to greater therapeutic outcomes in hair restoration. Clinical findings indicate dutasteride’s superior effects on hair count and mass in comparison to finasteride in terms of both quantitative and temporal metrics. While finasteride’s benefits tend to plateau after about 12 months of treatment, dutasteride demonstrates continued improvements up to 12 months and beyond.{{Harcha, W., Martínez, J., Tsai, T., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. Journal of the American Academy of Dermatology, 70 3, 489-498.e3. Available at: https://doi.org/10.1016/j.jaad.2013.10.049.}}

Topical vs. Oral Advantages 

Studies show that topical dutasteride is a safer option than oral with comparable and often better treatment outcomes. When applied locally to the scalp, dutasteride delivers targeted treatment with limited systemic exposure and a reduced risk of serious side effects. If present, adverse reactions to topical dutasteride tend to be transient and mild, in contrast to oral dutasteride’s potential systemic side effects like sexual dysfunction and mood disorders.{{Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in Treatment of Androgenetic Alopecia. QJM: An International Journal of Medicine. Available at: https://doi.org/10.1093/qjmed/hcae175.207.}},{{Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: https://doi.org/10.1159/000541395.}} 

This and other clinically proposed advantages of topical dutasteride are briefly summarized as follows: 

• Safe and Targeted Treatment: Oral dutasteride has systemic exposure through the bloodstream and therefore runs the risk of more serious side effects. Meanwhile, topical treatment targets only the scalp, lowering the risk of severe adverse reactions. Minor irritation at the site of application may occur and tends to resolve quickly. 
• Flexible Dosing: Topical formulations offer greater dose flexibility through modified concentrations, in contrast to the usually fixed doses of oral preparations. Common topical offerings range from a maintenance dose of 0.02% dutasteride to advanced therapies of 2%, allowing dose-dependent customization. 
• Increased Personalization: Topicals can easily integrate synergistic treatments like vasodilators (minoxidil), absorption enhancers (tretinoin), and anti-inflammatories (melatonin) for combination therapies that outperform dutasteride alone. These add-ons are prescribed based on patients’ individual needs and treatment goals.

Plus, patients have a choice of different delivery methods (e.g., sprays, gels, solutions), which can offer greater convenience and adherence.

• Long-term Outlook: Topical use is considered safer for long-term treatment due to its reduced systemic effects. Because hair restoration treatments’ benefits build with time, their suitability for prolonged use is paramount. 

Combined, these factors locate topical dutasteride as a more effective and flexible hair restoration intervention with a greater safety profile than its oral counterpart.{{Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in Treatment of Androgenetic Alopecia. QJM: An International Journal of Medicine. Available at: https://doi.org/10.1093/qjmed/hcae175.207.}},{{Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: https://doi.org/10.1159/000541395.}},{{Radhakrishnan, P., Mariyappan, G., Karthi, J., & Jaisumi, K. (2024). Formulating, Optimizing and Evaluation of Dutasteride Loaded Insitu-Emulgel for Androgenetic Alopecia. International Journal of Pharmaceutical Research and Applications. Available at: https://doi.org/10.35629/4494-0906631659.}}

Choosing the Best: What We Looked For

To help navigate the topical dutasteride market, we developed these quality benchmarks grounded in clinical expertise, scientific evidence, and patient feedback.

Clinical Efficacy

Quality dutasteride products demonstrate notable DHT reduction and improved hair growth within 3-6 months, with these effects continuing over 12 months or longer. The products recommended in this article were assessed based on documented DHT reductions, verified patient feedback, and peer-reviewed studies.

Safety Profile and Medical Oversight

Given the prescription status of topical dutasteride, we verified each telehealth provider’s legitimacy in terms of physician supervision, adherence to legal requirements, and adherence to sound safety protocols. These include proper diagnostic procedures before prescribing, as well as close follow-up care to monitor for side effects and adjust the treatment as needed for optimal outcomes. Trustworthy providers exclusively partner with licensed physicians specialized in hair restoration. 

When it comes to quality assurance, suppliers must partner only with authorized domestic pharmacies to source their compounded medications. Complete ingredient transparency and labeling of allergens establishes acceptable safety profiles.

Personalization Options

Varied patient needs call for customizable treatments that exceed standard one-size-fits-all protocols. Outstanding brands provide a personalized approach through extensive customization options, including variable concentrations, adjuvant blends (e.g., minoxidil), and various delivery formats (e.g., solutions and controlled-release gels). These tailored therapies are physician-crafted to safely elicit the best results. 

User Experience

Prolonged, uninterrupted treatment is necessary to achieve positive results, highlighting the importance of user comfort and satisfaction. Practical considerations, such as application convenience, precise instructions, manageable dose routines, and excellent customer support, all influence treatment adherence.

Cost Transparency

Because treatment sustainability also depends on affordability, we also examined billing models and price transparency. Premium suppliers have honest and reasonable pricing that covers primary treatment costs (prescriptions, consultations, deliveries, and monitoring), free of hidden fees that are common among telehealth providers. 

Selecting Your Ideal Treatment

Begin by assessing your hair loss level and treatment objectives, determining whether moderate maintenance or intensive regrowth protocols are needed. Further considerations include application method preferences (gels, solutions, sprays, etc.), helpful adjuvants, and skin sensitivities. Budgetary limitations and your required level of physician involvement also come into play. 

With these factors in mind, let’s dive into the following product reviews that highlight distinct approaches.

Our Top 8 Topical Dutasteride Products

#1: Ulo Dutasteride + Minoxidil Plus Rx

Pros:	Cons:
✓ PhD-scientist developed with thorough customization	✗ USA-only service for prescription treatments
✓ Customizable concentrations with adjuvant ingredients
✓ Board-certified physician oversight, monitoring, and tailored treatment protocols
✓ Verified quality and safety
✓ Full price transparency and free shipping

The top position goes to Ulo, a leader in clinical rigor and precision hair loss medicine. Known for their highly individualized treatments, cutting-edge protocols, and PhD oversight, Ulo’s offerings are among the most comprehensive and patient-centered available. Their dual topical dutasteride solution with minoxidil delivers potent DHT suppression and new growth stimulation, proven to be more effective than either therapy alone. 

Ulo’s topical systems feature customization across the spectrum, from dutasteride concentration (0.02% for lighter therapy to 0.2% for more aggressive intervention) to adjuvants like absorption enhancers, antioxidants, and vasodilators. Premium services include licensed dermatologist consultations, tailored treatment plans, and continued medical oversight, with a starting monthly subscription price of $84 and no added fees. 

All Ulo safety and medication sourcing practices adhere to the highest regulatory standards, including partnerships with certified domestic pharmacies and strict follow-up protocols. Full ingredient transparency and irritant-free formulations establish excellent safety profiles. Patients enjoy free prescription deliveries and responsive support through Ulo’s sleek telehealth platform.

Our Verdict: Ulo’s advanced dual formula harnesses the power of customized topical dutasteride to deliver the gold standard of hair loss therapy. With PhD-developed formulas, genuine customization, and complete medical oversight, this platform offers proven benefits through a transparent monthly subscription that starts at $84. Their dedication to upholding the highest standards of safe and effective care positions Ulo as the best choice for your hair restoration needs. 

#2 XYON Topical Dutasteride

Pros:	Cons:
✓ Proprietary SiloxysSystem™ Gel for timed release	✗ Premium pricing at $129/month
✓ Highest concentration (2% dutasteride) for aggressive protocols	✗ Limited customization options
✓ Physician oversight	✗ Not recommended for sensitive skin
✓ Service area includes the US and Canada

XYON stands out for its innovative, technology-driven approach, exemplified by its proprietary SiloxysSystem Gel delivery base, which contains delayed-release topical dutasteride at a high concentration of 2%. This controlled-release method allows for a higher dutasteride concentration and more targeted treatment, protecting against systemic exposure and potentially serious side effects. 

While this treatment is a strong option for advanced hair loss cases due to its potency, XYON emphasizes its advanced and proven delivery method over treatment customization features. Monotherapy involves a fixed dose of 2% dutasteride, which may be too strong for some patients. Excipients include ingredients like silicone that are not recommended for sensitive skin. 

XYON’s premium price point reflects not only its forward-looking strategy but also its high medical standards, as the platform offers qualified physician support throughout the process. 

Our Verdict: XYON’s topical dutasteride formulation delivers maximum treatment with minimal systemic risk through its unique delayed-release carrier gel. It is recommended for advanced hair loss patients who can tolerate higher doses and potential irritants, particularly those who don’t mind paying a premium for its advanced technology development. 

#3: Strut Health Topical Dutasteride Gel

Pros:	Cons:
✓ Good value at $69/month with full customization	✗ Lower maximum dutasteride concentration (0.1%)
✓ Alcohol-free, preservative-free options available	✗ Moderate doses may be insufficient for advanced hair loss cases
✓ Extensive customization of adjuvant ingredients	✗ Occasional gaps in customer service are cited
✓ Licensed medical oversight with hair loss specialization	✗ Service area excludes Arkansas

Strut Health is a solid mid-tier option that balances accessible pricing with medically guided customization, emphasizing cost-effectiveness over potency. The preservative- and alcohol-free dutasteride gel contains a moderate 0.1% dutasteride, with tailored add-on options including minoxidil, biotin, and tretinoin at varying concentrations. Capped at such a middling dose, this gentle gel formula is best for mild to moderate hair loss patients with sensitive or dry skin.

Fluocinolone, a corticosteroid, is also available as an adjuvant. While leading providers like Ulo avoid such ingredients due to potential safety concerns, Strut provides appropriate safety disclaimers and maintains an overall emphasis on ingredient transparency, backed by medical oversight.

Strut’s subscription fee of $69 per month for topical dutasteride treatment is a competitive offering, covering consultations, follow-ups, and prescription shipping. Patients cite flexible cancellation policies and rapid home deliveries as notable benefits. We detected some mixed reviews regarding delayed customer service responses and logistical issues.

Our Verdict: Strut Health offers a compelling value proposition with its topical dutasteride gel, priced at only $69 per month, and features that rival those of more expensive providers. The gentle formula with a limited 0.1% dutasteride concentration suits patients with moderate treatment needs who are seeking a budget-friendly option with flexible add-ons and legitimate medical oversight. 

#4: Blends Growth PRO Topical

Pros:	Cons:
✓ Doctor-founded with hair restoration specialization	✗ 90-day supply requirement may not suit all patients
✓ Competitive pricing at ~$45/month (90-day supply)	✗ Fixed formula despite “personalized” marketing claims
✓ Preservative-free, alcohol-free formula with 5 active ingredients	✗ Includes latanoprost with limited long-term safety data for scalp use
✓ 0.3% dutasteride and 7.5% minoxidil offer powerful DHT inhibition	✗ Lacks true customization compared to leading competitors
✓ Proprietary hydrating gel base with advanced formulation

Blends is a physician-founded company with a heavy focus on cutting-edge manufacturing methods and sophisticated formulations. Their small but specialized catalog includes this topical dutasteride treatment made with a proprietary gel base for timed medication release and scalp hydration. Free of alcohol and preservatives, the concentrated 0.3% dutasteride and 7.5% minoxidil formula offers powerful therapeutic effects.

Although Blends asserts the “personalized” and “customized” nature of its products, its Growth Pro Topical gel is actually a comprehensive fixed formula with three adjuvant ingredients in addition to dutasteride and minoxidil: tretinoin, latanoprost, and ketoconazole. Competitively priced at about $45/month (sold in 90-day batches), this offering stands out for its full ingredient transparency and high concentrations suited to aggressive treatment protocols.

However, the use of latanoprost poses concerns due to the lack of long-term studies confirming its safety and efficacy as a topical hair loss treatment. Despite marketing claims of customized protocols, Blends does not allow formulation adjustments to this fixed gel product. Although the monthly cost is lower than that of most leading brands of comparable quality, the minimum purchase requirement of a 90-day supply (~$135) may not suit all patients. 

Our Verdict: This physician-crafted gel formula from Blends is competitively priced, featuring high concentrations of synergistic ingredients for advanced hair loss treatment. Its positioning as a mid-level selection rather than a top choice is due to its false personalization claims and unproven add-on ingredient. 

#5: Happy Head Topical Rx Dutasteride & Minoxidil

Pros:	Cons:
✓ Dermatologist oversight with ongoing support	✗ Limited dutasteride concentration options
✓ 0.3% dutasteride and 8% minoxidil  formula with customizable add-ons, including ketoconazole	✗ Pricing increases after the initial months and can reach ~$109
✓ Established brand with a 6-month money-back guarantee	✗  Some formulations contain potential irritants
✓ User-friendly platform and free consultation	✗ Shipping and customer service inconsistencies

Happy Head represents a dependable option for targeted hair restoration, recognized for its dermatologist-backed and customizable treatments. This hybrid dutasteride-minoxidil solution offers a strong dose of 0.3% dutasteride with up to 8% minoxidil for effective DHT reduction. Elective adjuvants include retinoic acid and hydrocortisone. Anti-dandruff agent ketoconazole can be added for an additional fee. 

While some clinicians warn against the use of topical corticosteroids like hydrocortisone, Happy Head seems to follow established medical safety protocols with appropriate disclaimers. Inactive ingredients like alcohol and propylene glycol can irritate and should be approached with caution. Highly concentrated DHT blockers with harsh excipients require close medical oversight, and patients with sensitive skin may want to seek other options. 

Although transparent about costs, Happy Head’s variable pricing can grow quickly with treatment duration and formulation. Their topical dutasteride solution starts at $59 per month and shifts to $89 after the first six months. The anti-dandruff adjuvant can be added for $20, bringing the total to $109 per month, which exceeds the cost of some comparable providers. Mixed patient reviews cite issues with deliveries and logistical support.

Our Verdict: This combination treatment from Happy Head is a solid choice for patients in need of more aggressive treatment and concentrated formulas. Continued dermatologist oversight, personalization options, and potent formulations can help patients whose results may have stalled on other treatments. However, highly active ingredients and variable pricing may deter those seeking gentler therapies and fixed costs.

#6 Maximus Dutasteride+ Gel

Pros:	Cons:
✓ High level of personalization with physician-driven telehealth oversight	✗ Limited long-term safety data for some ingredient combinations
✓ Competitive monthly pricing	✗ Availability restricted to the U.S.
✓ Physician-guided treatment plans and ongoing clinical support	✗ No subscription flexibility (all via 90-day supply)
✓ Proprietary gel base designed for scalp absorption and minimal mess
✓ Evidence-informed protocols supported by board-certified physicians

 

Maximus Tribe’s Max-Absorb Gel is a highly customizable, prescription-only hair loss solution leveraging physician-driven telehealth and evidence-based formulation. At $54.99 for a 90-day supply, it offers a lot of value for those looking for efficacy and clinical support. The core formulation includes dutasteride (0.1%) with optional minoxidil, tretinoin, and fexofenadine, delivered in a proprietary gel base that is designed to minimize mess and maximize scalp coverage. 

Maximus prioritizes convenience and targeted care: onboarding and ongoing support are managed by board-certified doctors, and the medication is shipped directly to the patient for easy home application. While ingredient customization and clinical guidance are strengths, choices remain limited in comparison to other telehealth options (like Ulo). 

Our Verdict: Maximus offers a well-priced topical dutasteride gel that balances multi-ingredient efficacy with convenient home use and physician oversight. 

#7: Miiskin Dutasteride + Minoxidil

Pros:	Cons:
✓ Direct board-certified dermatologist consultations	✗ Total cost varies with third-party pharmacy fees
✓ Custom-compounded formulations with up to 3 active ingredients	✗ Basic compounding without advanced delivery systems
✓ No automatic subscriptions—pay per order	✗ Less specialized in hair loss compared to dedicated platforms
✓ Legitimate medical oversight with prescription flexibility
✓ Serves both the USA and Mexico

Miiskin differs from the subscription-based providers on this list, as it facilitates direct medical consultations between patients and qualified dermatologists. The pay-as-you-go model allows legitimate medical access without subscription requirements. Miiskin charges $59 for initial consultations and $30 for returning visits. Medication fees vary and are charged separately at the pharmacy where the medication is filled.

While the dermatologist-direct platform increases access to qualified care and prescription hair loss treatments, its simple compounded formulas lack the customization and specialization of leading brands. Ingredient disclosure is limited beyond general mentions of three-active-ingredient formulations and the listing of a combination of dutasteride and minoxidil therapy.

The model does not permit total cost calculation until third-party pharmacy checkout, separate from Miiskin’s billing process, which only covers prescribing dermatologist consultation fees.

Our Verdict: Although Miiskin offers medical legitimacy, the dermatology consultation platform lacks the treatment specialization and transparency of top dutasteride therapy sources. It may be a valuable tool for patients with hair loss to connect with qualified providers and access basic compounded formulas. 

#8 Musely The Hair Topical Solution – Classic

Pros:	Cons:
✓ Lowest cost option at $33/month	✗ Minimal medical oversight compared to competitors
✓ 0.3% dutasteride concentration in a customizable formula	✗ Limited customization options
✓ Aesthetic medicine platform with dermatologist involvement	✗ Medical rigor lacking
✓ Multi-ingredient formulations	✗ Less specialized hair loss expertise
	✗ Some ingredients are not recommended for sensitive skin

Musely’s topical dutasteride solution occupies the final slot on our list as the lowest-priced option at just $33 per month (plus a one-time $20 consultation fee at onboarding). The lower price point reflects less extensive offerings that are well-suited for patients who prefer a more self-directed approach. This tailored prescription formulation combines up to 0.3% dutasteride and 8% minoxidil with optional add-ons of ketoconazole to fight dandruff and hydrocortisone to reduce inflammation. 

It is less customizable than other options, characteristic of Musely’s simplified strategy. Excipients like propylene glycol and alcohol may deter ingredient-conscious consumers due to irritant potential. While such potent formulas and highly active ingredients offer more powerful treatment, they also carry a greater risk of adverse reactions and call for qualified medical supervision. 

However, unlike premium providers, Musely is not known for close medical oversight. In fact, the aesthetic medicine platform has a markedly superficial onboarding and assessment process that falls short of the thorough medical evaluations offered by top providers. Although clinicians are involved in the platform, follow-up care and specialized hair restoration knowledge are lacking, according to customer reviews. 

Our Verdict: Musely is included as a purely budget-friendly option for cost-conscious patients who understand the importance of self-monitoring and supplement with appropriate medical consultation. 

Bottom Line on Buying Topical Dutasteride Online

According to our thorough analysis, Ulo is the best choice for topical dutasteride therapy in 2026. This platform stands out for its rigorous scientific foundation, highly tailored treatments, and commitment to close medical oversight, outperforming the fixed protocols and misleading marketing claims of its peers. 

 

Rather than standardized approaches, Ulo’s PhD-designed therapies with built-in customization features meet the individual needs of each patient, representing the pinnacle of evidence-based precision care in the rapidly evolving field of hair restoration medicine.

Expectations and Timeline

Clinical findings support the following timeline of expected treatment outcomes in topical dutasteride therapy. Familiarity with these will ground your therapy in a realistic outlook, encouraging patience and prolonged adherence.{{Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in Treatment of Androgenetic Alopecia. QJM: An International Journal of Medicine. Available at: https://doi.org/10.1093/qjmed/hcae175.207.}},{{Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: https://doi.org/10.1159/000541395.}},{{Radhakrishnan, P., Mariyappan, G., Karthi, J., & Jaisumi, K. (2024). Formulating, Optimizing and Evaluation of Dutasteride Loaded Insitu-Emulgel for Androgenetic Alopecia. International Journal of Pharmaceutical Research and Applications. Available at: https://doi.org/10.35629/4494-0906631659.}}

• Early Stage (Months 1-3): Within days of beginning treatment, scalp DHT levels start to decline, although cosmetic improvements take longer to show as existing hair cycles complete. Some patients may experience temporary hair shedding in the first 2-8 weeks, which is considered a positive sign that the treatment is working by triggering new growth cycles. 

• Emergence Stage (Months 3-6): After about 3 months of continued therapy, subtle visible improvements typically begin to emerge. Existing strands become thicker, and previously inert hair follicles are reactivated to produce new shafts for measurable increases in hair count metrics.

• Maximization Stage (Months 6-18): This phase sees the most considerable improvements, as hair count and diameter continue to increase for a thicker, healthier appearance. The majority of patients reach optimal results within a year. 

• Maintenance Stage (Long-Term): After reaching peak outcomes, continuous daily application is necessary to sustain benefits. Studies show that indefinite treatment can maintain positive results, although occasional adjustments may be needed over time to account for typical signs of aging.

Risk Profile and Safety

Topical dutasteride is considered a safe hair loss intervention, particularly when weighed against oral formulas that can carry substantial risk due to systemic exposure. Nonetheless, informed risk assessment and familiarity with safety protocols are recommended before beginning any new treatment. Here is a brief overview of medical data on the safety and side effects of topical dutasteride.{{Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: https://doi.org/10.1159/000541395.}}

Common Side Effects

Adverse patient reactions to topical dutasteride are rare and typically limited to mild, localized scalp irritation that resolves in 2-4 weeks, occurring in only about 5-10% of new users. Depending on individual sensitivities and irritating formulation additives like alcohol, scalp dryness, flaking, and contact dermatitis are possible, though the latter is less common. Mild systemic side effects are extremely rare, documented in under 2% of patients. 

Serious Considerations

Also rare are severe allergic reactions and pronounced systemic side effects, which can include sexual dysfunction, mood disorders, and gynecomastia. These all warrant prompt medical intervention. Topical dutasteride is not recommended in patients with active scalp infections and hormonal disorders.

Topical dutasteride is strongly contraindicated in pregnant or nursing women and in those planning future pregnancies due to the risk of birth defects. Patients with known hypersensitivity to DHT blockers should also avoid use.

Safety and optimal treatment outcomes depend on regular medical follow-up evaluations, typically at three-month intervals in the first year. This enables early identification of problems and treatment response evaluation.

Conclusion: Best Topical Dustaride Products

Cutting-edge topical dutasteride formulations bridge the gap between pharmacological precision and patient satisfaction in hair restoration therapy. Available products represent a spectrum of targeted, proven treatments that are considered safer and more customizable than previous-generation modalities.

Our thorough review of the evolving market identified clear leaders, with Ulo setting itself apart as an exemplary provider of topical dutasteride. Its scientifically optimized protocols are tailored to meet the individual needs of each patient, with qualified medical supervision to ensure a safe and transformative treatment experience.

As hair restoration technology advances, leading topical dutasteride formulations, such as Ulo’s, are at the forefront, empowering users with convenient and clinically proven solutions that not only enhance appearance but also improve quality of life.

Explore Ulo’s advanced topical dutasteride treatments today.

Frequently Asked Questions 

Do I need a prescription for topical dutasteride? Yes, topical dutasteride is a prescription-only treatment in the United States. This ensures proper candidate screening and legitimate medical supervision throughout treatment.

When can I expect results? Initial DHT suppression on the scalp occurs within the first few days, but visible changes in hair growth typically emerge within 3-4 months.  Benefits generally reach their peak after 12-18 months of consistent application.

How do I apply topical dutasteride? Use the product applicator to deposit the treatment directly onto clean, dry scalp areas where you are experiencing hair loss. Allow it to absorb fully before using other hair products. Following application, avoid wetting the hair for several hours and wash your hands thoroughly.

Can I combine topical dutasteride with other treatments? Yes, the benefits of topical dutasteride can be enhanced through combination therapies, such as minoxidil. Consult your prescribing doctor to learn about safe and effective hybrid treatments.

What will happen if I stop treatment? When treatment is halted, scalp DHT levels gradually return to starting levels, which typically leads to resumed hair loss after several months.

How much does topical dutasteride cost? Pricing varies from about $30 to $135+ for a monthly supply, depending on concentration, formulation, brand, and telehealth services included. Leading brands provide comprehensive medical oversight and customization, offering transparent and flat-rate monthly subscription fees. 

Over the past several years, GLP-1 receptor agonist medications have rapidly transformed the treatment of obesity, insulin resistance, and type 2 diabetes. Drugs like semaglutide are now widely prescribed because they can produce meaningful weight loss while also improving metabolic health.

But as the number of users has increased, so have reports of potential side effects. Beyond commonly documented symptoms of nausea, vomiting, and digestive discomfort, many patients have started reporting something less expected – hair shedding during treatment.

Online forums and social media have multiple anecdotes from individuals who say their hair began thinning shortly after starting semaglutide. Others report that previously stable hair loss worsened during therapy.

This raises the question: Does semaglutide actually cause hair loss? At present, the scientific evidence does not provide a simple answer. Some data suggest a possible association between GLP-1 medications and hair loss, but none of the available studies demonstrate a clear cause-and-effect relationship.

In this article, we’ll examine the evidence in detail. We’ll review what semaglutide is, how it works, and the types of hair loss that may occur during treatment. We’ll also go through the scientific evidence so far and discuss the biological mechanisms that might explain the association between semaglutide and hair loss. With this, we hope to inform those interested in GLP-1 medications about what the evidence actually says about semaglutide and hair loss and who is really at risk.

Interested in Topical Minoxidil?

High-strength topical minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

What Is Semaglutide?

Semaglutide belongs to a class of medications called GLP-1 receptor agonists. 

These drugs mimic the activity of glucagon-like peptide-1 (GLP-1), a hormone naturally released by the intestines after eating. GLP-1 plays an important role in regulating blood sugar levels, appetite, and digestive function.

Clinically, semaglutide is prescribed for several conditions:

• Type 2 diabetes
• Obesity and chronic weight management
• Metabolic disorders involving insulin resistance

The drug itself is identical across different brand names, but approved for different purposes. For example:

• Ozempic is FDA-approved for diabetes management
• Wegovy is FDA-approved for chronic weight management

Despite the different labels, the active compound and mechanism remain the same. The popularity of semaglutide stems largely from its ability to reduce appetite and promote sustained weight loss.

How Do GLP-1 Agonists Work?

GLP-1 receptor agonists influence metabolism through several interconnected pathways.{{Kommu, S., Whitfield, P., (2025), Semaglutide. Available at: http://www.ncbi.nlm.nih.gov/books/NBK603723/ (Accessed: 27 February 2026)}}. These include:

#1 Increased insulin secretion

Semaglutide enhances glucose-dependent insulin release from the pancreas, helping regulate blood sugar levels

#2 Reduced glucagon production

The drug suppresses glucagon, a hormone that raises blood glucose levels.

#3 Slower gastric emptying

Food remains in the stomach longer, increasing feelings of fullness.

#4 Appetite suppression

Many patients naturally consume fewer calories during treatment because hunger signals are reduced.

The cumulative effect is sustained calorie reduction and progressive weight loss. Clinical trials have shown that semaglutide can lead to significant weight reduction when combined with lifestyle changes, like diet and exercise.{{Wadden, T.A., Bailey, T.S., Billings, L.K., Davies, M., Frias, J.P., Koroleva, A., Lingvay, I., O’Neil, P.M., Rubino, D.M., Skovgaard, D., Wallenstein, S.O.R., Garvey, W.T. (2021). Effect Of Subcutaneous Semaglutide Vs Placebo As An Adjunct To Intensive Behavioral Therapy On Body Weight In Adults With Overweight Or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 325(14). 1403-1413. Available at: https://doi.org/10.1001/jama.2021.1831}}

However, rapid weight loss can influence hair biology. This raises the question: Can semaglutide really cause hair loss?

Understanding Hair Growth

To evaluate whether semaglutide could influence hair loss, we first need to understand how hair grows.

Hair follicles cycle through 4 primary phases:

1. Anagen phase (growth phase): Hair actively grows. This phase can last several years.
2. Catagen phase (transition phase): The follicle shrinks and stops producing hair.
3. Telogen phase (resting phase): Hair remains in place but stops growing.
4. Exogen phase (shedding phase): The old hair falls out, allowing new hair to grow.

At any given time, roughly 85-90% of scalp hairs are in the growth phase.

Hair loss occurs when something disrupts this balance, either by shortening the growth phase or forcing too many hairs into the resting phase.

Several distinct conditions can cause this disruption.

Common Types of Hair Loss

Androgenic Alopecia (Pattern Hair Loss)

This is the most common form of hair loss. 

It happens when hair follicles gradually shrink in response to androgens (hormones). Over time, thick terminal hairs that contribute to the cosmetic appearance of hair density become thinner and shorter until they resemble short, fine, vellus hairs (“peach fuzz” hairs). This is known as follicle miniaturization.{{Oiwoh, S.O., Enitan, A.O., Adegbosin, O.T., Akinboro, A.O., Onayemi, E.O. (2024). Androgenetic Alopecia: A Review. Niger Postgrad Med J. 31(2). 85-92. Available at: https://doi.org/10.4103/npmj.npmj_47_24}}  

Typical patterns include:

• Receding hairline and crown thinning in men
• Diffuse thinning along the mid-scalp in women

This process occurs slowly over many years. However, increased shedding can sometimes accelerate visible thinning, particularly if hair density is already reduced.

Telogen Effluvium 

This is a temporary shedding condition.

In this disorder, a large number of hair follicles prematurely enter the telogen phase of the hair cycle. This later causes mass, premature shedding.{{Malkud, S., (2015). Telogen Effluvium: A Review. Journal Of Clinical And Diagnostic Research. 9(9). WE01-WE03. Available at: https://doi.org/10.7860/JCDR/2015/15219.6492}} 

Common triggers include:

• Illness
• Surgery
• Emotional stress
• Severe calorie restriction
• Rapid weight loss
• Nutritional deficiencies
• Medication changes

Telogen effluvium can occur 2 to 8 months after exposure to a trigger. Fortunately, telogen effluvium is usually reversible once the trigger is removed, and hair can regrow.

Alopecia Areata

This is an autoimmune condition in which the immune system attacks hair follicles.

This disorder typically produces patchy hair loss, often appearing as round bald spots on the scalp. Hairs can also miniaturize, like in androgenic alopecia. Although the condition can sometimes resolve spontaneously, it may require treatment to stimulate regrowth.{{Sibbald, C. (2023). Alopecia Areata: An Updated Review For 2023. J Cutan Med Surg. 27(3). 241-259. Available at: https://doi.org/10.1177/12034754231168839}}

Want to know more about alopecia areata? Read our article.

Semaglutide and Hair Loss: Are They Associated?

Because semaglutide is now used by millions of people worldwide, there have been several studies investigating whether hair loss might be associated with GLP-1 medications.

Evidence comes from:

• Clinical trials
• Case reports
• Adverse event databases
• Retrospective studies

Each type of investigation provides useful insight, but is also associated with important limitations that we must consider. We’ll go through each one separately and discuss what each one means. 

Clinical Trials

Randomized controlled trials represent the most rigorous method for evaluating drug safety. 

In clinical trials evaluating Ozempic as a treatment for type 2 diabetes, there were adverse reactions including nausea, vomiting, and diarrhea, but no reports of hair loss among the tested users.{{U.S. Food and Drug Administration, (2023), Drug Label: 209637s020s021lbl. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf (Accessed: 09 March 2026)}}

However, in clinical trials for Wegovy, the story is different. There were at least three randomized, double-blind, placebo-controlled trials conducted on adults using Wegovy who were either obese or overweight. Together, these trials included 3,377 adults who were treated with either 2.4 mg Wegovy or a placebo once weekly.{{U.S. Food and Drug Administration. (2025). Drug Label: 218316Orig1s000lbl. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf Accessed: 05 March 2026)}}

 Thousands of participants were monitored for side effects, and among these participants:

• 3% of semaglutide users reported hair loss
• 1% of placebo users reported hair loss

At first glance, this difference might suggest that semaglutide does increase the risk of hair loss. But several critical details remain unclear. The trials did not specify:

• The type of hair loss
• Whether shedding was clinically diagnosed or self-reported
• Whether hair loss correlated with the speed of weight loss or diet

Because hair loss occurs naturally in the population, it is difficult to determine whether the medication itself played a role.

Do these clinical trials show that semaglutide causes hair loss? No, but it shows there could be an association between semaglutide and hair loss.

Case Reports

Case reports detail the diagnosis, treatment, and follow-up of a single patient. They are particularly useful for recording rare or unexpected clinical outcomes. Recently, two case reports have documented hair loss occurring after treatment with semaglutide.

Before reviewing these reports, it’s important to understand what case reports can and cannot tell us. Because they focus on only one patient, their findings cannot be generalized to a broader population. In addition, the absence of key study design features, such as control groups or randomization, limits the ability to draw firm conclusions about cause and effect. Nonetheless, case reports can still provide evidence suggesting that an association between the described events may exist.

A handful of case reports have described hair loss occurring during semaglutide treatment. 

Case Report #1

A case report described a 23-year-old woman with obesity who had been taking semaglutide for weight management for 4 months. Her treatment began with weekly injections of 0.25 mg during the first 2 months, followed by an increased dose of 0.5 mg once weekly for the next 2 months. Around the 3rd month of therapy, she began to experience sudden hair loss, noticing several circular bald patches developing on her scalp.{{Alzahrani, W.S., Bahkali, S.A., Alharthy, R.F., Alsabban, A.S., (2025). Alopecia Areata Following Semaglutide Treatment For Weight Loss: A Case Report. JAAD Case Reports, 63, 44–46. https://doi.org/10.1016/j.jdcr.2025.06.012}} 

Dermatological examination of the scalp showed mild redness, but there was no scaling or other visible abnormalities of the scalp surface. Based on the pattern of hair loss and the clinical findings from the hair examination, the condition was consistent with a diagnosis of alopecia areata.

Following this assessment, the patient was instructed to discontinue semaglutide and begin treatment for alopecia areata. The management plan included intralesional corticosteroid injections, 2% ketoconazole shampoo, and topical 5% minoxidil. After undergoing this treatment regimen, hair regrowth was observed.

Case Report #2

A 2026 case report documented a 33-year-old man who had been prescribed semaglutide at a weekly dose of 2.4 mg. Shortly after beginning treatment, he observed a small area of hair loss that appeared within 2 days of receiving the injection. Over the following 6 weeks, the hair loss progressed and developed into a clearly visible bald patch measuring approximately 5 cm2 on the left side of his scalp.{{Cheng, J.-R., Zheng, J., Li, Y., Shi, H., Yang, N., Lei, Y., Wan, Y.-F. (2026). Weight Loss-Associated Alopecia Areata. American Journal of Therapeutics. Available at: https://doi.org/10.1097/MJT.0000000000001851}}

After being diagnosed with alopecia areata, the semaglutide treatment was discontinued. Within 2 months of stopping the medication, the patient showed improvement in his alopecia, with signs of hair recovery.

Do these case studies show semaglutide causes hair loss? No, but it shows that in rare cases, there could be an association between semaglutide use and the onset of alopecia areata. However, we must also consider that this onset could reflect coincidence or an already existing autoimmune predisposition. 

2024 FAERS Study

The FDA’s Adverse Event Reporting System, or FAERS, is an open-access database that gathers voluntary reports about possible drug side effects from both healthcare professionals and the public. Anyone can browse or search it, making it a key surveillance tool for examining safety trends.

In 2024, researchers turned to this system to explore a question gaining public attention: Could GLP‑1 receptor agonists be linked to hair loss? They analyzed all reports logged between 2022 and 2023 mentioning both GLP‑1 drugs and alopecia.{{Godfrey, H., Leibovit-Reiben, Z., Jedlowski, P., Thiede, R. (2025). Alopecia Associated With The Use Of Semaglutide And Tirzepatide: A Disproportionality Analysis Using The FDA Adverse Event Reporting System (FAERS) From 2022 To 2023. Journal Of The European Academy Of Dermatology And Venereology. 39. e153-e154. Available at: https://doi.org/10.1111/jdv.20197}}

The group used a disproportionality analysis, a well‑established statistical method that flags situations where a particular side effect appears in drug reports more often than expected. The outcome pointed to an intriguing pattern.

Hair loss appeared more frequently among users of two drugs in particular:

• Semaglutide: 199 cases
• Tirzepatide: 179 cases

For the remaining GLP‑1 medications, no elevated signal emerged: liraglutide (20 cases), dulaglutide (65 cases), exenatide (6 cases), and lixisenatide (0 cases).

The apparent concentration of hair loss reports with semaglutide and tirzepatide is notable. But the use of FAERS data comes with several major limitations that complicate interpretation.

• Reporting is open to everyone: Submissions may come from doctors, pharmacists, or patients themselves. Some describe medically verified diagnoses, while others reflect personal impressions without clinical confirmation. In this dataset, the researchers found that consumers submitted 84 % of reports, with clinicians accounting for the remaining 16 %.
• The information is publicly visible: Because anyone can access FAERS, media coverage, or social media chatter can amplify a perceived link, which in turn may drive more self‑reports, reinforcing the appearance of an association.
• The reports are often sparse in detail: They generally state only that hair loss occurred, offering no details about its type, severity, timing, or potential confounding factors like stress, nutrition, or genetics. Without such context, it’s nearly impossible to distinguish true drug‑related events from unrelated background cases.

Taken together, these limitations mean that while the data show a strong reporting signal for semaglutide and tirzepatide, the evidence stops well short of demonstrating that GLP‑1 drugs cause hair loss. 

Does this study show semaglutide causes hair loss? No, the findings highlight a pattern that warrants deeper, clinically controlled investigation rather than serving as confirmation of causation.

2025 Retrospective Studies

Retrospective studies analyze pre‑existing information, often patient records, to explore potential links between prior exposures and later outcomes. Although they resemble case studies in that they don’t include randomization or control groups, they can still provide useful insights and identify meaningful patterns.

Retrospective Study #1

A retrospective analysis published in 2025 reviewed the medical charts of 283 adults who had been prescribed GLP‑1 receptor agonists and later visited a dermatology clinic for concerns about hair loss between 2021 and 2023.{{Burke, O. (2025). Glucagon-Like Peptide-1 Receptor Agonist Medications And Hair Loss: A Retrospective Cohort Study. Journal Of The American Academy Of Dermatology. 92(5). 1141-1143. Available at: https://doi.org/10.1016/j.jaad.2025.01.046}}

The results broke down as follows:

• 84.1 % of patients did not experience any hair loss
• 1.2 % reported new‑onset hair loss despite having no prior history
• Of those who already had hair loss (approximately 13 % of the total number of people), over 90 % said their condition had worsened

Taken together, these findings suggest that the majority of people using GLP‑1 therapies do not develop hair loss. 

The small subset (around 1 %) who noticed new hair loss did so at a rate comparable to what would normally occur in the general population over a similar 2 year period. This raises the question of whether the reported hair loss was related to the medication itself or simply represented naturally occurring shedding.

Among those already experiencing hair thinning, the study noted that symptoms often worsened during GLP‑1 treatment. Semaglutide, in particular, showed the clearest association with increased androgenic alopecia, echoing what was seen in the FAERS analysis.

However, several caveats limit how confidently these results can be interpreted:

• Because this was a retrospective study, there was no randomization or control group, parameters that help identify the cause of hair loss. 
• Worsening of hair loss may simply reflect natural progression. 
• The duration of GLP‑1 treatment was not evaluated, which matters because drug‑induced shedding (such as telogen effluvium) can appear 2 to 8 months after a triggering event. 
• Hair loss was self‑reported, not confirmed through objective assessment methods such as standardized hair counts or dermatologist grading, leaving uncertainty over whether hair loss was clinically relevant 

Retrospective Study #2

In a separate large‑scale retrospective analysis, researchers examined healthcare data from more than 100 million patients to explore whether GLP‑1 receptor agonists might influence hair‑related outcomes.{{Akiska, Y.M., Vidal, S.I., Menta, N. (2025). Increased Incidence And Risk Of Hair Loss With Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study. EMJ. 13(1). 52-54. Available at: https://doi.org/10.33590/emjdermatol/TYEW1122}}

From this enormous dataset, the team isolated over 500,000 individuals who had no prior record of hair loss but were undergoing treatment with one of six GLP‑1 medications: liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or tirzepatide.

After 6 months of therapy, those taking GLP‑1 drugs showed:

• Elevated risk of androgenic alopecia
• Elevated risk of non‑scarring hair loss
• No significant change in telogen effluvium risk
• No significant change in alopecia areata risk

At the 12-month mark, the pattern had shifted slightly:

• Continued higher risk for androgenic alopecia
• Continued higher risk for non‑scarring hair loss
• A newly increased risk of telogen effluvium
• Still no change in risk of alopecia areata

The apparent absence of a link between GLP‑1 medications and alopecia areata is especially notable, as isolated case reports have previously suggested an association. But unfortunately, since this is a retrospective analysis, the study can not tell us why we see this result.

Do these retrospective studies show semaglutide causes hair loss? No, they raise a hypothesis that there may be an association that justifies further research, but no cause-and-effect relationship can be determined.

The Verdict On Semaglutide and Hair Loss

All of these studies suggest that there could be an association between semaglutide and hair loss. However, this doesn’t mean that the studies establish a direct cause-and-effect relationship. We need randomized and controlled clinical trials that specifically examine the relationship between semaglutide and hair loss before we can confidently say what is happening between these two factors.

How Might Semaglutide Contribute to Hair Loss?

We’ve explored whether there could be an association between semaglutide and hair loss. Now let’s consider why this association might exist in the first place.

Unfortunately, there are no studies exploring why this relationship might exist. However,  there are several plausible pathways.{{Desai, D.D., Sikora, M., Nohria, A., Bordone, L., Caplan, A.S., Shapiro, J., Lo Sicco, K.I. (2024). GLP-1 Agonists And Hair Loss: A Call For Further Investigation. International Journal Of Dermatology. 63. 1128-1130. Available at: https://doi.org/10.1111/ijd.17246}}

Rapid Weight Loss and Changes to Diet 

Rapid weight loss is one of the best-documented triggers of telogen effluvium. When calorie intake drops sharply, the body prioritizes essential physiological functions, which can exclude hair growth.

As a result, hair follicles may enter the resting phase prematurely, leading to shedding several months later. This phenomenon can be observed in those having undergone bariatric surgery (weight loss surgery), where significant weight loss and the dietary changes following the surgery frequently trigger temporary hair shedding months after.{{Cohen-Kurzrock, R.A., Cohen, P.R., (2021). Bariatric Surgery-Induced Telogen Effluvium (Bar SITE): Case Report And A Review Of Hair Loss Following Weight Loss Surgery. Cureus. 13(4). e14617. Available at: https://doi.org/10.7759/cureus.14617}},{{Rojas, P., Gosch, M., Basfi-Fer, K., (2011). Alopecia In Women With Severe And Morbid Obesity Who Undergo Bariatric Surgery. Nutricion Hospitalaria. 26(4). 856-862. Available at: https://doi.org/10.1590/s0212-16112011000400028}},{{Nadler, E.P., Youn, H.A., Ginsburg, H.B., Ren, C.J., Fielding, G.A., (2007). Short-Term Results In 53 US Obese Pediatric Patients Treated With Laparoscopic Adjustable Gastric Banding. Journal Of Pediatric Surgery. 42(1). 137-142. Available at: https://doi.org/10.1016/j.jpedsurg.2006.09.014}},{{Nadler, E.P., Youn, H.A., Ren, C.J., Fielding, G.A., (2008). An Update On 73 US Obese Pediatric Patients Treated With Laparoscopic Adjustable Gastric Banding: Comorbidity Resolution And Compliance Data. Journal Of Pediatric Surgery. 43(1). 141-146. Available at: https://doi.org/10.1016/j.jpedsurg.2007.09.035}} It can also be seen in those with rapid weight loss as a result of a calorie-restricted diet.{{Kang, D.H., Kwon, S.H., Sim, W.Y., Lew, B.L., (2024). Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Annals Of Dermatology. 36(6). 384-388. Available at: https://doi.org/10.5021/ad.24.043}}

For people without any other underlying hair loss condition, hair will likely return to normal in a few months. But for those who have a predisposition towards androgenic alopecia or alopecia areata, we could hypothesize that the premature shedding from telogen effluvium could worsen their condition. Why? Because as more hair sheds, follicle miniaturization accelerates. So for those who already have these conditions, rapid weight loss and dietary changes from semaglutide could plausibly worsen their condition. For those who were not aware they had the condition, it could accelerate the noticeable onset of hair loss. This could lead them to mistakenly attribute hair loss to the drug.

Nutritional Changes

Semaglutide reduces appetite dramatically, which, as a consequence, reduces food intake. While this supports weight loss, it can lead to insufficient intake of key nutrients, including:

• Protein
• Iron
• Zinc
• Vitamin D
• B vitamins

Hair follicles require adequate nutrition to maintain normal growth cycles, and deficiencies in these nutrients could impair follicle function. A “negative event” like nutrient deficiency may also trigger telogen effluvium, or even alopecia areata. In line with this, alopecia areata has been associated with deficiencies in dietary protein and vitamin D.{{Pham, C.T., Romero, K., Almohanna, H.M., Griggs, J., Ahmed, A., Tosti, A. (2020). The Role Of Diet As An Adjuvant Treatment In Scarring And Nonscarring Alopecia. Skin Appendage Disord. 6(2). 88-96. Available at: https://doi.org/10.1159/000504786}},{{Bhat, Y.J., Latif, I., Malik, R., Hassan, I., Sheikh, G., Lone, K.S., Majeed, S., Sajad, P. (2017). Vitamin D Level In Alopecia Areata. Indian Journal Of Dermatology. 62(4). 407-410. Available at: https://doi.org/10.4103/ijd.IJD_677_16}}. Also, studies show that GLP-1 agonist users with weight loss often do not have sufficient nutrient intake.{{Johnson, B., Milstead, M., Thomas, O. (2025). Investigating Nutrient Intake During Use Of Glucagon-Like Peptide-1 Receptor Agonist: A Cross-Sectional Study. Frontiers In Nutrition. 12. 1566498. Available at: https://doi.org/10.3389/fnut.2025.1566498}} These insufficiencies could very plausibly cause hair loss, and if telogen effluvium were to occur, it could conceivably accelerate any underlying androgenic alopecia as we’ve discussed.

Inflammation

Semaglutide treatments like Ozempic and Wegovy are known to cause gastrointestinal issues, including diarrhea. Diarrhea is characterized by interstitial inflammation. Although there is no evidence showing this link, we could speculate that inflammation of the gut could trigger inflammation all the way to the scalp. An inflammation event like this might trigger alopecia areata in those already predisposed to this condition.

Disturbance to the Hair Cycle

In 2006, GLP-1 was found at high levels in the hair follicles of newborn mice, and was found to activate a signalling pathway in skin cells that promotes cell growth and division. This led to a theory that GLP-1 may be important for the development of hair follicles.{{List, J.F., He, H., Habener, J.F. (2006). Glucagon-Like Peptide-1 Receptor And Proglucagon Expression In Mouse Skin. Regulatory Peptides. 134(2–3). 149-157. Available at: https://doi.org/10.1016/j.regpep.2006.02.007}}

The idea that GLP-1 may be associated with hair biology could provide a clear link to how semaglutide, a GLP-1 mimic, may influence hair growth. However, this was an animal study, and the influence of GLP-1 on the development of human hair follicles has not been shown. What happens in animals does not always translate into humans. So for now, this link in humans remains unknown.

Altered Hormonal and IGF-1 Signaling

Hair follicles naturally respond to several hormonal signaling pathways, including insulin and insulin-like growth factor 1 (IGF-1). Namely, insulin is known to modulate the availability of IGF-1 in the body, and IGF-1 is known to stimulate hair follicle proliferation, inhibit hair follicle death, and promote the transition from the telogen phase to the anagen phase.{{Hsieh, W.J., Qiu, W.Y., Percec, I., Chang, T.M., (2025). Insulin-Like Growth Factor 1 (IGF-1) In Hair Regeneration: Mechanistic Pathways And Therapeutic Potential. Current Issues In Molecular Biology. 47(9). 773. Available at: https://doi.org/10.3390/cimb47090773}}

One case study demonstrates the link between insulin and hair growth. In this study, a 54-year-old woman with diabetes was experiencing hair loss. She was initially given minoxidil, but use of this treatment did not benefit her hair loss. She was subsequently given insulin therapy. After 2 months, she experienced a reduction in hair fall and had noticeable hair regrowth.{{Kant, R., Barnwal, S., Sharma, S.K., Thakur, K. (2021). Reversal Of Alopecia By Insulin Therapy In Uncontrolled Type 2 DM: A Case Report. Journal Of Diabetology. 12(4). 533-537. Available at: https://doi.org/10.4103/jod.jod_66_21}}

As we’ve discussed, case studies have a number of limitations. However, this case does show a link between insulin and hair growth. GLP-1 medications like semaglutide are known to 1) change insulin signaling after food intake, and B) promote reduced food intake. In the latter case, reduced food intake could lower the amount of insulin naturally produced by the body, a phenomenon documented in those taking GLP-1 medications.{{{Jørgensen, S.W., Hjort, L., Gillberg, L., Justesen, L., Madsbad, S., Brøns, C., Vaag, A.A. (2021). Impact Of Prolonged Fasting On Insulin Secretion, Insulin Action, And Hepatic Versus Whole Body Insulin Secretion Disposition Indices In Healthy Young Males. American Journal Of Physiology Endocrinology And Metabolism. 320(2). E281-E290. Available at: https://doi.org/10.1152/ajpendo.00433.2020}},{{Alhowiti, A., Mirghani, H. (2025). The Effects Of GLP-1 Agonists On HbA1c And Insulin Dose Among Patients With Type 1 Diabetes. Frontiers In Endocrinology. 16. 1550938. Available at: https://doi.org/10.3389/fendo.2025.1550938}},{{Luo, Y., Yang, S., Zeng, H., Liu, S., Zhang, Y., Li, J.E., Liu, J. (2025). Both Subcutaneous Semaglutide And Calorie Restriction Improves Pancreatic Cell Hyperplasia And Gut Microbiota In High-Fat Diet-Induced Obese Mice. Nutrition And Metabolism. 22(1). 95. Available at: https://doi.org/10.1186/s12986-025-00987-0}}

Because GLP-1 medications influence insulin signaling, which in turn could influence IGF-1 activity and hair growth, it is theoretically plausible that semaglutide medications could also influence hair cycling. However, direct evidence supporting this mechanism remains limited.

Distinguishing Between Telogen Effluvium, Androgenetic Alopecia, and Alopecia Areata

If you’re experiencing hair loss, it’s important to establish what kind of hair loss you might be having before any treatment can be recommended. 

This is how you can distinguish between the three primary causes of hair loss.

Hair Loss Condition	Symptoms
Telogen effluvium	Diffuse hair shedding that is temporary. It may happen 2 to 8 months after a major change or event, like beginning semaglutide treatment.
Androgenic alopecia	Progressive thinning that happens gradually over time. You may have a family history of balding. Thinning may be accelerated by the use of semaglutide.
Alopecia areata	Sudden patchy hair loss with a smooth bald spot and hair thinning. You may have a family history of autoimmune disease.

Should You Be Concerned?

For most people, the current evidence suggests that hair loss during semaglutide treatment is uncommon. If you have no signs of hair loss and don’t have a family history of androgenic alopecia or alopecia areata, then you probably do not have to worry.

However, some individuals may be more likely to notice shedding. You may be at higher risk if:

• You already have androgenic alopecia or alopecia areata
• Androgenic alopecia or alopecia areata runs in your family
• You lose weight very rapidly while using semaglutide
• Your diet becomes highly restrictive during semaglutide use

What Can I Do to Prevent Hair Loss with Semaglutide?

Because telogen effluvium can “reveal” androgenic alopecia, or even alopecia areata, faster than you would have seen naturally, there is a possibility that taking semaglutide could indirectly accelerate hair loss by triggering excessive hair shedding.

However, there are several strategies to help minimize hair shedding during semaglutide therapy:

• Avoid excessive calorie restriction: Gradual weight loss reduces physiological stress and lowers the likelihood of telogen effluvium.
• Prioritize protein intake: Hair is primarily composed of keratin, a structural protein. Adequate protein intake supports normal hair growth.
• Monitor micronutrients: Make sure you’re getting enough iron, zinc, vitamin D, and B vitamins, as these all play a role in hair growth.
• Track shedding patterns: If shedding begins, consider whether it started 2 to 8 months after significant weight loss, which is typical for telogen effluvium.
• Consult a dermatologist: A professional evaluation can help determine whether shedding is temporary or related to androgenic alopecia or alopecia areata, and if so, whether it is appropriate for you to start a hair loss treatment while you’re taking semaglutide, like oral finasteride.

You can learn more about the risks of oral finasteride and how to prevent them here.

Interested in Oral Finasteride?

Oral finasteride & minoxidil available, if prescribed*

Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you.

Click Here For 15% Off

*Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.

Final Thoughts

Reports of hair loss during semaglutide treatment have increased alongside the growing popularity of GLP-1 medications. Current research suggests that most users do not experience new hair loss, but some may experience temporary shedding as a result of telogen effluvium, and those with pre-existing hair loss may notice a worsening of their condition. 

However, no study has directly demonstrated that semaglutide is the cause of hair loss. Instead, hair changes observed during treatment more likely reflect the physiological effects of rapid weight loss, including calorie restriction, nutritional changes, and physiological stress. 

More research is needed to clarify the relationship between GLP-1 medications and hair biology. For now, individuals considering semaglutide therapy should focus on maintaining balanced nutrition, pursuing gradual weight loss, and monitoring hair health during treatment to minimize potential hair loss.